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Abstract 
Staphylococcus aureus is a highly successful human pathogen capable of colonising and 
spreading easily between humans while causing a wide range of infections, including life 
threatening bacteraemias, endocarditis and pneumonia. Virulence gene expression is regulated 
primarily by the staphylococcal accessory gene regulator (agr) in a cell density-dependent 
manner termed quorum sensing. Strains of S. aureus, particularly community-associated 
methicillin resistant S. aureus (CA-MRSA), carrying the genes for a pore forming exotoxin, the 
Panton Valentine Leukocidin (PVL), have been spreading worldwide over the last 10 to 15 years. 
As high level production of exotoxins has been implicated in the success of the CA-MRSA clone 
USA300, a collection of PVL producing clinical isolates from Nottingham were studied with the 
aim of understanding why PVL production might vary between strains. 
Sequence typing of the Nottingham strain collection revealed that high PVL producing ST22 agr 
group 1 and low PVL producing ST30 agr group 3 strains were the most common types. PVL 
production was stimulated by addition of the type specific exogenous autoinducing peptide 
(AIP), which activates the agr sensor AgrC, and inhibited by the AgrC antagonist (ala5)AIP-1 if 
added before a critical cell population density was reached.  Analysis of the pvl promoter 
identified predicted binding sites for RNA polymerase and the SarA protein family of regulators. 
Promoter pull down experiments confirmed the binding of several staphylococcal regulators to 
both the agr and pvl promoters including SarA, SarS, Rot and MgrA indicating that these are 
likely to play a role in the regulation of PVL production. 
Analysis of the agr locus of high and low PVL producing strains found that a low PVL producing 
ST22 agr group 1 strain TS13 had a single nucleotide polymorphism (SNP) conferring an N267I 
substitution in the cytoplasmic domain region of agrC not present in a high PVL producing ST22 
strain TS14. Whole genome sequencing of these strains revealed them to be closely related to 
each other, differing by less than 200 SNPs across their core genomes. While not possessing an 
SCCmec element, they carried phages encoding pvl and the immune evasion complex (IEC) 
comprising staphylokinase, the chemotaxis inhibitory protein (CHIPS) and the staphylococcal 
complement inhibitor (SCIN).  
AgrC N267I reduced sensitivity to AIP in a bioluminescent reporter for agr which responds to 
but does not produce AIP. Introducing AgrC N267I into an agr reporter which both produces 
and senses AIP resulted in delayed autoinduction. This appeared to explain the delay in AIP 
autoinduction observed in TS13 as compared with TS14 with resulting low PVL production. 
Other naturally occurring agrC cytoplasmic mutations including T247I and I311T/A343T 
reduced AIP sensitivity and were associated with delayed autoinduction and reduced exotoxin 
production. 
PVL production is closely regulated by agr with expression mediated by several staphylococcal 
regulators in a cell population density dependent manner. Mutations in agrC occur naturally, 
delay autoinduction, can have a marked impact on exotoxin production and may be a form of 
adaptation to niches where high level agr expression is not required. 
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1 Introduction 
 
1.1 Staphylococcus aureus 
1.1.1 Cell structure and phylogeny 
Staphylococcus aureus, a member of the family Staphylococcaceae, belongs to the phylum 
Firmicutes, a diverse collection of Gram positive organisms traditionally classified as having low 
GC content (Figure 1.1).  
Analysis of signature insertions in the sequences of a number of important conserved genes, 
including DNA gyrase and RNA polymerase, between phyla suggests that the Firmicutes were 
one of the earliest eubacterial groupings to develop. Both the Firmicutes and the Archaea lack 
many signature insertions in conserved genes which are present in other, particularly Gram 
negative, eubacterial phyla (Griffiths & Gupta, 2004).  
As geological data suggests that the early atmosphere of the earth did not contain oxygen, 
anaerobic Firmicutes such as the Clostridia were probably the earliest members of the phylum 
to develop. The great oxygenation event is believed to have occurred approximately 2.5 to 3 
billion years ago as a consequence of the activity of photosynthesizing cyanobacteria and would 
have presumably enabled the development of the facultatively anaerobic and aerobic members 
of the class Bacilli (Crowe et al, 2013; Holland, 2006). 
The thickened cell wall characteristic of the Firmicutes and other Gram positive bacteria gives 
the bacterial cell a protective structure against environmental hazards, such as osmotic and 
shearing forces, that would otherwise damage the cell membrane and destroy the cell. The cell 
wall also facilitates cell division and inhibits uncontrolled uptake of foreign DNA. The simpler 
Gram positive cell structure with a single inner membrane is believed to have been the 
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precursor of the double membrane structure characteristic of Gram negative bacteria 
(Errington, 2013).  
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Figure 1.1  The phylum Firmicutes 
A diagrammatic representation of the phylum Firmicutes tracing the subgroupings which 
contain the staphylococci. Selected families, genera and species are shown within the order 
Bacillales. Groupings are displayed according to the latest information available on the Names 
for Life website (http://doi.namesforlife.com/10.1601/tx.3874, accessed 16th November 
2013). 
 
 
Firmicutes
Bacilli
Clostridia
Erysipelotrichia
Negativicutes
Thermolithobacteria
Phylum OrderClass Genus
Bacillales
Lactobacillales
Family
Bacillaceae
Listeriaceae
Staphylococcaceae
Gemella
Macrococcus
Salinococcus
Staphylococcus
Species
S. aureus
S. capitis
S. epidermidis
S. haemolyticus
S. lugdunensis
4 
 
1.1.2 Overview of staphylococcal virulence factors and clinical features 
Although the ancestral forms of the class Bacilli are understood to have existed long before the 
emergence of multicellular eukaryotic organisms, the staphylococci have nonetheless become 
highly adapted to host colonization. Staphylococcus epidermidis is a ubiquitous colonizer of 
human skin, while S. aureus is carried persistently by around 20 % and intermittently by 30 % 
of healthy people (Sakwinska et al, 2009; Wertheim et al, 2005). 
Staphylococcal virulence is dependent on a diverse array of virulence factors giving the bacteria 
capacity for colonization, tissue destruction and invasion, immune evasion, and long term 
survival. The stepwise acquisition of virulence genes has facilitated the ongoing spread and 
survival of staphylococci in human and animal populations.  
To adhere to mucosal and other epithelial surfaces such as the anterior nares, axillae, 
oropharynx and perineum, S. aureus uses a number of cell surface bound adhesive proteins 
termed MSCRAMMS (Microbial Surface Components Recognising Adhesive Matrix Molecules). 
These are anchored to the cell wall peptidoglycan by sortase and enable binding to a number 
of different molecules such as fibronectin (FnbA), fibrinogen (ClfA) and collagen (Cna) (Foster 
& Höök, 1998). Colonisation of the anterior nares in particular is facilitated by clumping factor 
B binding to epithelial cells, with the recently characterized SasX protein also having a role in 
some CA-MRSA strains (Li et al, 2012; Wertheim et al, 2008). The capacity to spread quickly 
from inanimate surfaces to host surfaces and back again is essential for staphylococcal 
dissemination, either through direct contact or sometimes aerosolisation. Hand hygiene 
initiatives, screening, isolation and decolonization aimed at reducing MRSA infections in 
hospitals during the last 15 to 20 years appear to have been very effective in limiting this surface 
contact reliant spread (Coia et al, 2006). As S. aureus can colonise a host for prolonged periods 
without causing infections unless certain circumstances permit, it is generally considered to be 
an opportunistic pathogen. 
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Progression from colonisation to disease is usually dependent on breaches of the physical 
barrier provided by intact skin through abrasions, surgery or hair follicle trauma such that 
bacteria can invade into tissue directly or via the bloodstream to establish abscesses (Cheng et 
al, 2011). Once in the bloodstream, MSCRAMMs are understood to play a vital role in 
endothelial adherence, along with wall teichoic acid (WTA) and a secreted, non-anchored, 
adhesive protein, the extracellular adherence protein (Eap) (Edwards & Massey, 2011). 
Endovascular infections such as endocarditis are initiated by adherence to, often damaged, 
endothelium mediated by the fibronectin binding proteins with subsequent accumulation of 
fibrin, erythrocytes, platelets and other cellular debris forming vegetations (Beynon et al, 2006; 
Que et al, 2005). 
Following endothelial adherence at organ sites and other tissues, extravasation occurs via a 
number of mechanisms including endocytosis, transport within professional phagocytes and 
perhaps paracytosis by interfering with tight junctions between cells (Edwards & Massey, 
2011). Staphylococci are notorious for their capacity to survive within various cell types, even 
neutrophils, through inhibition of phagosome lysosome fusion, neutralization of phagosome 
contents by staphyloxanthin, resistance to lysozyme and subsequent escape into the cell 
cytoplasm (Clauditz et al, 2006; Foster, 2005; Gresham et al, 2000). Once bacteria have gained 
access to tissues, S. aureus has a veritable arsenal of enzymes which can destroy surrounding 
cells and structures including proteases, lipases, hyaluronidase, nuclease, Staphylokinase and 
haemolysins (Burlak et al, 2007). Iron scavenging and uptake is also essential at this stage to 
meet the nutritional requirements of the pathogen (Skaar et al, 2004). The inflammation 
generated by cell damage would then generate a wider immune response, resulting in the influx 
of neutrophils to the site. 
Staphylococci are experts in immune evasion and subversion, presumably reflecting an ancient 
and lengthy conflict between host and pathogen. As mentioned already, S. aureus is adept at 
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survival within neutrophils, however, numerous other strategies are employed to prevent 
phagocytosis happening in the first place. The prophage encoded virulence factors CHIPS 
(Chemotaxis inhibitory protein) and SCIN (Staphylococcal complement inhibitor) interfere with 
chemotaxis (de Haas et al, 2004; Rooijakkers et al, 2005a) and complement activation 
respectively. Clumping factor A triggers staphylococcal agglutination and adherence to fibrin, 
presumably making opsonisation and phagocytosis more difficult (Higgins et al, 2006). Protein 
A binds to the Fc region of IgG conferring additional antiphagocytic protection by providing a 
 ‘ĐĂŵŽƵĨůĂŐĞ ? ŽĨ ŝŶĞĨĨĞĐƚŝǀĞůǇ ďŽƵŶĚ ŝŵŵƵnoglobulins (Peterson et al, 1977). Capsular 
polysaccharide is also well characterized for its antiphagocytic properties (Thakker et al, 1998). 
In addition to these defensive strategies, some strains of S. aureus are capable of directly lysing 
neutrophils through production of leukocidins and phenol soluble modulins  W these will be 
discussed in more detail later in section 1.2. 
While evasion of the immune response gives bacteria more time to replicate and disseminate 
throughout the host, subversion of the immune response is a more pernicious strategy which 
directly contributes to clinical syndromes. The best known example of this is the toxic shock 
syndrome toxin 1 (TSST-1), although similar toxic shock syndromes can be caused by the other 
pyrogenic toxin superantigens (PTSAgs) such as the staphylococcal enterotoxins. Superantigens 
interfere with antigen presentatioŶƚŽĐĂƵƐĞĂƉĂƚŚŽŐĞŶŝĐ ‘ĐǇƚŽŬŝŶĞƐƚŽƌŵ ?ǁŚŝĐŚůĞĂĚƐƚŽƚŚĞ
fever, haemodynamic instability and the characteristic widespread blanching rash associated 
with toxic shock (Dinges et al, 2000). 
Abscess formation appears to be another form of immune subversion relying, in part, on the 
immune response. Developing abscesses appear to be made up of a central nidus of replicating 
Staphylococci surrounded by a fibrin deposit, promoted by coagulase and clumping factor A 
and an outer ring of necrotic neutrophils (Cheng et al, 2011). Bacterial replication will continue 
within an abscess capsule until rupture and dissemination of bacteria into the bloodstream or 
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skin surface occurs, thus continuing the cycle. Abscess formation is the central component of 
many of the disease processes associated with S. aureus including skin and soft tissue 
infections, cavitating pneumonia, osteomyelitis and other end organ abscesses such as in the 
kidneys and brain. The capacity for the bacteria to continually metastasize and disseminate 
back into the bloodstream at a later time is associated with recurrent infections. Bacterial 
endocarditis is a notorious source of continual bacteraemia and frequently occurs in 
conjunction with infections at other sites such as septic arthritis, discitis and infected 
pulmonary emboli (Beynon et al, 2006). 
As discussed above, staphylococci will tend to persist at former abscess sites through forming 
biofilms within cellular debris or surviving within host cells. Biofilm formation promotes long-
term bacterial survival by providing protection from the immune system and inhibiting 
penetration of antibiotics (O'Neill et al, 2008). Biofilms are particularly problematic in the 
context of implanted prosthetic devices as once an infection is established these are virtually 
impossible for the immune system to sterilize. Examples of infections associated with 
prosthetic material include joint and heart valve replacements, intravenous and intraperitoneal 
catheters and cardiac pacing systems. 
Viewed as a whole, S. aureus is an extremely versatile pathogen with an impressive arsenal of 
virulence factors. Able to respond to virtually every facet of the innate immune system, the 
bacteria can quickly gain access to a variety of niches in the host from where it is difficult to 
eradicate. 
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1.1.3 Antimicrobial resistance 
Over the past three decades S. aureus has gained notoriety in the public consciousness largely 
by virtue of the rising prevalence of methicillin resistant hospital-acquired infections during the 
1980s and 1990s (Boyce & Causey, 1982; Johnson, 1998; Witte, 2004). The loss of efficacy of 
the beta-lactam group of antibiotics has presented an awkward therapeutic challenge as the 
traditional intravenous alternative vancomycin suffers from both reduced bactericidal activity 
and a narrow therapeutic window (Pope & Roecker, 2007; Rybak et al, 2009), with increasing 
resistance also reported (Cunha, 2005; Sakoulas & Moellering, 2008). Although extremely 
dangerous in immunocompromised patients, usually due to co-morbidities, recent surgery or 
indwelling prosthetic devices, these strains have previously not presented a significant threat 
outwith this context; clinical studies comparing bacteraemia due to healthcare associated 
methicillin resistant S. aureus (HA-MRSA) and methicillin sensitive S. aureus (MSSA) have 
tended to suggest that worse outcomes in HA-MRSA bacteraemia derive from extended 
hospitalisation, treatment and host factors as opposed to differences in innate bacterial 
virulence (Harbarth et al, 1998; Hershow et al, 1992; Melzer et al, 2003; Wolkewitz et al, 2011). 
Methicillin resistance is the result of the insertion of a mobile genetic element, the 
staphylococcal resistance cassette SCCmec, encoding several genes of unknown origin possibly 
transferred from another bacterial species (Ito et al, 1999). The mecA gene encodes a modified 
ƉĞŶŝĐŝůůŝŶďŝŶĚŝŶŐƉƌŽƚĞŝŶWW ? ?ǁŚŝĐŚŚĂƐůŽǁ affinity for the penicillinase resistant beta lactam 
antibiotics routinely used to treat S. aureus infections such as flucloxacillin (Matsuhashi et al, 
1986). Insertion of SCCmec is dependent on site-specific recombinases called cassette 
chromosome recombinases A and B (CcrA and CcrB) which recognize a unique sequence within 
the orfX gene (Katayama et al, 2000). The SCCmec element itself contains an insertion site 
allowing for integration of multiples copies of SCCmec. 
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Several SCCmec allotypes have been recognised which vary in terms of total size of the cassette, 
sequence differences in the recombinases genes, genes immediately adjacent to mecA and 
additional genetic material, including resistance genes for other antibiotics (Hiramatsu, 1995). 
Many of the HA-MRSA strains originally spreading in hospitals harbour SCCmec types I to III. By 
contrast, an emerging phenomenon of Community-acquired MRSA (CA-MRSA) has been 
recognised which have a smaller staphylococcal chromosomal cassette type, usually IV, but also 
V and VI, containing mecA, but often lack the multi-drug resistance of hospital strains (Ma et al, 
2002; Vandenesch et al, 2003).  
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1.2 Panton Valentine Leukocidin 
1.2.1 Clinical associations with PVL 
If the 1980s and 1990s were marked by the rise of HA-MRSA, the emerging threat posed by S. 
aureus over the last 10 years has been due to an increase in virulent strains originating in 
community settings, often causing disease in young immunocompetent people. The two 
aspects to this trend which have been extensively studied are the emergence of CA-MRSA and 
the potential association with a phage-encoded pore forming toxin, the Panton Valentine 
leukocidin (PVL). 
The genes encoding the two components of the PVL toxin lukS-PV and lukF-PV are carried on 
bacteriophages, insert into well-defined sites in the bacterial chromosome, and are transcribed 
from a single promoter (Kaneko et al, 1998). As the PVL genes are phage-borne they have not 
only spread rapidly by clonal expansion of successful CA-MRSA clones but are also capable of 
spreading between lineages by horizontal gene transfer. 
The precise role of PVL in the pathogenesis of CA-MRSA and more generally in S. aureus 
infections has been the subject of much debate. This body of literature has been complicated 
by the extraordinary success in the United States of a single PVL positive CA-MRSA clone, 
designated USA300 by pulsed field gel electrophoresis. A study of 1055 representative isolates 
collected nationally in the US between 2004 and 2006 revealed clonal expansion of USA300 
from 12 % of clinically isolated S. aureus to 38 % (O'Hara et al, 2012). In a multicenter study of 
presentation to emergency departments, USA300 was the pathogen isolated most commonly 
from skin and soft tissue infections (SSTIs) (Moran et al, 2006). USA300 has been associated 
with necrotising pneumonia and is now epidemic in the United States (Hidron et al, 2009; 
Klevens et al, 2007). Having begun as a community problem, USA300 has also spread into 
American hospitals, becoming an important cause of surgical wound infections and hospital 
acquired pneumonias (Pasquale et al, 2013). 
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Due to the rise of USA300, elucidating the unique role of PVL, which is carried by the majority 
of CA-MRSA and a significant reservoir of MSSA strains, has proven difficult. The clearest 
epidemiological association with S. aureus carrying the PVL genes appears to be SSTIs; a recent 
meta-analysis found a clear association of PVL with SSTIs but not invasive infections. Patients 
with PVL positive infections were also more likely to require surgery (Shallcross et al, 2013). A 
seven year study of skin infections presenting to a dermatology department in France found 
that 97 out of 225 (42.5 %) Staphylococcal SSTIs were caused by PVL positive strains, with a 
strong association with folliculitis (Del Giudice et al, 2011). In a large multicenter trial of 
complicated SSTI, PVL positive USA300 was the most common strain isolated. Abscesses caused 
by PVL strains were larger but resolved faster following drainage (Bae et al, 2009). A study of 
SSTIs caused by MSSA in the Bronx area of New York found that 36 % of these were PVL positive 
and had similar outcomes to PVL positive CA-MRSA strains, with PVL infections being more 
likely to require incision and drainage (Kaltsas et al, 2011). 
Apart from SSTIs the other associations have been with osteomyelitis in children and 
necrotising pneumonia. The meta-analysis by Shallcross et al (2013) also indicated that 
osteomyelitis caused by PVL positive strains could be associated with increased morbidity. 
Furthermore, a study comparing bone and joint infections in children caused by PVL positive 
and PVL negative S. aureus found that long-term complications, prolonged treatment and 
requirement for surgical drainage were all associated with PVL (Dohin et al, 2007). 
An early case series published by the Staphylococcal Pathogenesis Group in Lyon, France, noted 
that S. aureus causing necrotising pneumonia in previously immunocompetent people were 
PVL positive (Gillet et al, 2002). These cases were characterised by an influenza-like prodrome, 
haemoptysis, leucopoenia and rapid disease progression, with a high mortality rate.  Although 
the numbers of cases of life-threatening necrotising pneumonia are infrequent and sporadic, 
there have been numerous other case reports of similar clinical cases associated with PVL. In a 
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recent study of 148 cases of necrotising pneumonia due to PVL, patients had a 40 % overall 
mortality, rising to 75 % if they had leucopoenia at presentation, with a median survival of 4 
days (Khanafer et al, 2013). Leucopoenia was associated with co-infection with influenza. 
Molecular analysis of a collection of post-mortem lung tissue from 66 cases of necrotising 
pneumonia showed the majority of cases were PVL positive (Denison et al, 2013). 
Aside from the clinical syndromes discussed above, there may be other potential associations 
with PVL that have not yet been recognised, particularly in uncommon infections. A study of 
patients presenting to an ophthalmology department in the UK found that 9 out of 95 strains 
of S. aureus causing keratitis over the study period were PVL positive. The PVL positive cases 
were associated with worse outcomes and need for surgery (Sueke et al, 2013). 
While the rise of PVL in the United States is clearly due to clonal expansion of USA300, reports 
by the United Kingdom Health Protection Agency (HPA) noted a rising incidence of PVL positive 
strains in the UK, both MRSA and MSSA, which typically cause recurrent  SSTIs and occasionally 
more severe disease (Ellington et al, 2009).  
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1.2.2 CA-MRSA virulence 
CA-MRSA, while particularly problematic in the United States, is now a worldwide problem. 
Elsewhere in the world, PVL positive CA-MRSA clones have been extremely successful in certain 
countries; the European clone ST80-MRSA-IV is highly prevalent in Greece (Vourli et al, 2009), 
while in Australia, although CA-MRSA strains have been present for some time, the highly 
ǀŝƌƵůĞŶƚ  ‘YƵĞĞŶƐůĂŶĚ ? ĐůŽŶĞ ^d ? ?-MRSA-IV is now predominant in Eastern Australia and an 
important cause of osteomyelitis, septic arthritis and necrotising pneumonia (Nimmo & 
Coombs, 2008). The ST30-MRSA-IV Southwest Pacific Clone emerged from Asia but is also 
prevalent in other parts of the world (Chen et al, 2013). While the vast majority of CA-MRSA 
strains encode the genes for the Panton Valentine Leukocidin (PVL), this may not always be the 
case (Otter et al, 2009). 
Research has focused on why emerging CA-MRSA clones have been so successful over a short 
period of time. Compared to HA-MRSA, the smaller SCCmec elements, usually type IV, carried 
by CA-MRSA strains are understood to reduce the fitness burden (Collins et al, 2010). Strains 
which are predominantly circulating in the community would not necessarily benefit from 
multiple resistance genes as their antibiotic exposure will be lower than in hospital settings. 
In addition to the PVL genes, the success of USA300 and other CA-MRSA has been attributed to 
a combination of the smaller SCCmec element, enhanced expression of core genome virulence 
determinants and acquisition of other mobile genetic elements (MGEs) such as the arginine 
catabolic mobile element (ACME) (Otto, 2013). Eukaryotic cells produce polyamines, including 
spermidine and spermine, from arginine which are toxic to S. aureus. The function of ACME in 
promoting colonisation and persistence is two-fold; ACME encoded speG converts spermidine 
and spermine to non-toxic acetylated forms, while the arginine deaminase system (ACME-arc) 
produces ammonia from arginine breakdown, enabling S. aureus to survive the low pH 
environment of the skin surface (Joshi et al, 2011; Thurlow et al, 2013). Core genome virulence 
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determinants which could enhance virulence through over expression include alpha-
haemolysin and the phenol soluble modulins (PSMs). PSMs are amphipathic peptides which are 
pore forming and could have detergent-like damaging effects on membranes, particularly at 
high concentrations (Vandenesch et al, 2012). 
 
1.2.3 Continuing global spread of PVL positive strains 
As PVL is not routinely screened for, comprehensive data on the prevalence of PVL positive S. 
aureus is not available. A review of the literature over the past year, however, appears to 
indicate ongoing global spread of PVL in both MSSA and CA-MRSA strains. 
A study of 142 Spanish children with SSTIs caused by S. aureus found that 46 (32 %) of isolates 
were PVL positive of which 33 were MSSA (Barrios López et al, 2013). A Lebanese study of nasal 
carriage in schoolchildren found a PVL positivity rate of around 15 %, with 60 % of children 
presenting with abscesses carrying a PVL positive strain (Beyrouthy et al, 2012). In one study 
from Benin, out of 136 SSTI and osteomyelitis isolates, only 25 % were MRSA but 70  % were 
PVL positive, presumably reflecting a local outbreak (Sina et al, 2013). 
Elsewhere in the world, high rates of PVL were reported in studies of SSTIs in China and 
Australia, and also a study of bacteraemia in India, in which 16 % of isolates were PVL positive 
(Bennett et al, 2013; Eshwara et al, 2013; Zhao et al, 2012). 
PVL positive strains have been previously noted to spread rapidly in situations where there is 
frequent close contact between individuals such as in schools, prisons, sports facilities and 
homes (Klevens et al, 2007). The spread of PVL in military settings is also a largely unrecognised 
but potentially important problem. A recent study of clinically isolated S. aureus at Camp 
Bastion, Afghanistan, found 41 % of isolates were PVL positive (Johnstone & Matheson, 2013). 
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Either through association with CA-MRSA or successful locally circulating strains of MSSA, it 
appears as though PVL is continually spreading around the world. As this virulence factor is 
likely here to stay and will be encountered frequently in clinical settings, it is imperative that 
we gain as clear an understanding as possible about its role in staphylococcal pathogenesis and 
spread. 
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1.2.4 Mechanism of action of PVL 
PVL is not a recently discovered protein toxin; it was initially identified by Van deVelde in 1894, 
characterised by its ability to lyse human neutrophils and subsequently associated with skin 
and soft tissue infections by Sir Philip Panton and Francis Valentine in 1932 (Boyle-Vavra & 
Daum, 2007; Panton et al, 1932). PVL is a member of a family of bi-component pore forming 
leukocidins along with gamma haemolysin, LukED and LukAB. All of these toxins have so-called 
fast and slow components, characterised by electrophoretic mobility. Gamma haemolysin is a 
slight exception to this rule in that it has two interchangeable slow components; HlgA and HlgC, 
which combine with one fast component HlgB. The slow components usually bind to the cell 
membranes first, forming a hetero-octamer with four F and four S subcomponents 
(Vandenesch et al, 2012) (Figure 1.2). The formation of membrane pores by the established 
toxin structure leads to efflux of cell contents, particularly ions (Meunier et al, 1995). In vitro 
studies have demonstrated that PVL exhibits a concentration dependent effect, ranging from 
the induction of cell apoptosis to frank necrosis (Genestier et al, 2005). Across cell types and 
animal species, PVL has particular affinity for human neutrophils (Löffler et al, 2010). 
In addition to direct cell lysis through membrane pore formation, other potential effects of PVL 
have been postulated. There is some evidence to suggest that PVL enhances inflammation by 
binding to leukocytes and stimulating the NLRP3 (NLR family, pyrin domain-containing 3) 
pathway, a cascade of responses which leads to the upregulation of inflammatory cytokines, 
particularly interleukin 1ɴ  (Holzinger et al, 2012). In a study of PVL effects on osteoblasts, the 
toxin inhibited cell proliferation, inducing apoptosis and inflammation (Jin et al, 2013). If the 
bacteria are phagocytosed, PVL appears to play a role in endosomal escape, intracellular 
replication and triggering apoptosis from within the cell (Chi et al, 2013). Direct stimulation of 
inflammatory pathways and release of inflammatory granules from neutrophils may explain the 
severity of pneumonia observed in conjunction with influenza. Epithelial and ciliary damage by 
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influenza reduces staphylococcal clearance and attracts neutrophils which are then lysed, 
creating a vicious cycle of inflammation (Niemann et al, 2012).  
 
1.2.5 Animal model data 
In an attempt to define the contribution of PVL to S. aureus infections, particularly with CA-
MRSA strains, various animal models have been employed with conflicting results. Some of the 
early studies appeared to indicate that PVL did not influence pathogenesis at all, generating 
some controversy. 
One of the earliest mouse studies involved the inoculation of purified recombinant PVL toxin 
into the lungs of mice, which appeared sufficient to induce haemorrhagic necrosis (Labandeira-
Rey et al, 2007). In addition, a laboratory strain RN6390 complemented with a plasmid 
containing the lukSF-PV genes caused necrotising pneumonia in the same model where as an 
isogenic PVL negative strain did not. In contrast, other studies using clinical strains such as 
USA300 with isogenic lukSF-PV knockouts in mouse models of skin infection and pneumonia 
did not demonstrate any difference in disease severity or outcome (Bubeck Wardenburg et al, 
2008; Voyich et al, 2006). This led to much speculation as to the validity of the study by 
Labandeira-Rey and whether their results using laboratory strains could be extrapolated to 
clinical infections (Villaruz et al, 2009). As the strain causing necrotising pneumonia contained 
a multi-copy plasmid expressing high levels of PVL, an alternative explanation is that a very high 
toxin concentration was required to cause the observed pathology. MSSA and MRSA strains 
that exhibited higher production of PVL caused larger abscesses and worse inflammation than 
lower producing strains in a mouse skin infection model (Varshney et al, 2010).  
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S. aureus
Figure 1.2  The Panton Valentine Leukocidin 
PVL is secreted by S. aureus as two subcomponents, LukS-PV and LukF-PV, which form a hetero-
octamer on the cell membrane of polymorphonuclear neutrophils (PMNs). The resulting 
formation of membrane pores leads to efflux of cell contents and cell death. In addition to 
impairing the innate immune response to staphylococci, neutrophil lysis also contributes to 
tissue inflammation and necrosis through the release of inflammatory mediators or reactive 
oxygen species (ROS). Adapted from Boyle-Vavra and Daum (2007).  
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Contributing to the growing debate about the importance of PVL and the pathogenicity of 
USA300 in particular, Li and colleagues published an analysis of the genetic evolution of CC8 
CA-MRSA (Li et al, 2009b). In this paper, they noted that USA300 appeared to have developed 
from its parent strain USA500 through acquisition of mobile genetic elements, including a 
phage containing the lukSF genes. However through comparison of these two strains with other 
epidemic MRSA clones, it was noted that both USA300 and USA500 exhibited increased 
expression of the accessory gene regulator (agr), alpha haemolysin and phenol soluble 
modulins (PSMs), as well as heightened capacity to lyse neutrophils and erythrocytes, and cause 
dermonecrosis in mice.  They concluded that the enhanced virulence of USA300 resulted from 
greater exotoxin expression, probably due to higher activity of agr and other staphylococcal 
regulators, rather than the acquisition of the lukSF-PV genes, which USA500 does not possess. 
They failed to explain however, why it is USA300, not USA500 which is currently epidemic in 
the United States, or concede that increased regulatory activity in USA300 is also likely to result 
in increased PVL expression in addition to the other exotoxins. As mentioned previously, other 
agr regulated exotoxins including alpha-haemolysin, which is produced by many clinical strains 
of S. aureus, and the cytolytic PSMs are considered as alternative virulence factors in CA-MRSA 
infections (Bubeck Wardenburg et al, 2007; Wang et al, 2007). It seems likely that these toxins 
work in concert with PVL; Hongo and colleagues demonstrated that PVL induced lysis of 
neutrophils was enhanced by the presence of PSMs (Hongo et al, 2009). A recent study has also 
suggested that perhaps increased expression of these toxins in CA-MRSA is due to a 
modification of the agr regulon, the magnitude of the downstream effects of agr expression, 
rather than being solely due to increased agr expression (Cheung et al, 2011). 
While the mouse models summarized above have produced conflicting data, it has since been 
observed that mouse neutrophils have reduced susceptibility to PVL when compared with the 
neutrophils of humans and other animal species, such as rabbits, casting doubt on whether 
these data could be extrapolated to human infections (Löffler et al, 2010). While PVL can act 
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directly on membranes at high concentrations, the toxin appears to target the human 
complement receptor C5a, allowing it to trigger apoptosis at low concentrations and explaining 
the species specific effects observed (Spaan et al, 2013). 
A series of rabbit models have given a clearer indication that PVL contributes to outcomes of 
staphylococcal infections. A rabbit osteomyelitis model comparing USA300 with an isogenic PVL 
knockout demonstrated that infections lasted longer and were associated with greater bony 
deformity and tissue injury with the PVL positive strain (Crémieux et al, 2009). A similar study 
involving a rabbit model of pneumonia and similar isogenic USA300 PVL positive and negative 
strains also demonstrated enhanced lung necrosis and worse survival rates in the PVL positive 
group (Diep et al, 2010). A follow-up study demonstrated a role for linezolid in treatment, 
suppressing PVL production and improving outcomes (Diep et al, 2013). 
Results of rabbit models have not however been unanimous. In a rabbit abscess model, 
outcomes were improved, with smaller abscesses, in rabbits infected with alpha-haemolysin or 
PSM alpha knockouts, while no effect was observed with a PVL knockout mutant (Kobayashi et 
al, 2011). In a study comparing different CA-MRSA clones, SSTIs in a rabbit model were of 
comparable size between PVL positive and negative strains, although larger in strains which 
expressed high levels of alpha-haemolysin and phenol soluble modulins (Li et al, 2010). Another 
rabbit model of SSTI however did report a difference in abscess size between a PVL positive 
strain and isogenic PVL knockout mutant (Lipinska et al, 2011). 
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1.2.6 The importance of gene expression 
Weighing up the evidence available to date from in vitro and animal studies, it would appear 
that both the presence of the PVL toxin genes and the strain background have a role to play in 
defining the severity of PVL-associated infections. The observation that USA300 exhibits high 
level agr expression, and a greater sensitivity of toxin expression to changes in agr, when 
compared with other strains in vitro and in animal models is interesting for two reasons; the 
mechanism behind this difference in agr expression is not fully understood and, furthermore, 
uncovering this may shed significant light on the role of this and other regulators in 
staphylococcal pathogenesis. While targeting specific virulence factors like PVL with vaccines 
or monoclonal antibody therapy has been suggested as one approach to treating severe 
staphylococcal infections, pinpointing and interfering with key staphylococcal regulators 
responsible for multiple virulence factors is a compelling strategy for reducing the burden of 
staphylococcal disease. 
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1.3 Regulation of virulence in S. aureus 
1.3.1 Two component signal transduction systems and quorum sensing 
Two component systems (TCSs) are widespread in bacteria and enable recognition of 
environmental and cytoplasmic signals coupled to an intracellular response. This coupling 
usually involves a histidine protein kinase (HPK) which is autophosphorylated at a histidine 
residue in response to the stimulus and then transfers this phosphate to a response regulator 
(RR) (Grebe & Stock, 1999). This basic pattern can be complicated by the involvement of 
additional components such as other sensors or multiple phosphate transfer steps. TCSs fulfil a 
plethora of functions including control of chemotaxis, sporulation, exoprotein production, 
nutrient uptake, metabolism and environmental stress responses (Stock et al, 1989). 
 
1.3.1.1 TCSs in S. aureus 
S. aureus has a number of TCSs; in the sequenced strain N315, 16 putative TCS have been 
identified, interacting with each other as well as regulating target genes independently (Cheung 
et al, 2004; Matsuo et al, 2010; Novick, 2003) (Table 1.1). The function of TCSs in S. aureus 
include those involved in autolysis regulation and antimicrobial peptide (AMP) resistance, 
homeostasis, oxidative, thermal, pH and membrane stress responses, quorum sensing and 
virulence gene regulation (Novick & Jiang, 2003). This is an important consideration when 
attempting to relate in vitro gene regulation to the context of in vivo infection where a 
multitude of environmental variables exist. 
There are a number of these systems whose primary function is in resisting AMPs or other 
antibiotics. BraRS is responsible for resistance to bacitracin and also the lantibiotics nisin and 
nukacin ISK-1 through sensing inhibition of or binding to membrane anchored lipid II in 
conjunction with BraDE (Hiron et al, 2011). GraRS senses the presence of cationic AMPs and 
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confers resistance to them through modifying cell wall teichoic acids, increasing their positive 
charge. GraRS is also activated in response to oxidative or thermal stress, possibly due to its 
role in modifying cell wall components and has been linked to downstream effects on cell wall 
biosynthesis and virulence gene regulation (Falord et al, 2011). VraDE is activated by 
coordinated expression of BraRS and GraRS and acts as a detoxification module, particularly for 
bacitracin resistance (Kawada-Matsuo et al, 2013). VraRS responds to inhibition of cell wall 
biosynthesis through the action of cell wall active antibiotics such as vancomycin or cationic 
AMPs. VraRS is involved in regulating a number of cell wall related pathways including cell wall 
biosynthesis and protein folding (Pietiäinen et al, 2009). 
Overlapping with antimicrobial resistance, are those systems which control autolysin genes in 
response to cell wall or membrane disturbance. WalKR, also known as YycGF, senses 
disturbance to cell wall integrity through changes in osmotic pressure, including the action of 
lysostaphin, and controls peptidoglycan biosynthesis and turnover with downstream control of 
several autolysin genes including AtlA and LytM (Dubrac et al, 2007). ArlRS and LytRS also sense 
changes in cell wall or membrane integrity and regulate murein hydrolases. As autolysins are 
also involved in adherence to surfaces, these systems also play a role in biofilm formation 
(Brunskill & Bayles, 1996; Fournier & Hooper, 2000; Sharma-Kuinkel et al, 2009). 
TCSs have been identified with important homeostatic functions for iron, potassium and 
nitrogen. The Heme-sensor system HssRS plays an important part in iron homeostasis by 
preventing excess accumulation of intracellular heme. High concentrations of extracellular 
heme lead to upregulation of the heme efflux system HrtAB thus ensuring that intracellular 
levels are controlled (Torres et al, 2007). KdpDE is primarily understood to be involved in K+ 
homeostasis, directly regulating a K+ pump. It also appears to have a much wider role, not only 
sensing changes in osmolarity and coordinating response to osmotic stress, but also having a 
number of downstream effects on virulence genes including cell surface proteins and exotoxins 
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(Freeman et al, 2013). It could therefore be considered as part of the wider stress response and 
may have a role to play in response to phagocytosis. NreBC is activated in low oxygen conditions 
and regulates nitrate reductases and transporters, enabling nitrate respiration in oxygen 
depleted environments (Schlag et al, 2008). Although not well characterized, YhcSR is also 
thought to play a role in nitrate respiration (Sun et al, 2005). 
SrrAB responds to both hypoxia and nitrosative stress caused by nitrous oxide. Downstream 
regulation of genes involved in cytochrome biosynthesis, nitrous oxide detoxification, 
anaerobic metabolism and production of polysaccharide intracellular adhesin (PIA) results in 
adaptation to these stress conditions (Kinkel et al, 2013; Pragman et al, 2004). PIA production 
is understood to be important for protection against non-oxidative neutrophil killing 
mechanisms (Ulrich et al, 2007).  
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Table 1.1  Two component systems in S. aureus 
A summary of 13 of the 16 putative TCSs which have been characterised in S. aureus. The 
histidine kinase and response regulator pairings are shown (HK followed by RR), with the 
principal signals, functions and key references. Several of the TCSs are known by more than one 
name. AMP = antimicrobial peptide. AIP = autoinducing peptide 
Name Signal Functions References 
ArlRS Cell wall /membrane 
integrity 
Autolysis regulation, biofilm 
formation 
Fournier & Hooper 
(2000) 
AgrCA AIP Quorum sensing, virulence 
gene regulation 
Novick et al (1995) 
BraRS/ 
NsaRS 
AMPs AMP resistance Hiron et al (2011) 
 
GraRS/ 
ApsRS 
Cationic AMPs, 
membrane charge 
AMP resistance, oxidative and 
thermal stress response 
Falord et al (2011) 
 
HssRS 
 
Haem Iron homeostasis Torres et al (2007) 
KdpDE K+ , osmolarity Potassium transport, osmotic 
stress response 
Freeman et al (2013) 
LytRS Cell wall /membrane 
integrity 
Autolysis regulation, biofilm 
formation 
Brunskill & Bayles 
(1996) 
NreBC Oxygen depletion Nitrate respiration, anaerobic 
growth 
Schlag et al (2008) 
SaeRS 
 
Hydrogen peroxide, 
pH, osmolarity 
Virulence regulation, oxidative 
stress response 
Geiger et al (2008) 
Jeong et al (2012) 
SrhRS/ 
SrrAB 
Oxygen depletion, 
nitrous oxide 
Hypoxic and nitrosative stress 
response 
Kinkel et al (2013) 
Pragman et al (2004) 
VraRS AMPs, cell wall active 
antibiotics 
AMP, antibiotic resistance Pietiäinen et al (2009) 
WalKR/ 
YycFG 
Osmotic pressure, 
lysostaphin 
Cell wall turnover, autolysis, 
biofilm formation 
Dubrac et al (2007) 
YhcSR Nitrate Control of cell growth, nitrate 
respiration 
Sun et al (2005) 
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1.3.1.2 The SaeRS TCS 
SaeRS is thought to fulfill an integral role in virulence gene expression in vivo, responding to cell 
membrane perturbation due to changes in pH, oxidative stress and osmolarity, particularly 
useful in coordinating a response to phagocytes (Geiger et al, 2008). SaeRS is under the control 
of two promoters. The P3 promoter lies immediately upstream of SaeRS and is repressed by 
SaeR, creating a negative feedback mechanism such that the Sae locus will return to a steady 
state following upregulation. Further upstream, the P1 promoter controls transcription of both 
SaePQ and SaeRS, is activated by agr but repressed by SigB (Geiger et al, 2008). SaePQ form a 
complex with SaeS, promoting phosphatase activity and resetting the TCS to a resting state 
(Jeong et al, 2012). While SaeRS activation initially results in the upregulation of both cell 
surface protein and exotoxin genes, SaePQ enables differential activation of these genes as the 
exotoxin gene promoters have higher affinity for phosphorylated SaeR and so respond to lower 
concentrations. dŚŝƐ ŐŝǀĞƐ ^ĂĞZ^ ƚǁŽ  ‘ŵŽĚĞƐ ? ŽĨ ĂĐƚŝŽŶ ĚĞƉĞŶĚŝŶŐ ŽŶ ǁŚŝĐŚ ƉƌŽŵŽƚĞƌ ŝƐ
activated, enabling upregulation of both sets of virulence genes by P3, or primarily exotoxin 
genes by P1 (Jeong et al, 2012). SaeRS therefore regulates virulence genes in a coordinated 
manner with agr while retaining the flexibility to upregulate both exotoxin and cell surface 
protein genes. The capacity to respond to environmental signals and membrane damage 
represent an important mechanism for high level induction of virulence genes in vivo. 
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1.3.1.3 Quorum sensing 
When the signal recognised by TCSs is produced by the bacteria, cell density dependent signal 
ĂĐĐƵŵƵůĂƚŝŽŶ ŽĐĐƵƌƐ ƚŚƌŽƵŐŚ Ă ƉŽƐŝƚŝǀĞ ĨĞĞĚďĂĐŬ ůŽŽƉ ? Ă ƉŚĞŶŽŵĞŶŽŶ ŬŶŽǁŶ ĂƐ  ‘ƋƵŽƌƵŵ
sensing ?  ?QS) (Williams et al, 2000). In several Gram negative bacteria, N-acyl homo-serine 
lactones act as this signal, diffusing through cell membranes and binding to intracellular 
receptors (Withers et al, 2001). In Gram positive bacteria, small post-translationally modified 
peptides fulfil this role by binding to cell surface receptors (Winzer & Williams, 2001). QS 
systems can control various subsets of genes depending on the organism. In Bacillus subtilis 
and Streptococcus pneumoniae, QS systems regulate genetic competence while in other 
bacteria such as Lactococcus lactis, the production of antimicrobial peptides are controlled by 
QS (Kleerebezem et al, 1997). In S. aureus, the accessory gene regulator (agr) QS system 
regulates a large number of genes, including those associated with exotoxin expression, cell 
surface proteins and metabolism (Novick, 2003). 
As global regulation of toxin expression could be an important determinant of severity in PVL 
associated infections, particularly in CA-MRSA, a summary of the current understanding of the 
most important regulatory systems in S. aureus; principally agr, and the staphylococcal 
accessory regulator SarA and its homologues, are presented below, followed by specific details 
pertaining to the toxins of interest described above. 
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1.3.2 The accessory gene regulator (agr) 
1.3.2.1 Mechanism of action and function 
agr is pivotal to gene regulation in S. aureus, allowing for the coordinated expression of a 
multitude of genes involved in toxin production, adhesion, cell metabolism and growth (Recsei 
et al, 1986). agr consists of two operons controlled by divergent promoters agrP2 and agrP3 
which initiate respectively the transcription of RNAII, responsible for density dependent 
signaling, and RNAIII, the effector RNA, which in turn stimulates or represses a host of other 
genes (Janzon et al, 1989; Novick et al, 1995) (Figure 1.3). RNAIII, which also encodes the toxin 
delta-haemolysin, was first identified as restoring an agr regulatory phenotype to an agr null 
mutant and is one of the first examples of target gene regulation by RNA through an antisense 
mechanism (Morfeldt et al, 1995; Novick et al, 1993). The RNAII transcript encodes four genes 
agrBDCA conferring functions in signal generation, release and detection. AgrB, a 
transmembrane peptidase, processes the AgrD propeptide, resulting in the secretion of small 
auto inducing peptides (AIPs) (Qiu et al, 2005; Saenz et al, 2000). These possess an endocyclic 
ring of between 7 and 9 amino acids in length with a central cysteine residue (Mayville et al, 
1999). The AIPs, bind to the transmembrane histidine kinase receptor AgrC, resulting in 
phosphorylation of intracellular AgrA which has strong affinity for the P2 promoter immediately 
activating it, and weaker affinity for P3 (Koenig et al, 2004; Lina et al, 1998). The result is a 
positive feedback loop in which accumulation of AIP leads to further AIP production and 
eventual activation of P3 when a threshold concentration is reached. There are four agr groups 
in S. aureus, each with a different AIP sequence and corresponding AgrC receptor where the 
AIP of one group will only activate its cognate AgrC receptor while inhibiting heterologous AgrCs 
(Ji et al, 1997).  
As the upregulation of agr depends on an accumulation of AIP, a classical QS pattern is observed 
where simultaneous release of AIP by a dense group of cells results in coordinated gene 
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regulation. This is normally observed in vitro during the transition from exponential to 
stationary phase (Ji et al, 1995), but is also understood to occur during an infection as bacteria 
growing within a confined space such as an abscess or hair follicle will undergo this transition 
quickly; producing toxins enabling tissue destruction and metastasis to other body sites 
(Loughman et al, 2009). agr expression by internalised bacteria occurs within the host 
endosome shortly before escape (Qazi et al, 2001). 
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Figure 1.3  The accessory gene regulator 
The accessory gene regulator (agr) (A) in S. aureus encodes a quorum sensing system whereby 
the AgrD propeptide is post-translationally modified and exported by AgrB in the form of a 
cyclic thiolactone autoinducing peptide (AIP). AgrC, a histidine protein kinase, is 
autophosphorylated in response to AIP with subsequent phosphotransfer to the response 
regulator AgrA. AgrA binds to the agrP2 and agrP3 promoters resulting in positive feedback of 
AIP production and transcription of the regulatory mRNA RNAIII when an activation threshold 
is reached. RNAIII upregulates exotoxin gene expression and downregulates cell surface protein 
expression, both directly and through modifying the translation of other regulators such as the 
repressor of toxin (rot). Adapted from Rutherford and Bassler (2012). 
The structure of the agr group 1 peptide AIP-1 is shown in B. Substituting the 5th amino acid, an 
aspartate, for an alanine (marked with an arrow) results in a cross-group AgrC antagonist 
(ala5)AIP-1 (McDowell et al, 2001). Adapted from Jensen et al (2008). 
 
  A 
B 
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1.3.2.2 Role in pathogenesis 
The agr system has demonstrated clinical importance. agr mutants have reduced capacity to 
cause abscesses as compared with the wild type when tested in various murine and rabbit 
models including septic arthritis, skin abscess, osteomyelitis and endocarditis (Abdelnour et al, 
1993; Cheung et al, 1994; Cheung et al, 2011; Gillaspy et al, 1995). Although agr mutants are 
recovered from clinical specimens, they tend to be from chronic infections such as in cystic 
fibrosis and device-related infections where the bacteria often survive within a biofilm (Goerke 
& Wolz, 2004). The phenotype of an agr mutant is characterised by low to absent production 
of exotoxins, with corresponding upregulation of protein A and other cell surface associated 
proteins (Recsei et al, 1986). As toxin production, and therefore toxin-mediated pathology, 
appears to be heavily reliant on a functional agr, therapeutic interference with agr has been 
considered as a strategy for treating acute infections. The co-inoculation of a type I strain with 
type II AIP prevented abscess formation, demonstrating the potential merit of this approach 
(Wright et al, 2005a). Through substitution of the endocyclic aspartate for an alanine in AIP-1, 
a cross group inhibitory AIP has been developed with activity in the nanomolar range (Chan et 
al, 2004; McDowell et al, 2001) (Figure 1.3B). Conversely, inhibition of agr has been shown to 
enhance initial biofilm development (Vuong et al, 2000), which could theoretically exacerbate 
or predispose to chronic or device-related staphylococcal infection where biofilms play a major 
role, an effect which has been observed in S. epidermidis agr mutants (Vuong et al, 2004); 
further in vivo modelling data is required to investigate this possibility.  
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1.3.3 The Sar protein family 
While agrP2 and agrP3 primarily respond to activation by a phosphorylated AgrA, other 
regulatory proteins also bind and modulate their function, predominantly members of the S. 
aureus regulator SarA protein family (Cheung & Projan, 1994; Chien & Cheung, 1998). The 
regions of the agrP2 and agrP3 promoters to which SarA in particular bind have been well 
characterised through a variety of methods (Chien & Cheung, 1998; Sterba et al, 2003). As SarA 
interaction activates these promoters, this influences the threshold concentration of AIP 
required for agrP3 activation and subsequent RNAIII transcription. agr activity, in turn, alters 
the transcription of SarA and a number of SarA homologues, described below, creating complex 
regulatory networks which allow the bacteria to respond to different environmental pressures. 
The integrated, layered network of regulation between agr, Sar proteins and other regulators 
is summarised in Figure 1.4. 
The SarA protein family consists of a number of related regulatory proteins, some of which have 
only been recently identified. All of these proteins are understood to share in common a winged 
helical structure, believed to be important for their DNA binding function (Liu et al, 2006). SarA 
is a 124-residue protein which forms a dimeric structure with a single DNA binding domain (Liu 
et al, 2006). Some of the family, such as the 250-residue protein SarS, are larger and contain 
two domains within a single monomeric structure (Cheung et al, 2008). MgrA is similar to SarA 
but shares a greater percentage of its sequence with a regulatory protein found in Gram 
negative bacteria, MarR (Ingavale et al, 2005). The family can therefore be divided into three 
groups; the single domain proteins SarA, SarR, SarT, SarV, SarX and Rot, the double domain 
proteins SarS, SarU and SarY and the MarR homologs, MgrA and SarZ (Cheung et al, 2008) 
(Figure 1.5). 
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Figure 1.4  Integrated virulence gene regulation in S. aureus 
The agr quorum sensing system integrates with the Sar proteins to form a regulatory network 
enabling coordinated gene regulation in response to cell density and other environmental 
signals. While agr is primarily activated by AIP through quorum sensing, it is also upregulated 
by SarA, SarU and downregulated by SigB. agr expression can also be altered following the 
activation of various TCSs (e.g. SrrAB) in response to environmental signals, although this may 
also be mediated by Sar proteins such as SarR and SarA. RNAIII inhibits the translation of Rot 
and SarT mRNA while promoting exotoxin gene translation. Repression of SarT and Rot result 
in reduced activation of SarS and cell surface protein gene expression (e.g. spa) but 
derepression of exotoxin genes (e.g. hla) and SarU. SaeRS can upregulate exotoxin genes 
directly in response to environmental signals, particularly oxidative stress. Many of the Sar 
proteins, including SarZ and SarA, can also bind directly to target gene promoters to alter gene 
transcription. 
Adapted from Felden et al (2011) and Cheung et al (2008). 
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Figure 1.5  Structural comparison of members of the SarA protein family 
The SarA protein family can be grouped into 3 depending on protein structure. The single 
domain proteins such as SarA and SarR dimerise to form a winged-helix structure, with each 
dimer consisting of 5 ɲ-helixes and 3 ɴ-strands. The double domain proteins, including SarS and 
SarU, have a monomeric structure consisting of two homologous but non-identical halves 
(labelled below as SarS1 and SarS2), also forming a similar winged-helix. MgrA and SarZ have 
an asymmetrical structure and share greater sequence similarity with the MarR-like regulatory 
proteins found in Gram negative bacteria. Adapted from Cheung et al (2008). 
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1.3.3.1 SarA 
The sarA locus was initially identified in a transposon mutant exhibiting numerous changes in 
the expression of extracellular and cell wall associated proteins (Cheung et al, 1992). SarA 
regulates target genes by directly binding to their promoter regions and also indirectly by 
modulating agr activity as described above (Liu et al, 2006). While the interplay of SarA and 
other regulators is extremely complicated, the overall impact of SarA activity appears to be to 
enhance post-exponential exotoxin expression (Cheung et al, 2004). SarA is expressed in vivo 
and appears to play an important role in pathogenesis; in a rabbit model of endocarditis an 
agr/sar double mutant was more attenuated than an agr single mutant (Cheung et al, 1994). 
 
1.3.3.2 Other SarA homologs 
The other SarA homologs have both overlapping and divergent functions, combining together 
to form a regulatory network. SarS primarily upregulates protein A expression while acting as a 
repressor of exotoxin expression (Tegmark et al, 2000). SarS expression is dependent on SarT 
which is, in turn repressed by RNAIII and SarA; SarS therefore acts divergently but in 
coordinated equilibrium with agr (Cheung et al, 2004).  
Rot (repressor of toxin) was initially identified by screening a transposon mutant library in an 
agr null background for restoration of exotoxin and protease expression (McNamara et al, 
2000). It has a similar function to SarS, also acting in an opposing manner to the classical 
paradigm of the agr response; repressing toxin genes while upregulating cell surface proteins 
(Saïd-Salim et al, 2003). RNAIII can bind to the rot transcript, preventing its translation 
(Geisinger et al, 2006). Furthermore mutation of rot in an agr null strain restored virulence in a 
rabbit model of endocarditis, suggesting suppression of rot may be a key feature of the agr 
response in vivo (McNamara & Bayer, 2005). 
36 
 
The MarR homolog MgrA is involved in autolysis regulation  W an MgrA mutant exhibited 
increased autolysis (Ingavale et al, 2005). In addition, MgrA also displays similar function to the 
agr response, upregulating expression of exotoxin genes (Luong et al, 2006). As MgrA has only 
been identified relatively recently, the significance of this co-regulation of autolysis and 
virulence genes is not fully understood but raises interesting questions about the impact of the 
bacterial stress response on virulence, and the interplay between antibiotic resistance and 
bacterial virulence in vivo. 
Genome analysis is continuing to reveal transcriptional factors with homology to existing Sar 
proteins. SAUSA300_2452 was identified by analysing the USA300 genome and found to share 
close homology with SarZ and MgrA, with several other MarR like proteins also identified 
elsewhere in the genome (Ibarra et al, 2013). 
 
1.3.4 The sigma factor SigB 
The sigma factor SigB is a key component of the staphylococcal stress response and in a normal 
strain background will repress agr activity, particularly following exposure to environmental 
stresses (Cheung et al, 1999). The laboratory strain NCTC8325-4 has a deletion in the rsbU gene 
which encodes a positive regulator of SigB. An rsbU restored derivative SH1000 exhibited 
reduced exotoxin production, presumably due to SigB mediated inhibition of agr expression 
(Horsburgh et al, 2002).  A mutation in the genes for a kinase pknB, a positive regulator of sigB, 
in clinical strains, including USA300, resulted in the opposite effect; agr activity and 
consequently exotoxin production were upregulated in response to environmental stress, 
enhancing virulence in a murine skin abscess model (Tamber et al, 2010). 
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1.3.5 Regulation of specific toxins 
Of the three exotoxins principally implicated in the pathogenesis of CA-MRSA and other PVL 
associated infections, the regulation of alpha haemolysin is the best understood. It can be 
considered as the classical example of exotoxin regulation in S. aureus, usually used as an 
indicator of exotoxin expression in the studies of staphylococcal regulators referred to above. 
Expression of alpha haemolysin was linked to bacterial growth as early as 1971 and 
subsequently found to be primarily regulated by agr via RNAIII (Duncan & Cho, 1971; Recsei et 
al, 1986). 
By contrast, the regulation of PVL has not been comprehensively investigated, although there 
is reasonable evidence to suggest that agr plays an important role (Bronner et al, 2000; Cheung 
et al, 2011). A number of studies have examined the effect of antibiotic exposure on PVL 
expression since  sub-inhibitory concentrations of beta-lactam antibiotics provoke an increase 
in transcription of the lukSF-PV genes (Dumitrescu et al, 2007) as has previously been observed 
for alpha haemolysin (Ohlsen et al, 1998). Protein synthesis inhibitors appear to suppress 
translation but not transcription of several toxin genes, including lukSF-PV (Stevens et al, 2007). 
The full mechanism for beta-lactam-mediated induction of toxin is currently unknown; however 
a more recent study employing strains carrying mutations in key regulators identified a 
potential role for both SarA and Rot (Dumitrescu et al, 2011). As the strain used in this study, 
RN6390, carries a mutation in rsbU which results in the phenotype of a sigB mutant, this finding 
should be interpreted with caution. The mechanism proposed by Dumitrescu et al (2007) is that 
SarA and Rot are recruited following antibiotic binding to specific PBPs, notably PBP1, with the 
involvement of the autolysis regulatory system as a potential intermediary step. As, unlike 
alpha haemolysin and PSMs, the lukSF-PV genes are carried on a phage, Wirtz et al (2009) were 
able to induce PVL toxin expression through stimulation of phage replication by mitomycin C, 
although this did not occur in USA300 as the prophage appeared to have a defect resulting in 
failed excision. The potential for PVL upregulation beyond the activity of core staphylococcal 
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regulators is an interesting prospect; expression of the lukSF-PV genes as measured by RT-PCR 
of pus from drained abscesses was greater than could be explained by agr activity alone, 
although interaction with human neutrophils appeared to increase pvl expression 
independently of agr, explaining some of this discrepancy (Loughman et al, 2009). 
Cheung and colleagues demonstrated that the genes for PSMs beta, psmɴ1 and psmɴ2, are 
expressed more than 60 fold greater in a wild type USA300 strain over an agr mutant (Cheung 
et al, 2011). This effect was more dramatic than changes observed in RN6390 or the HA-MRSA 
strain 252, and was suggested as a contributing factor to the virulence of USA300. The PSMs 
are regulated through an agr dependent but RNAIII independent mechanism, with the 
promoter instead responding directly to binding of phosphorylated AgrA (Queck et al, 2008). 
As the recurring theme with all three of these toxins is the regulation of expression by agr and 
related regulators, this does lend itself to a potential unifying theory of pathogenesis where 
both high level strain specific and induced in vivo activity of major regulators is important. 
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1.4 Study aims 
The recent global spread of PVL producing CA-MRSA and MSSA is a threat to public health and 
so, it is incumbent on us to gain a clearer understanding as to why these strains are so 
successful. The balance of the literature indicates a role for the PVL toxin, other cytolytic toxins 
such as the PSMs and global regulation of virulence factors. Much of the research so far has 
focused on CA-MRSA, particularly USA300, with comparatively little known about PVL 
expression in MSSA strains. Although PVL expression is known to be, at least partially, regulated 
by agr, a comprehensive understanding of PVL toxin regulation is lacking. 
The aims of this study are as follows: 
x To determine whether PVL toxin expression varies in locally circulating MSSA strains 
and to explore why this variation occurs. 
x To gain a better understanding of how agr regulates PVL expression and to determine, 
whether there is a potential role for quorum sensing inhibitors in managing PVL 
associated infections. 
x To study locally successful MSSA isolates in detail through whole genome sequencing, 
placing them in context with globally important lineages.  
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2 Materials and Methods 
 
2.1 Growth media and antibiotics 
Unless otherwise stated, all media were prepared using distilled water and sterilised by 
autoclaving for 20 min at 6.9 kPa, 121 oC. 
 
2.1.1 Brain heart infusion (BHI) 
Brain heart infusion (Oxoid)   37 g/L 
Bacteriological agar No. 1 (1.5 % (w/v)) was added to prepare BHI agar. 
 
2.1.2 CYGP 
Casamino acids (Becton Dickinson)  10 g/L 
Yeast extract (Oxoid)    10 g/L 
Glucose (Sigma)    5 g/L 
Sodium chloride (Fisher scientific)  5.9 g/L 
 ? ? ?DƐƚŽĐŬƐŽůƵƚŝŽŶŽĨɴ-glycerophosphate (Sigma) was prepared in deionised water, filter 
sterilised and added to the media at a concentration of 40 ml/L before use. 
 
2.1.3 Lysogeny Broth (LB) 
Tryptone (Oxoid)    10 g/L 
Yeast extract (Oxoid)    5 g/L 
Sodium chloride (Fisher scientific)  10 g/L 
Bacteriological agar No. 1 (1.5 % (w/v)) was added to prepare LB agar. 
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2.1.4 Tryptone soya broth (TSB) 
Tryptone soya broth (Oxoid)   30 g/L 
Bacteriological agar No. 1 (1.5 % (w/v)) was added to prepare tryptone soya agar. 
 
2.1.5 LK 
Tryptone (Oxoid)    10 g/L 
Yeast extract (Oxoid)    5 g/L 
KCl      16 g/L 
 
2.1.6 Antibiotics 
Growth media for E. coli were supplemented as required with: carbenicillin (Cb) at 50 µg/ml, 
ampicillin (Amp) at 50 µg/ml or kanamycin (Kan) at 50 µg/ml. Growth media for S. aureus were 
supplemented with: erythromycin (Ery) at 10 µg/ml, chloramphenicol (Cm) at 10 µg/ml or 
tetracycline (Tet) at 10 µg/ml. 
  
42 
 
2.2 Bacterial strains and plasmids 
2.2.1 Bacterial strains 
2.2.1.1 S. aureus 
Strains of S. aureus used in this study are listed in Table 2.1. Strains were kept at -80 oC in 
glycerol stocks for long-term storage or at -4 oC on BHI agar for short term storage. 
For standard growth, strains were grown aerobically in BHI or CYGP broth at 37 oC with shaking 
at 250 rpm. Optical density was measured at 600 nm (OD600), using a Jenway 6705 
spectrophotometer. 
 
2.2.1.1.1 Sourcing of clinical strains 
Clinical isolates were cŽůůĞĐƚĞĚĨƌŽŵƚŚĞůŝŶŝĐĂůDŝĐƌŽďŝŽůŽŐǇ>ĂďŽƌĂƚŽƌǇĂƚYƵĞĞŶ ?ƐDĞĚŝĐĂů
Centre (Nottingham University Hospitals NHS Trust). Once identified by the clinical laboratory, 
isolates were stored on nutrient agar slopes (Oxoid). Isolates were retrieved from slopes by 
plating on Columbia agar (Oxoid) and grown overnight at 37 oC. 
Clinical strains were also provided by collaborators at Bath University (Ruth Massey, Maisem 
Laabei) or ordered from NARSA (Network for Antimicrobial Resistance in Staphylococcus 
aureus, Virginia, United States). 
 
2.2.1.1.2 Growth with exogenous AIPs 
Specific AIPs (AIP-1, AIP-2, AIP-3) and agr inhibitors, including the global inhibitor (ala5)AIP-1 
(McDowell et al, 2001), were provided by Dr. Weng Chan, Centre for Biomolecular Sciences, 
University of Nottingham. For agr activation and inhibition experiments, 100 nM of the desired 
AIP was added to the culture medium prior to inoculation unless stated otherwise. 
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Table 2.1  S. aureus laboratory strains used in the study 
Name Genotype Source 
RN4220 8325-4 restriction negative derivative rsbU- (Kreiswirth et al, 1983) 
ROJ48 ZE ? ? ? ?ȴĂŐƌ P PErmB agrP3-lux TetR ErmR (Jensen et al, 2008) 
ROJ143 ROJ48 pAgrC1agrA (Jensen et al, 2008) 
ROJ154 ROJ48 pAgrC3agrA Rasmus Jensen (Unpublished) 
TS112 ROJ48 pAgrC-N267I This work 
TS113 ROJ48 pAgrC-I311T This work 
TS114 ROJ48 pAgrC-Y251F This work 
TS115 ROJ48 pAgrC-A343T This work 
TS119 ROJ48 pAgrC-N267I-Y251F This work 
TS120 ROJ48 pAgrC-I311T-A343T This work 
TS143 ROJ48 pAgrC-L245A This work 
TS144 ROJ48 pAgrC-F264A This work 
TS145 ROJ48 pAgrC-N308A This work 
TS152 ROJ48 pAgrC-T247I This work 
CYL12349 RN4220 attB2 Ɖz> ? ? ?ȴ ? ? (Lei et al, 2012) 
MY15 ROJ48 attB2::P2agrC1agrA Maho Yokoyama 
(Unpublished) 
MY20 ROJ48 attB2::P2agrC1agrA AgrC-N267I Maho Yokoyama 
(Unpublished) 
BH1ȴŵĞĐ , ?ȴŵĞĐ P PdĞƚR (Rudkin et al, 2012) 
 
TetR = Tetracycline resistance. ErmR = Erythromycin resistance. 
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Table 2.2  S. aureus clinical isolates used in the study 
Name Characteristics and clinical details if known agr 
group 
Source 
TS1 ST1518 MSSA spa t1941 PVL+ 
Fatal necrotising pneumonia 
1 NUH NHS Trust 
TS2 ST772 MRSA spa t657 PVL+ 
Thigh abscess 
2 NUH NHS Trust 
TS3 MRSA PVL-  
Perineal wound 
4 NUH NHS Trust 
TS4 MRSA PVL-  
Recurrent boils 
1 NUH NHS Trust 
TS5 ST772 MSSA spa t657 PVL+ 
Axillary boil 
2 NUH NHS Trust 
TS6 ST22 MSSA spa t6642 PVL+ 
Wound infection following hip surgery 
1 NUH NHS Trust 
TS7 ST30 MSSA spa t021 PVL+ 
Nasal carriage 
3 NUH NHS Trust 
TS8 ST772 MSSA spa t657 PVL+ 
Facial abscess 
2 NUH NHS Trust 
TS9 ST22 MSSA spa t6642 PVL+ 
Wound infection following hip surgery 
1 NUH NHS Trust 
TS10 MSSA PVL- 
Abdominal wound infection 
1 NUH NHS Trust 
TS11 MSSA PVL- 
Dialysis fistula infection and recurrent bacteraemia 
2 NUH NHS Trust 
TS12 ST30 MSSA spa t021 PVL+ 
Wound infection 
3 NUH NHS Trust 
TS13 ST22 MSSA spa t005 PVL+ 
Leg abscess 
1 NUH NHS Trust 
TS14 ST22 MSSA spa t005 PVL+ 
Leg ulcer 
1 NUH NHS Trust 
TS15 ST30 MSSA spa t021 PVL+ 
Recurrent boils 
3 NUH NHS Trust 
TS16 ST30 MSSA spa t021 PVL+ 
Thigh abscess 
3 NUH NHS Trust 
TS17 ST22 MSSA spa t852 PVL+ 
Nasal carriage 
1 NUH NHS Trust 
TS18 ST22 MSSA spa t005 PVL+ 
Foot wound 
1 NUH NHS Trust 
TS19 ST22 MSSA spa t310 PVL+ 
Back abscess 
1 NUH NHS Trust 
TS20 ST22 MSSA spa t005 PVL+ 
Knee bursitis 
1 NUH NHS Trust 
TS21 ST88 MSSA spa t6769 
Empyema 
3 NUH NHS Trust 
TS22 MSSA PVL- 
Recurrent bacteraemia 
2 NUH NHS Trust 
TS23 ST22 MSSA spa t6642 PVL+ 
Cellulitis and bacteraemia in an IVDU 
1 NUH NHS Trust 
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TS24 ST22 MSSA spa t005 PVL+ 
Cellulitis on foot and bacteraemia 
1 NUH NHS Trust 
TS25 ST22 MSSA spa t6642 PVL+ 
Severe pneumonia following a viral illness 
3 NUH NHS Trust 
TS27 MRSA PVL+ 
Recurrent boils 
1 NUH NHS Trust 
TS31 MSSA PVL+ 
Necrotising pneumonia 
1 NUH NHS Trust 
TS32 MSSA PVL+ 
Prostatic abscess 
1 NUH NHS Trust 
TS33 MSSA PVL+ 
Bacteraemia associated with prostatic abscess 
1 NUH NHS Trust 
SANOT01 MRSA PVL+ 
Aortic root abscess 
3 NUH NHS Trust 
NRS123 MW2/USA400 CC1 Type IVa MRSA PVL+ 
 
3 NARSA 
NRS133 NCTC8325 MSSA 
 
1 NARSA 
NRS162 ST30 MSSA 
 
3 NARSA 
NRS255 CC80 Type IV MRSA 
 
3 NARSA 
NRS384 USA300 CC8 Type IVa MRSA 
 
1 NARSA 
TW20 ST20 
 
1 Ruth Massey 
HU24 ST239 AgrC-I311T-A343T 
 
1 Ruth Massey 
IU12 ST239 AgrC-I311T 
 
1 Ruth Massey  
DEU9 ST239 AgrC-I311T-A343T 
 
1 Ruth Massey  
BH1CC CC8 type II MRSA 
 
1 (O'Neill et al, 
2008) 
ICP5014 ST239 
 
1 Ruth Massey 
ICP5062 ST239 AgrC-T247I 
 
1 Ruth Massey  
 
MSSA = Methicillin sensitive S. aureus. MRSA = Methicillin resistant S. aureus. NUH = 
Nottingham University Hospitals. CC = Clonal complex. ST = Sequence type. PVL = Panton-
Valentine Leukocidin. IVDU = intravenous drug user.  
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2.2.1.2 E. coli 
TOP10 E. coli (F- ŵĐƌA?(mrr-hsdRMS-mcrBC) I 80 ůĂĐA?D ? ?A?ůĂĐy ? ?ƌĞĐ ?ĚĞŽZĂƌĂ ? ? ?A?(ara-
leu) 7697 galK rpsL (StrR) endA1 nupG) (Invitrogen) was used for plasmid manipulation and 
propagation. Growth conditions were similar to S. aureus except that LB broth was used as the 
growth medium. 
 
2.2.2 Plasmids 
Plasmids used in this study are listed in Table 2.3. 
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Table 2.3  Plasmids used in this study 
Name Genotype Source 
pSK5630  pSK1 rep and par rrnBT1 bla cat CmR (Grkovic et al, 2003) 
pSKermP2 pSK5630 ermB P2agr ErmR, CmR (Jensen et al, 2008) 
pAgrC1agrA pSKermP2 agrC1 agrA ErmR, CmR (Jensen et al, 2008) 
pAgrC3agrA pSKermP2 agrC3 agrA ErmR, CmR Rasmus Jensen (Unpublished) 
pAgrC-N267I pAgrC1agrA AgrC-N267I This work 
pAgrC-I311T pAgrC1agrA AgrC-I311T This work 
pAgrC-Y251F pAgrC1agrA AgrC-Y251F This work 
pAgrC-A343T pAgrC1agrA AgrC-A343T This work 
pAgrC-N267I-Y251F pAgrC1agrA AgrC-N267I-Y251F This work 
pAgrC-I311T-A343T pAgrC1agrA AgrC-I311T-A343T This work 
pAgrC-L245A pAgrC1agrA AgrC- L245A This work 
pAgrC-F264A pAgrC1agrA AgrC- F264A This work 
pAgrC-N308A pAgrC1agrA AgrC- N308A This work 
pAgrC-T247I pAgrC1agrA AgrC- T247I This work 
pLL102 Derivative of pCL25 carrying attP2 
TetR 
(Lei et al, 2012) 
pEJM5 pLL102 TetR , KanR Ewan Murray (Unpublished) 
pEJM6 pEJM5 P2agrC1agrA TetR, KanR Ewan Murray (Unpublished) 
pMYP3 pLL102 P2agrC1agrA AgrC-N267I 
TetR, KanR 
Maho Yokoyama 
(Unpublished) 
 
TetR = Tetracycline resistance. ErmR = Erythromycin resistance. CmR = Chloramphenicol 
resistance. KanR = Kanamycin resistance. 
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2.3 DNA purification techniques 
2.3.1 Genomic DNA preparation 
Genomic DNA was extracted from S. aureus as follows: 5 ? ? ʅů ŽĨ ŽǀĞƌŶŝŐŚƚ ĐƵůƚƵƌĞ ǁĂƐ
centrifuged at 17,000 x g for 5 min and the supernataŶƚĚŝƐĐĂƌĚĞĚ ? ?ʅůůǇƐŽƐƚĂƉŚŝŶ5 mg/ml 
 ?^ŝŐŵĂ ? ? ?ʅůZEĂƐĞ1 mg/ml (Qiagen ?ĂŶĚ ? ? ?ʅůĞŶǌǇŵĂƚŝĐůǇƐŝƐďƵĨĨĞƌ ? ? ? mM Tris pH 8, 2 
mM EDTA, 1.2 % (v/v) Triton X-100) were added to each pellet and incubated for 30 min at 37 
°C. Purification of DNA was then performed using a DNeasy kit (Qiagen), according to the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ P ? ?ʅůŽĨƉƌŽƚĞŝŶĂƐĞ<ĂŶĚ ? ? ?ʅůďƵĨĨĞƌ>ǁĞƌĞĂĚĚĞĚĂŶĚŵŝǆĞĚ
by vortexing. This was incubated at 70 oĨŽƌ ? ?ŵŝŶďĞĨŽƌĞƚŚĞĂĚĚŝƚŝŽŶŽĨ ? ? ?ʅů ? ? ?A? ?ǀ ?ǀ ?
ethanol.  The resulting mixture was transferred into a DNeasy mini spin column and centrifuged 
in a microfuge at 10,500 x g for 1 min, discarding the flow through and collection tube. 500 µl 
buffer AW1 was then added, the column centrifuged at 10,500 x g for 1 min and the flow 
through and collection tube discarded. After this, 500 µl buffer AW2 was added and the column 
spun for 17,000 x g for 3 min. Finally, 100 µl sterile deionised water was added, incubated for 1 
min at room temperature and then centrifuged at 10,500 x g for 1 min to elute the DNA. 
 
2.3.2 Plasmid preparation 
2.3.2.1 Plasmid preparation from E. coli 
Cells were grown overnight in LB broth with addition of the appropriate antibiotics to maintain 
selective pressure.  A 1.5 ml aliquot was removed and centrifuged at 17,000 x g for 2 min and 
the supernatant removed. Plasmid extraction and purification was then performed using a 
QIAprep Spin Miniprep kit (Qiagen) according to the manufactureƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ P ? ? ?A?ůďƵĨĨĞƌ
P1 was added followed by 250 µl buffer P2, mixed by inversion and left to stand for 3 min. 350 
µl buffer N3 was added to the mixture and vortexed thoroughly to produce a homogeneous 
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suspension which was then centrifuged at 17,000 x g for 10 min in a microfuge. The supernatant 
was transferred into spin columns with collection tubes and centrifuged at 17,000 x g for 1 min 
with flow through discarded. 500 µl PB buffer was added before centrifuging for a further 1 min 
at 17,000 x g, discarding the flow through. Finally, 750 µl PE buffer was added, centrifuging for 
1 min at 17,000 x g, discarding the flow through, and then centrifuging for a further 1 min to 
remove any residual ethanol from the spin column. The plasmid DNA was eluted by adding 50 
µl sterile deionised water, incubating at room temperature for 1 min and centrifuging at 17,000 
x g for 1 min. 
 
2.3.2.2 Plasmid preparation from S. aureus 
Cells were grown overnight in BHI broth with addition of the appropriate antibiotics. A 3 ml 
aliquot was removed and centrifuged at 17,000 x g for 2 min and the supernatant removed. 
Cells were resuspended in 250 ʅů P1 lysis buffer from a QIAprep Spin Miniprep Kit (Qiagen) with 
the addition of 5 ʅů ůǇƐŽƐƚĂƉŚŝŶ5 mg/ml (Sigma) and incubated for 30 min at 37oC. Plasmid 
extraction and purification was performed with the QIAprep Spin Miniprep kit as described 
above. 
 
2.3.3 RNA preparation 
Bacterial isolates were inoculated from overnight cultures at a 1:500 dilution and grown in BHI 
broth for 4 h, until mid exponential phase. 1 ml of RNA Protect (Qiagen) was added to 0.5 ml of 
each bacterial culture before pelleting the mixture by centrifugation at 5,200 x g for 10 min and 
removing the supernatant. Pellets were stored at -80 oC prior to extraction of RNA. 
195 µl of TE buffer (10 mM Tris HCl, pH 8.0, 1 mM EDTA) and 5 µl lysostaphin 5 mg/ml (Sigma) 
were added to the pellets prior to extraction. The mixture was incubated at room temperature 
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for 20 min and vortexed regularly. RNA was extracted and purified using an RNeasy Mini kit 
 ?YŝĂŐĞŶ ?ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ P  ? ? ?A?ů Z>d ďƵĨĨĞƌ ? ĐŽŶƚĂŝŶŝŶŐ  ?A?ůɴ-
mercaptoethanol, was added to the mixture, mixed by vortexing and centrifuged at 13,000 x g 
for 2 min. The supernatant was decanted into a new tube and 500 µl 100 % ethanol (v/v) added 
before 600 µl aliquots were transferred to spin columns, centrifuging at 13,000 x g for 1 min 
after each aliquot was added. 700 µl buffer RW1 was then added and the column centrifuged 
at 13,000 x g for 1 min, discarding the flow through and collection tube. After this, 500 µl RPE 
was added, the column centrifuged at 13,000 x g for 1 min, a further 500 µl RPE added and the 
column centrifuged again at 13,000 x g for 2 min. To elute the RNA, the column was placed in 
a microfuge tube, 100 µl sterile RNAse free water (Qiagen) added and incubated at room 
temperature for 1 min before centrifuging at 13,000 x g for 1 min. 
Before conversion to cDNA, RNA samples were treated with Turbo DNase (Ambion) according 
ƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ P ? ?A?ůǆ ? ?dƵƌďŽEĂƐĞďƵĨĨ ƌĂŶĚ ?A?ů ? ?h ?dƵƌďŽEĂƐĞ
was added to 100 µl RNA sample and incubated at 37 oC for 30 min. The RNA was then re-
purified with the RNeasy Mini kit as described above. The absence of genomic DNA was verified 
by PCR as described in 2.4.2, using the RNA preparation as template and a genomic DNA 
preparation as the positive control.  
 
2.3.4 Purification of PCR products 
PCR products were purified using a QIAquick spin column (Qiagen) according to the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ PŝŶĚŝŶŐďƵĨĨĞƌǁĂƐĂĚĚĞĚƚŽWZƉƌŽĚƵĐƚĂƚĂƌĂƚŝŽŽĨ ?ǀŽůƵŵĞƐ
to 1 and mixed by vortexing. The mixture was transferred to a spin column in a collection tube 
and centrifuged at 17,000 x g for 1 min, with the flow through discarded.  750 µl binding buffer 
was then added to the spin column, centrifuged at 17,000 x g for 1 min, discarding the flow 
through and then centrifuged at 17,000 x g for a further 1 min to remove any residual ethanol. 
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Finally, the column was transferred to a microfuge tube, 50 µl sterile deionised water added, 
incubated at room temperature for 1 min and centrifuged at 17,000 x g for 2 min to elute the 
DNA. 
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2.4 DNA manipulation techniques 
2.4.1 Primer design 
Primers were designed by analyzing the required amplification regions with Vector NTI 
software (Invitrogen).  Predicted melting and annealing temperatures were calculated with the 
New England Biolabs Tm calculator (www.neb.com/tools-and-resources/interactive-tools/tm-
calculator). Once designed, primer specificity was verified with a BLAST search 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
Primers were synthesized by Sigma-Aldrich and stored at -20oC as 10 µM working solutions or 
100 µM stock solutions. For use in the promoter pull down experiments, forward primers were 
ƐǇŶƚŚĞƐŝǌĞĚ ǁŝƚŚ  ? ? ďŝŽƚŝŶǇůĂƚŝŽŶ ? &Žƌ ƵƐĞ ŝŶ ƐŝƚĞ-directed mutagenesis, all primers were 
ƐǇŶƚŚĞƐŝǌĞĚǁŝƚŚ ? ?ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ?&ŽƌƵƐĞŝŶƋƵĂŶƚŝƚĂƚŝǀĞZd-PCR, primers were designed as 
previously published by Dumitrescu et al (Dumitrescu et al, 2011) and purified by 
polyacrylamide gel electrophoresis. The primers used for agr ƐĞƋƵĞŶĐŝŶŐŐƌ ?഻ ?Őƌ ?഻ ?
AgrB F, agrC R were originally designed by Traber et al (Traber et al, 2008). 
Primers used in the study are listed in Table 2.4. 
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Table 2.4  Primers used in the study 
Name ^ĞƋƵĞŶĐĞ ? ? ?ƚŽ ? ? ? Application 
AgrBDCAF ACAACTCATCAACTATTTTCC agr amplification 
AgrBDCAR GATTTACAATTGAATACGCCG agr amplification 
Pvl F ATGTCCTTTCACTTTAATTTCATGAGTTTT pvl testing 
Pvl R CATGCTACTAGAAGAACAACACACTATGG pvl testing 
AgrpromoR B (B)ACAACTCATCAACTATTTTCC Pulldown 
AgrpromoR TCTCTTTTGAAGATACGTGGC Pulldown 
PvlpromoF TACTTATATTGCTAATAGTGG Pulldown 
PvlpromoF B (B)TACTTATATTGCTAATAGTGG Pulldown 
PvlpromoR ATTCTCAATATTGTTATCAGC Pulldown 
AgrD1234F TATGCACCTGCAGCTACTAA agr typing 
AgrD1234R TCATGACGGAACTTGCGC agr typing 
Agrfull F GCAACGCGAAAATATACCTG agr sequencing 
Agrfull R GCGTTGCTGCAATAGTGACA agr sequencing 
AŐƌ ?഻ AAAGAGATGAAATACAAACG agr sequencing 
AŐƌ ?഻ ATTAACAACTAGCCATAAGG agr sequencing 
AgrB F AATAAAATTGACCAGTTTGC agr sequencing 
agrC R GAATAATACCAATACTGCGAC agr sequencing 
AgrC-N267I-F (P)AGACAATTTACAAATGAATGCTATAAAATTA SDM 
AgrC-N267I-R (P)TTCATAGGTACAATAATTTTATTGAAATAAT SDM 
AgrC-Y251F-F (P)CACTTTCAGAATTCATTCGAGAAGATGA SDM 
AgrC-Y251F-R (P)TCGTTAAGATATTGACATAATCATGACG SDM 
AgrC-A343T-F (P)GATAATGCAATTGAGACATCAACTGAAA SDM 
AgrC-A343T-R (P)AAGAATAATACCAATACTGCGACTTAAATC SDM 
AgrC-I311T-F (P)AAATGAATATTCCGACTAGTATCGAAATACC SDM 
AgrC-I311T-R (P)CTTGTGCACGTAAAATTTTCGCAGTAAT SDM 
AgrC-L245A-F (P)ATTATGTCAATATCGCAACGACACTTTCAG SDM 
AgrC- L245A-R (P)CATGACGGAACTTGCGCA SDM 
AgrC-F264A-F (P)GGCCTACGTGATTATGCTAATAAAAATATTGTACC SDM 
AgrC- F264A-R (P)AGGCATGTCATCTTCTCGAATGTA SDM 
AgrC-N308A-F (P)GCACAAGAAATGGCTATTCCGATTAGTATC SDM 
AgrC- N308A-R (P)ACGTAAAATTTTCGCAGTAATTAAGCCTT SDM 
AgrC- T247I-F4 (P)TACTTTCAGAATACATTCGAGAA SDM 
AgrC- T247I-R4 (P)TCGTTAAGATATTGACATAATCAT SDM 
GyrB F GGTGGCGACTTTGATCTAGC qRT-PCR 
GyrB R TTATACAACGGTGGCTGTGC qRT-PCR 
LukS-PV F AATAACGTATGGCAGAAATATGGATGT qRT-PCR 
LukS-PV R CAAATGCGTTGTGTATTCTAGATCCT qRT-PCR 
RNAIII F GGGATGGCTTAATAACTCATAC qRT-PCR 
RNAIII R GGAAGGAGTGATTTCAATGG qRT-PCR 
EJM63 ATACGAATTCCCATGGCAACTATTTTCCATCACA agr cloning 
EJM65 ATCGGATCCGTTAACTGACTTTATTATC agr cloning 
 
(P) =  ? ?ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ?  ? ?A?  ? ?ďŝŽƚŝŶǇůĂƚŝŽŶ ?^DA?ƐŝƚĞĚŝƌĞĐƚĞĚŵƵƚĂŐĞŶĞƐŝƐ ? qRT-PCR = 
quantitative real time PCR. 
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2.4.2 PCR amplification 
A high-fidelity DNA polymerase, Phusion (New England Biolabs), was used in all reactions. 
Components of a standard 50 µl reaction, made up with sterile deionised water, were as 
follows: 
5 x Phusion HF buffer    10 µl 
dNTPs      200 µM each 
Primers      0.5 - 1 µM each 
Template     1 pg  W 10 ng 
Phusion DNA polymerase   1 U 
 
PCR reactions were carried out on a T3000 ThermoCycler (Thistle Scientific). Standard settings 
used were: 
1 cycle  Initial denaturation 98 oC  2 min 
30 cycles Denaturation  98 oC  10 s 
  Annealing  55-69 oC 30 s 
  Extension  98 oC  30 s per kb (2 min minimum) 
1 cycle  Final extension  72 oC  2 min 
PCR products were stored at -20 oC. 
 
2.4.3 Agarose gel electrophoresis 
DNA samples were separated by electrophoresis in 1.5 % (w/v) agarose gels made up with 1 x 
TAE buffer (40 mM Tris acetate, 2 mM EDTA ph 8.5). To enable visualization of DNA, ethidium 
bromide was added to the molten agarose at a final concentration of 0.4 µg/ml. Samples were 
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prepared in DNA loading buffer (Promega) and gels run in 1 x TAE at 100 V for 30 to 60 min. A 
1 kb DNA ladder (Promega) was also run on the gel to enable comparison of DNA fragment size. 
After electrophoresis, bands were visualized using a UV transilluminator. 
 
2.4.4 Ligation of PCR products 
DNA Ligase enzyme (Invitrogen) was used for ligation as follows: 7 µl PCR product was mixed 
with 2 µl x 10 ligase buffer, 1 µl ligase enzyme and 10 µl sterile deionised water. The mixture 
was incubated at room temperature overnight before use. 
 
2.4.5 Small scale DNA sequencing 
Following purification of PCR products or preparation of plasmid, DNA was sent to Source 
Bioscience Life Sciences (Nottingham) for sequencing along with aliquots of the appropriate 
sequencing primers. 
 
2.4.6 Sequence analysis 
All sequence analysis and alignment, except for analysis of next generation sequencing data, 
was carried out using Vector NTI Advance 11.0 software (Invitrogen) with consensus sequences 
shown in yellow, partial matches in blue and non-consensus bases shown in white. GenBank 
reference sequences were obtained from the National Center for Biotechnology Information at 
www.ncbi.nlm.nih.gov. Reference sequences used are listed in Table 2.5. Next generation 
sequencing data was analysed as described in 2.8. 
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Table 2.5  S. aureus reference sequences used in this study 
Name Description GenBank Accession ID 
NCTC 8325 Laboratory MSSA, agr group 1 reference CP000253.1 
HO 5096 0412 HA-MRSA, SCCmec IV, representative of EMRSA-15 HE681097.1 
MW2  ? ?ɌDt ? ? CA-MRSA, SCCmec IV, agr group 3 reference NC_003923.1 
N315  HA-MRSA, SCCmec II, agr group 2 reference BA000018.3 
h^ ? ? ? ? ?Ɍ^>d ? CA-MRSA, SCCmec IV CP000255.1 
ɌWs> Prophage carrying the pvl gene NC_012784 
ɌƚƉ ? ? ?-1 Prophage isolated from ST22 spa-310 strain EF462197 
ɌƚƉ ? ? ?-3 Prophage isolated from ST22 spa-310 strain EF462199 
 
 
 
  
57 
 
2.4.7 Molecular characterisation of clinical isolates 
S. aureus agr types were determined by amplifying and sequencing agrD with agrD1234F and 
agrD1234R primers. The resulting sequences were aligned to reference strains of known agr 
type. 
spa typing and Multi-Locus Sequence Typing (MLST) were carried out by Kome Otokunefor 
(Otokunefor et al, 2012). 
 
2.4.8 Reverse transcriptase PCR 
cDNA was synthesised from RNA samples with Superscript II reverse transcriptase (Invitrogen) 
ĂĐĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ P ? ?A?ůZEƉƌĞƉĂƌĂƚŝŽŶ ?ĂƉƉƌŽǆŝŵĂƚĞůǇ ?A?Ő ?ǁĂƐ
mixed with 1 µl dNTPs (10 mM) and incubated at 65 oC for 5 min before addition of 4 µl 5x first 
strand buffer and 2 µl 0.1 M DTT. This mixture was left at room temperature for 2 min before 
addition of 1 µl superscript II enzyme, made up to 20 µl total with sterile deionised water. The 
reaction mixture was heated to 25 oC for 10 min, 42 oC for 50 min and 70 oC for 10 min to 
generate the cDNA. 
cDNA was cleaned up with a QIAquick PCR purification kit (Qiagen) as described in 2.3.4 and 
yields verified using a Nanodrop ND-1000 spectrophotometer (Labtech) testing for ssDNA at a 
wavelength range of 220 nm to 350 nm with an extinction coefficient of 33 ng-cm/µl. cDNA 
samples were stored at -20 oC prior to comparative gene quantification. 
 
2.4.9 Quantitative real-time PCR  
cDNA templates were amplified using a Power SYBR Green Master mix (Life Technologies 
Corporation) according to the manufacturer ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?ǁŝƚŚĂŵƉůŝĨŝĐĂƚŝŽŶƌĞĐŽƌĚĞĚďǇĂŶ
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AB7500 Real-time PCR System (Applied Biosystems). The PCR mixture for each well consisted 
of: 
2 x SYBR Green Master mix   12.5 µl 
Forward primer     0.75 µl 
Reverse primer     0.75 µl 
cDNA template     2 µl 
Deionised water    9 µl 
The primers for gyrB F, gyrB R, lukS-PV F, lukS-PV R, RNAIII F and RNAIII R (Table 2.4) were first 
tested using serial dilutions of a single cDNA template to ensure primers worked efficiently at 
a 1:1 ratio of forward to reverse primer.  
Once primer efficiency had been established, comparative cycle threshold (CT) values were 
recorded for each combination of primer and template in triplicate. The comparative CT values 
were used to calculate relative expression of the target genes lukS-PV and RNAIII, with gyrB 
acting as a constitutively expressed control. 
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2.5 Transformation techniques 
2.5.1 Transformation of E. coli 
2.5.1.1 Preparation of E. coli electrocompetent cells 
4 ml of overnight culture was placed in 400 ml LB and incubated at 37 oC with shaking to OD 
0.4-0.6. The flask was placed on ice with occasional swirling for 20 min before centrifugation at 
4000 x g, 4oC for 10 min. After the supernatant was poured off, pellets were resuspended in 25 
ml ice cold sterile water and spun again. This wash step was repeated twice before 
resuspension of the pellets in 10 % (v/v) glycerol in water. Aliquots were snap frozen in liquid 
nitrogen and stored at -80 oC. 
 
2.5.1.2 Transformation of E. coli by electroporation 
10 µl of plasmid or ligated PCR product was added to an aliquot of electrocompetent cells and 
transferred to a 1 mm electroporation cuvette, keeping cells on ice throughout. Electrical 
current was delivered at 200 ɏ, 1.75 kV and 25 µF before addition of 1 ml LB broth. Cells were 
incubated for 1 h at 37 oC for recovery before plating 200 µl onto LB agar, containing the 
appropriate antibiotic for selection, and incubated at 37 oC overnight. 
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2.5.2 Transformation of S. aureus 
2.5.2.1 Preparation of S. aureus electrocompetent cells 
A single colony was placed in 500 ml BHI broth and grown for 14 h overnight at 37 oC with 
shaking. This was diluted to OD 0.1 in 500 ml BHI and grown to OD 0.4-0.6, allowing growth for 
no longer than 90 min at 37 oC with shaking. The resulting culture was split into 10 x 50 ml tubes 
and centrifuged for 10 min at 3,400 x g with supernatant discarded, before resuspension of the 
pellets in 25 ml deionised water and further centrifugation for 10 min at 3,400 x g. This wash 
step was repeated twice more, before resuspension of the pellets in 20 ml 10 % (v/v) glycerol 
in water. After centrifugation for 10 min at 3,400 x g, the pellets were re-suspended in 10 ml 
10 % (v/v) glycerol and incubated for 30 min at room temperature. Following a final 
centrifugation, pellets were pooled and resuspended in the residual 10 % (v/v) glycerol left after 
decanting of the supernatant with 60 µl aliquots taken and frozen immediately at -80 oC. 
 
2.5.2.2 Transformation of S. aureus by electroporation 
5, 10 or 15 µl of plasmid preparation was added to a 50 µl aliquot of electrocompetent cells 
and transferred to a 1 mm electroporation cuvette. Electrical current was delivered at 100 ɏ, 
2.3k V and 25 µF before immediate addition of 1 ml BHI broth. Cells were incubated for 3 h at 
37 oC for recovery before plating 200 µl onto BHI agar containing the selection antibiotic for 
growth at 37 oC overnight. 
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2.5.3  Phage transduction 
The construction of S. aureus strains MY15 and MY20 by phage transduction was carried out by 
Maho Yokoyama as part of her MSc project, as described below. 
A plasmid, pEJM6, was constructed by introducing the wild type group 1 agrP2BDCA genes, 
amplified with primers EJM63 and EJM65, onto the integrative plasmid pEJM5. pEJM6 was 
transformed into a chromosomal integration strain of Staphylococcus aureus, CYL12349, with 
selection for kanamycin resistance, resulting in integration of agrP2BDCA at an attB2 site on 
CYL12349. 
Phage lysate was prepared from the CYL12349 intermediate strains by mixing 200 µl overnight 
culture with LK broth and phage buffer (1 mM MgSO4, 4 mM CaCl2, 50 mM Tris-HCl, 100 mM 
EĂů ? ?Ő ?>ŐĞůĂƚŝŶƉŽǁĚĞƌŝŶĚĞŝŽŶŝƐĞĚǁĂƚĞƌ ?ŝŶĂ ? P ?ƌĂƚŝŽ ? ? ? ?A?ůɌ ? ?ZE ? ? ?0B lysate was 
added and the mixture incubated at 30 oC with shaking until clear. 
KŶĐĞƉƌĞƉĂƌĞĚ ?ƚŚĞůǇƐĂƚĞƐǁĞƌĞƵƐĞĚƚŽƚƌĂŶƐĚƵĐĞƚŚĞȴagr::agrP3-lux bioreporter ROJ48 as 
follows; 1.8 ml LK broth, 10 µl 1 M CaCl2, 200 µl overnight ROJ48 culture and 200-500 µl phage 
lysate were incubated for 45 min at 37 oC with shaking. 1 ml of 20 mM trisodium citrate was 
added to the mixture and incubated on ice for 5 min followed by centrifugation at 17,000 x g. 
for 2 min. The pellet obtained was resuspended in 1 ml 20 mM trisodium citrate and placed on 
ice for 2.5 h. 200 µl of the mixture was plated on tryptic soy agar containing 10 mM trisodium 
citrate and incubated at 37 oC. Following transduction, the resulting colonies of ROJ48 were 
confirmed to have the agrP2BDCA genes integrated at an ectopic chromosomal location, 
following phage integration, creating the S. aureus strain MY15.  
MY20 was made by introducing AgrC-N267I into pEJM6 by site directed mutagenesis, to make 
pMYP3, before integrating onto CYL12349 and transduction with ROJ48 as described above. 
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2.6 Protein analysis 
2.6.1 Exoprotein sample preparation  
The desired S. aureus clinical isolates for analysis were inoculated into CYGP broth and grown 
overnight, unless otherwise stated. A volume equivalent to an OD600 of 5 was calculated using 
the formula: volume = OD600/5. The calculated volume of culture was centrifuged at 17,000 x g 
for 5 min and the supernatant removed and filter sterilised. 100 % (w/v) trichloroacetic acid 
was added to the supernatant in a microfuge tube at a final concentration of 10 % (v/v), 
incubating on ice for 1 h. The mixture was centrifuged at 17,000 x g for 5 min and the 
supernatant ĚŝƐĐĂƌĚĞĚ ? ? ? ?ʅůĂĐĞƚŽŶĞǁĂƐĂĚĚĞĚƚŽƚŚĞŵŝĐƌŽĨƵŐĞƚƵďĞĂŶĚƚŚĞƚƵďĞǀŽƌƚĞǆĞĚ
thoroughly to disrupt the pellets. After centrifugation at 17,000 x g for 5 min, the pellets were 
ǁĂƐŚĞĚǁŝƚŚĂĨƵƌƚŚĞƌ ? ? ?ʅůĂĐĞƚŽŶĞǁŚŝĐŚǁĂƐƌĞŵŽǀĞĚĨŽůůŽǁŝŶŐĐĞŶƚƌŝĨƵŐĂƚŝŽn. The pellets 
ǁĞƌĞĂůůŽǁĞĚƚŽĚƌǇĨŽƌ ?ŵŝŶŝŶĂŝƌ ?ĂĨƚĞƌǁŚŝĐŚ ? ?ʅů^^-PAGE buffer (Nupage) was added. 
Samples were heated to 80 oC for 3 min prior to loading. 
 
2.6.2 SDS-PAGE 
Routine SDS-PAGE was performed using a 12 % (w/v) acrylamide resolving gel consisting of: 
30 % (w/v) acrylamide/Bis (BioRad)   4 ml 
1.5 M Tris-HCl (pH 8.8)     2.5 ml 
Deionised water     3.35 ml 
10 % (w/v) SDS       ? ? ?ʅů 
10 % (w/v) ammonium persulphate (APS)   ? ? ?ʅů 
TEMED        ? ?ʅů 
The APS and TEMED were added immediately before pouring, and a layer of isopropanol was 
added to the top of the gel after pouring.  
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Once the resolving gel had set, the isopropanol was removed and a stacking gel added, placing 
a comb on top immediately to create separate wells. The stacking gel consisted of: 
30 % (w/v) acrylamide/Bis (BioRad)   0.83 ml 
0.5 M Tris-HCl (pH 6.8)     0.62 ml 
Deionised water     2.5 ml 
10 % (w/v) SDS       ? ?ʅů 
10 % (w/v) ammonium persulphate (APS)   ? ?ʅů 
TEMED        ?ʅů 
Once the stacking gel had set, the comb was removed and the gel placed in a Protean II (BioRad) 
gel-running tank filled with SDS-PAGE running buffer (14.4 g/L glycine, 3 g/L Tris base, 1 g/L SDS 
in deionised water).  Samples (5 to 20 µl) were loaded into the wells, with purified LukF 
(provided by Charles Okolie, Microbiology, Centre for Biomolecular Sciences) and alpha-
haemolysin (Sigma) used as positive controls.  10 µl of Novex Sharp protein standard 
(Invitrogen) was also loaded to determine protein sizes. Proteins were separated by 
electrophoresis at 150 V until the blue dye front of the sample buffer reached the base of the 
gel.  
 
2.6.3 Coomassie blue staining 
Proteins were visualized by staining with SimplyBlueTM Safe Stain (Novex) according to the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ P'ĞůƐǁĞƌĞĨŝƌƐƚƐŽĂŬĞĚŝŶĚĞŝŽŶŝƐĞĚǁĂƚĞƌĨŽƌ ? ?ŵŝŶ ?ĐŚĂŶŐŝŶŐƚŚĞ
water after 5 min. The gels were covered in the staining fluid and left for 1 h. Finally, gels were 
rinsed and left to destain in deionised water for a further h or until the protein bands could be 
clearly seen.  
 
64 
 
2.6.4 Immunoblots 
Proteins were first separated by SDS-PAGE as described in 2.6.2.  A BioTrace®NT nitrocellulose 
membrane (PALL life sciences, USA) was cut to the same size as the SDS-PAGE gel and protein 
transferred from gel to membrane using the BioRad II Mini-Cell and Electroblotting Module 
ĂĐĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?dƌĂŶƐĨĞƌǁĂƐĐĂƌƌŝĞĚŽƵƚŝŶďůŽƚƚŝŶŐďƵĨĨĞƌ ?14.4 
g/L glycine, 3 g/L Tris, 1 g/L SDS in deionised water) at a fixed current of 140 mA for 1 h. The 
membrane was stained reversibly with Ponceau S solution (Sigma) to confirm successful protein 
transfer before proceeding to immunoblot. After rinsing with deionised water, the membrane 
was blocked in 5 % (w/v) skimmed milk in phosphate buffered saline (PBS pH 7.4) for 2 h or 
overnight. 
Immunoblotting was performed by incubating the membrane with 1/1000 (v/v) anti-LukF or 
1/2000 (v/v) anti-Hla mouse monoclonal antibodies (Prof. L. Durrant, School of Medicine, 
University of Nottingham), in 5 % (w/v) skimmed milk in PBS for 1 h. After 2 x 15 min washes 
with PBS Tween (PBS pH 7.4 with 0.05 % (v/v) Tween 20), the membrane was incubated in 
secondary antibody solution containing 1/3000 (v/v) protein A-Horseradish peroxidise 
conjugate (Sigma) in conjugate buffer (50 mM Tris, 100 mM NaCl pH 8.0) for 1 h.  
Following 2 x 15 minute washes in conjugate buffer containing 0.05 % (v/v) Tween 20, the 
membrane was coated in ECL substrate (GE Healthcare) for 2 min and exposed to film 
(Amersham Hyperfilm ECL, GE Healthcare) in the dark room. 
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2.7 Promoter pull down experiments 
2.7.1 Generation of biotinylated promoter probes by PCR 
Biotin labeled primers (Table 2.4) were used to amplify the pvl and agr promoter regions by 
PCR. Ten 50 µl PCR reactions were used per sample which were then pooled and purified as 
described in 2.3.4 with elution in 200 µl sterile deionised water. The DNA concentration of the 
PCR product was not measured prior to use. 
 
2.7.2 Preparation of lysed cell extracts 
Bacterial cultures were grown overnight in 10 ml CYGP before 1:100 dilution into 400 ml of 
CYGP and incubated for 5 h with shaking. Cultures were centrifuged for 10 min at 3,400 x g to 
pellet the bacteria.  Pellets were resuspended in 2 ml of lysis buffer (100 mM NaCl, 10 mM Tris-
HCl pH 8, 1 mM EDTA, 0.05 % (v/v) Triton X-100) before addition of 40 µl of lysostaphin 5 mg/ml. 
After incubation for 1 h at 37 oC, the mixture was homogenised with a Precellys 24 homogenizer 
(Precellys) for 3 cycles, incubating on ice for 5 min between cycles. The lysate obtained was 
centrifuged at 13,000 x g for 10 min to remove any residual cell debris. 20 µl of 100 mM PMSF 
protease inhibitor (Invitrogen) and 50 µl salmon sperm DNA (Invitrogen) was added per 1ml of 
lysate.  
 
2.7.3 Binding of proteins to the promoter fragments 
Following preparation of lysed cell extract, 100 µl of Dynabeads (Invitrogen Dynabeads M-280 
Streptavadin) were placed in a microfuge tube for each sample to be tested. Using a magnetic 
rack, the beads were washed with 1 ml wash buffer 2 X (2 M NaCl, 10 mM Tris-HCl pH 7.4, 1 
mM EDTA) three times before resuspension in 200 µl of the biotinylated promoter PCR product 
for 30 min. 
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After three washes of the beads with 1 ml wash buffer 1 X (1 M NaCl, 5 mM Tris-HCl ph 7.4, 0.5 
mM EDTA), 1 ml of lysed cell extract was added and incubated for 4 h at room temperature, or 
overnight. The beads were washed again for four times with 1 ml lysis buffer (100 mM NaCl, 10 
mM Tris-HCl pH 8.0, 1 mM EDTA, 0.05 % (v/v) Triton X-100) before resuspension in 20 µl elution 
buffer (1.2 M NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.05 % (v/v) Triton X-100).  
 
2.7.4 Separation and identification of promoter bound proteins 
The eluted fraction was mixed with 20 µl SDS-PAGE loading buffer (NuPage, Invitrogen) and 20 
µl loaded onto a 4-12 % precast SDS-PAGE gel (NuPage Novex, Invitrogen) in MES buffer (50 
mM MES, 50 mM Tris base, 0.1 % (w/v) SDS, 1 mM EDTA pH 7.3) and run at 150 V for 1 h. After 
Coomassie blue staining, bands of interest were cut from the gel and sent to the Protein and 
Nucleic Acid Chemistry Laboratory (University of Leicester) for sequencing by mass 
spectrometry. Protein identifications were returned as a list of proteins in each gel band and a 
relative quantification given which accounts for % of spectra and protein molecular weight. 
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2.8 Construction of agr bioreporters and bioreporter assays 
2.8.1 Construction of the group 1 and 3 agr bioreporters 
An agrP3-lux bioreporter strain, ROJ48, was constructed previously by replacing the agr locus 
in RN4220 with an agrP3-luxABCDE promoter fusion and ermB, which confers resistance to 
erythromycin (Jensen et al, 2008). 
Plasmids, based on pSKerm (conferring chloramphenicol and ampicillin resistance), were 
constructed with agrCA of either group 1 or 3 under the control of the agrP2 promoter and 
used to transform ROJ48 to create the group 1 bioreporter ROJ143 (Jensen et al, 2008) and the 
group 3 bioreporter ROJ154 (Rasmus Jensen, unpublished). 
 
2.8.2 Site-directed mutagenesis of the agr group 1 bioreporter 
 ? ?ƉŚŽƐƉŚŽƌǇůĂƚĞĚƉƌŝŵĞƌƐĐontaining the desired point mutations in agrC (Table 2.4) were used 
to amplify the group 1 bioreporter plasmid pAgrC1agrA. PCR products were purified and ligated 
as described in 2.4.4 to create circularized plasmid. 10 µl of ligation product was transformed 
with TOP 10 E. coli, selecting for ampicillin resistance. Plasmid was prepared from a selection 
of successful transformants and sequenced to confirm the desired mutations were present. 
Plasmids with the correct sequence were transformed into ROJ48, selecting for 
chloramphenicol resistance, to create mutant bioreporters. 
 
2.8.3 Bioluminescent reporter assay 
Bioreporter strains were grown overnight at 37 oC in BHI medium with the addition of 
chloramƉŚĞŶŝĐŽů  ? ?ʅŐ ?ŵů ƚŽŵĂŝŶƚĂŝŶƚŚĞƐĞůĞĐƚŝǀĞƉƌĞƐƐƵƌĞŽŶƚŚĞƉůĂƐŵŝĚ ?ƵůƚƵƌĞƐǁĞƌĞ
ĚŝůƵƚĞĚ ? ? ? ?ĂŶĚŝŶĐƵďĂƚĞĚĨŽƌĂĨƵƌƚŚĞƌ ?Ś ? ? ?ʅůŽĨƌĞƉŽƌƚĞƌĐƵůƚƵƌĞǁĂƐƉůĂĐĞĚŝŶƚŽǁĞůůƐŝŶ
Ă  ? ?ǁĞůůŵŝĐƌŽƚŝƚƌĞ ƉůĂƚĞĂŶĚ  ? ?ʅůŽĨ ĞŝƚŚĞƌ ƚĞƐƚ ĐƵůƚƵƌĞ ƐƵƉĞƌŶĂƚĂŶƚŽƌ Ɛynthetic AIP was 
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added, with each sample tested in triplicate. Synthetic AIPs were used as positive controls, with 
ŵĞĚŝƵŵŽŶůǇ ĨŽƌŶĞŐĂƚŝǀĞĐŽŶƚƌŽůƐ ?,/ĐŽŶƚĂŝŶŝŶŐĐŚůŽƌĂŵƉŚĞŶŝĐŽů  ? ?ʅŐ ?ŵůǁĂƐĂĚĚĞĚƚŽ
ĞĂĐŚǁĞůů ?ƚŽĂƚŽƚĂůǀŽůƵŵĞŽĨ ? ? ?ʅů ?ĂŶĚƚŚĞƉůĂƚĞ incubated in an Infinite 200 PRO microplate 
luminometer (Tecan) overnight. Light and OD600 were measured every 15 min over 12 h.  
Data were plotted as relative light units per cell density (RLU/OD) over time in Excel (Microsoft 
Corp.). Peak values from each concentration of AIP were calculated and exported to PRISM2 
program (GraphPad, San Diego, CA). An EC50 value was then generated for each reporter based 
on the variable slope sigmoidal dose response curve. All assays were conducted in triplicate. 
 
2.8.4 Measurement of AIP production over the growth curve 
1 ml of overnight culture from each test isolate was pelleted and washed 3 times in fresh BHI. 
Bacteria were inoculated at a 1:500 dilution in BHI and incubated at 37 oC with shaking. At fixed 
time points, 1 ml of culture was removed, centrifuged and the supernatant filter sterilised. 
Supernatants collected at several time points were analysed with the bioluminescent reporter 
assay, compared to a full dilution range of AIP. If there was sufficient AIP present in the 
supernatants to saturate the bioreporter, assays were repeated with serial dilutions of 
supernatant. Peak values of RLU/OD for each test supernatant were then compared with the 
values generated from the AIP standard curve in order to determine the AIP concentration 
present.  
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2.9  Whole genome sequencing analysis 
Genomic DNA was prepared as described in 2.3.1 and sent to the DeepSeq Facility (University 
of Nottingham) where it was sequenced using a MiSeq benchtop sequencer (Illumina) with a 
2x 150 bp paired end run. 
The raw data was processed with the assistance of a Bioinformatician, Hardeep Naghra (Centre 
for Biomolecular Sciences, University of Nottingham).  
Illumina reads were first mapped to the EMRSA-15 representative genome HO 5096 0412 
(Holden et al, 2013) with the Burrows-Wheeler alignment tool (Li & Durbin, 2009) using the 
default settings. 
Variants were then called with mpileup and bcftools (Li et al, 2009a) using default settings and 
filtering out base quality scores lower than 15. Single nucleotide polymorphisms (SNPs) with 
less than 5 reads were also removed. 
The resulting analyses were produced in *.vcf format which could be analysed, along with the 
BWA alignments, using Artemis 14.0.0 software (Wellcome Trust Sanger Institute, Cambridge). 
A de novo assembly was attempted with velvet de novo assembly software (Zerbino & Birney, 
2008) to find any large unmapped reads. Unmapped reads were analysed with the Basic Local 
Alignment Search Tool (BLAST) at blast.ncbi.nlm.nih.gov (National Center for Biotechnology 
Information, United States). 
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3 Variable PVL production relates to agr activity 
 
3.1 Introduction 
3.1.1 Regulation of exotoxin production in S. aureus 
The regulation of exotoxin virulence determinants in S. aureus relies on the activity of global 
regulators, predominantly agr and the Sar proteins, coordinated in response to environmental 
conditions by TCSs (Bronner et al, 2004). In addition, sigma factors interact with RNA 
polymerase to control regulator and virulence gene transcription in a growth or stress response 
dependent manner (Bronner et al, 2004). Gene promoter regions which are situated upstream 
of transcriptional and translational start codons contain sites for DNA binding proteins to bind 
and either stimulate or repress transcription (Arvidson & Tegmark, 2001). Furthermore, 
translation of mRNAs can be modified through the formation of complexes with regulator RNAs 
(Geisinger et al, 2006). 
There are complex interactions between regulators; for example SarS is expressed during early 
exponential phase while agr activity is low, enhancing protein A expression, while during mid 
to late exponential phase, agr is highly expressed, repressing SarS and hence protein A 
expression while upregulating exotoxins (Arvidson & Tegmark, 2001). 
As an exotoxin, PVL appears to conform to the established paradigm of exotoxin regulation in 
S. aureus, being positively regulated by agr. The precise nature by which agr and the other 
major regulators regulate the pvl genes, which are found on a prophage, is not fully known. 
 
3.1.2 Variable pvl expression by clinical strains 
Enhanced expression of pvl and other exotoxins has been observed by some clinical strains 
compared to others, particularly the CA-MRSA strain USA300 (Li et al, 2009b). The reasons 
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behind variable expression are unclear, although variations in agr activity are believed to be 
important. Whether higher concentrations of secreted PVL exacerbate the severity of infections 
is also not known, although there are some indications that this may be the case. Neutrophils 
either undergo apoptosis or necrosis through exposure to PVL in a concentration dependent 
manner (Genestier et al, 2005). Enhanced expression of agr and core virulence determinants 
by CA-MRSA was associated with reduced survival in a rabbit model (Li et al, 2010). While 
studying in vitro expression gives an indication of the potential of a strain for high level toxin 
expression, it should be borne in mind that this may not always correlate well with expression 
in vivo (Xiong et al, 2002). 
While expression of PVL and other exotoxins has been well studied in CA-MRSA strains, 
particularly USA300, less attention has been paid to PVL MSSA strains which are likely to be 
more diverse, from a greater range of strain backgrounds and hence possess a highly 
heterogeneous phenotype. 
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3.1.3 Chapter Overview  
1. A collection of clinical strains isolated in Nottingham were characterised by molecular 
and phenotypic methods including MLST and analysis of exotoxin production. 
2. The variations in exotoxin production between strains were explored with reference to 
agr, investigating the impact of exogenous AIPs on PVL production. 
3. A promoter pull down assay was developed and used to identify potential regulators 
binding to the agr and pvl gene promoters. 
4. Sequence analysis of the gene promoters and whole agr locus sequence of selected 
strains was carried out to identify polymorphisms that could explain variable exotoxin 
production. 
5. The genomes of two closely related MSSA type 22 strains, TS13 and TS14 with divergent 
PVL phenotypes were sequenced and compared with ST22 strain HO 5096 0412 which 
represents the widespread U.K. EMRSA-15 clone. 
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3.2 Results 
3.2.1 Characterisation of a collection of PVL positive clinical isolates 
A collection of PVL positive clinical isolates were characterised as a starting point for the study. 
Many of these isolates had been initially gathered from the Clinical Microbiology department 
ĂƚYƵĞĞŶ ?ƐDĞĚŝĐĂůĞŶƚƌĞEŽƚƚŝŶŐŚĂŵas part of an MSc project. The aim was to gather strains 
that would represent a range of infections, sample types and patient demographics. Isolates 
were initially identified by the Clinical Microbiology laboratory from clinical samples as S. 
aureus based on colonial appearance, Gram staining, production of catalase and DNAse. This 
was confirmed by the laboratory through a further panel of metabolic tests, and antibiotic 
sensitivities ascertained by a disc diffusion method. 
Twenty five strains were collected initially (TS 1-25), the majority (n=20) of which were PVL 
positive by PCR as previously tested by the Staphylococcus Reference Unit (Laboratory of 
Healthcare Associated Infection, Colindale). Characteristics of the PVL positive clinical isolates 
are summarized in Table 3.1. Clinical presentations included abscesses, infected skin ulcers, 
bacteraemia, pneumonia and carriage isolates. dŚĞƉĂƚŝĞŶƚƐ ?ĂŐĞƐƌĂŶŐĞĚĨƌŽŵ ?ƚŽ ? ?years 
(mean 45.4) with 56% being male. Nearly all (92 %) of the strains were MSSA, reflecting both 
the local epidemiology at the time the strains were collected, and also the frequency of 
identification of a locally circulating PVL-positive MSSA with a characteristic antibiogram 
(gentamicin and trimethoprim resistant only). The majority of PVL positive strains were isolated 
from skin and soft tissue infections, predominantly from swabs submitted to the laboratory by 
general practitioners or hospital admissions units. Two strains (TS6 and TS9) were isolated from 
post-operative infections during a hospital ward-based outbreak. Strains TS1 and TS25 caused 
severe community acquired pneumonia, both resulting in admission to intensive care.  Both of 
these cases of pneumonia had a history suggestive of preceding viral upper respiratory tract 
infection, although a respiratory virus could not be detected in either case.  
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The patient infected with TS1, a 30 year old lady, deteriorated rapidly following admission with 
haemoptysis, severe breathlessness and leucopenia. Despite early treatment with intravenous 
antibiotics, sedation and ventilation, she sadly died less than 72 h into her admission. Post 
mortem analysis of her lung tissue indicated she had died from a severe necrotizing pneumonia, 
most likely as a result of infection with PVL producing S. aureus. This clinical case shares a 
number of similarities with those described by Gillet and colleagues in their clinical case series 
of young immunocompetent patients with necrotizing pneumonia resulting from PVL positive 
S. aureus (Gillet et al, 2002). 
 
3.2.1.1 Molecular characteristics of the strain collection 
Once collected, the strains were genotyped by a number of methods to ascertain which of the 
isolates were more closely related to each other. 
The PVL positive isolates had already been submitted to the Staphylococcus Reference Unit 
(Laboratory of Healthcare Associated Infection, Colindale) where they were tested for the 
presence of PVL and a number of other toxin genes, including tst and enterotoxins, by PCR.  This 
data is included in Table 3.1. 
 
3.2.1.1.1 Testing for the lukSF genes 
Genomic DNA was prepared from all 25 isolates as described in 2.3.1 and presence or absence 
of the PVL genes was confirmed by PCR using the primers pvl F and pvl R (Table 2.4). This gave 
identical results to the reference laboratory; PCR with genomic DNA from the PVL negative 
controls TS3, TS4, TS10, TS11 and TS22 did not result in amplification whereas amplification 
occurred for DNA from the PVL positive isolates. 
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3.2.1.1.2 agr typing 
The entire agr locus of each of the clinical isolates was amplified using the primers AgrBDCAF 
and AgrBDCAR (Table 2.4). The PCR product was sent for sequencing with the cross group AgrD 
primer AgrD1234F. Sequences were aligned with reference genomes representing different agr 
types; S. aureus NCTC 8325, N315 and MW2 for agr types 1, 2 and 3 respectively (see Table 2.5 
for reference sequence descriptions). Depending on which reference genome each agrD gene 
sequence aligned to, the clinical isolates were assigned to one of the three agr groups. One 
isolate, TS3, which did not align to any of the references was found to encode the agr group 4 
AIP and so was assigned to agr group 4. agr group 1 was the predominant group in the 
collection (n=13) followed by group 3 (n=6) and group 2 (n=5). 
 
3.2.1.1.3 MLST and spa typing 
A PCR based method for identifying the Multi-Locus Sequence Type (MLST) and spa type of 
each isolate was performed by Kome Otokunefor (Otokunefor et al, 2012). Seven housekeeping 
genes were amplified by PCR and sequenced before comparing the sequence data to the MLST 
database (http://saureus.mlst.net/) in order to assign each strain to a specific MLST type. 
Shared sequence types occurred only within agr groups as expected. The divergence of agr 
groups is believed to have been an early event in the development of S. aureus, placing much 
of the divergence into strain types after this event (Wright et al, 2005b). 
ST22/agr1 strains (n=10) were the most common of which 5 were the same spa type, t005. The 
ST22 group, all of which were only resistant to gentamicin and trimethoprim, appeared to 
represent the PVL positive gentamicin and trimethoprim resistant isolates which were being 
encountered frequently in the Clinical Microbiology laboratory at the time they were collected 
for the study (2008 to 2010).  
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Other common types were ST30/agr3 (n=4) and ST772/agr2 (n=3).  There was no obvious 
pattern in the distribution of sequence types among the different clinical presentations (skin 
infections, pneumonia, bacteraemia, carriage) although the strain collection is too small to 
make valid statistical comparisons.   
TS1 was found to have a previously unidentified sequence type ST1518. 
 
3.2.1.2 Exotoxin Production 
An important aim of the study was to find out how PVL toxin levels vary between clinical 
isolates. A monoclonal antibody directed against one of the two subcomponents of the PVL 
toxin, LukF, was available (Prof. L. Durrant, School of Medicine, University of Nottingham) and 
so was used to perform western blots against culture supernatants. 
Every PVL positive clinical isolate in the collection was tested by performing western blots on 
exoprotein extracts from culture supernatants collected at several time points. Clinical isolates 
were inoculated into CYGP medium at a 1:1000 final concentration from overnight cultures, 
incubated at 37 oC with shaking at 250 rpm and supernatant collected at several time points. 
Proteins were precipitated from the supernatants and normalised as described in 2.6.1, 
separated by SDS-PAGE, transferred to a nitrocellulose membrane and western blots 
performed with the anti-LukF monoclonal antibody as described in 2.6.4. The level of PVL 
production was determined semi-quantitatively by comparing the band sizes on the western 
blots between isolates.  
Some of the isolates produced a much greater quantity of PVL toxin than others (Figure 3.1). 
For some of the isolates, PVL toxin was barely detectable (Figure 3.2). As growth had been slow 
with a 1:1000 inoculum, the experiment was repeated with a 1:500 inoculum (Figure 3.3) which 
was used for all subsequent experiments. 
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As the quantities of PVL production by clinical strains could not be compared with precision 
ƚŚĞǇǁĞƌĞĐůĂƐƐĞĚĂƐĞŝƚŚĞƌ ‘ůŽǁ ? ?ƐŝŵŝůĂƌƚŽd^ ? ?ĂŶĚd^ ? ? ? ? ‘ŵĞĚŝƵŵ ? ?ƐŝŵŝůĂƌƚŽdS1 an  TS27) 
Žƌ ‘ŚŝŐŚ ? ?ƐŝŵŝůĂƌƚŽd^ ? ? ? ? 
Although a fixed quantity of 100 ng LukF control protein was used for the initial comparisons of 
PVL exotoxin production between all of the TS clinical strains, several different concentrations 
of LukF control were used for subsequent experiments. The concentration of LukF used is 
indicated on the figures so that tentative comparisons can be made between immunoblots. 
Alpha haemolysin (Hla) is a well characterised staphylococcal toxin controlled by agr. An 
antibody to Hla was also used to perform western blots on the same exoprotein preparations 
used for PVL detection to determine whether there was any correlation between the levels of 
PVL and Hla produced.  Isolates which exhibited higher PVL production also showed higher 
levels of Hla (Figures 3.1, 3.3). This finding suggested that the differences noted in PVL 
production could be, at least in part, consequent on differential expression of agr. 
  
 Table 3.1  Characteristics of PVL positive clinical isolates  
ST = sequence type. IVDU = intravenous drug user. NK = not known. se =  staphylococcal enterotoxin.
Name Clinical details agr type Sequence type spa type Other genes of interest LukF expression 
TS1 Fatal necrotising pneumonia 1 ST1518 t1941  Medium 
TS2 Thigh abscess 2 ST772 t657 mecA, sea, sec, seg, sei Low 
TS5 Axillary boil 2 ST772 t657 sea, sec, seg, sei Low 
TS6 Wound infection following hip surgery 1 ST22  t6642 seg, sei High 
TS7 Nasal carriage 3 ST30  t021  sea, seg, sei Low 
TS8 Facial abscess 2 ST772  t657 sea, sec, seg, sei Low 
TS9 Wound infection following hip surgery 1 ST22  t6642 seg, sei High 
TS12 Wound infection 3 ST30  t021 seg, sei Low 
TS13 Leg abscess 1 ST22  t005 seg, sei Low 
TS14 Leg ulcer 1 ST22  t005 seg, sei High 
TS15 Recurrent boils 3 ST30  t021 seg, sei Low 
TS16 Thigh abscess 3 ST30  t021 sea, seg, sei Low 
TS17 Nasal carriage 1 ST22  t852 seg, sei High 
TS18 Foot wound 1 ST22  t005 seg, sei High 
TS19 Back abscess 1 ST22 t310 seg, sei High 
TS20 Knee bursitis 1 ST22  t005 seg, sei High 
TS21 Empyema 3 ST88  t6769 seg, sei Low 
TS23 Cellulitis and bacteraemia in an IVDU 1 ST22 t6642 seg, sei High 
TS24 Cellulitis on foot and bacteraemia 1 ST22  t005 seg, sei High 
TS25 Severe pneumonia following a viral illness 3 ST1  t3342 sed, seg, sei Low 
TS27 Recurrent boils 1 CC8 t008 mecA Medium 
TS31 Necrotising pneumonia 1 NK NK  High 
TS32 Prostatic abscess 1 NK NK  High 
TS33 Bacteraemia associated with prostatic abscess 1 NK NK  Low 
NRS162 Not known 3 ST30 NK  Low 
NRS255 Not known 3 CC80 NK mecA (SCCmecIV) Low 
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Figure 3.1  Exotoxin production by TS1 and TS14 during growth 
Immunoblot (A) probed with anti-LukF and anti-Hla (alpha haemolysin) antibodies and SDS-
PAGE gel (B) showing exotoxin production during growth in CYGP medium. Each lane is labelled 
with the sampling time (h), which is also shown on a growth curve (C). TS14 produced much 
higher quantities of PVL and alpha haemolysin than TS1. The LukF control (500ng,*) forms 
oligomers seen on the SDS-PAGE gel as heavier bands (B). MW = Molecular Weight markers. 
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Figure 3.2  Exotoxin production by TS12, TS16, TS27, NRS162 and NRS255 during growth 
Immunoblots (A) probed with anti-LukF antibodies showing exotoxin production during growth 
in CYGP medium. Each lane is labelled with sampling time (h), which is also shown on a growth 
curve (B). TS12, TS16, NRS162 and NRS255 all produced low quantities of PVL with TS27 
showing moderate PVL production. 200 ng of LukF was used for the immunoblot with TS12 and 
TS16, with 10 ng of LukF used for the immunoblot with TS27, NRS162 and NRS255. 
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Figure 3.3  Exotoxin production by TS13 and TS14 during growth 
Immunoblots (A) probed with anti-LukF and anti-Hla (alpha haemolysin) antibodies and SDS-
PAGE gels (B) showing exotoxin production during growth in CYGP medium. Each lane is labelled 
with sampling time (h), which is also shown on a growth curve (C). TS14 produced higher 
quantities of both PVL and alpha haemolysin than TS13. 10 ng of LukF control was used. MW = 
Molecular Weight markers. 
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CYGP medium was used as previous work in the laboratory had shown it stimulated agr 
expression, making it easier to detect any toxins present in culture supernatants. Exoprotein 
extracts from a high (TS14) and a low level toxin (TS13) producer were tested in a variety of 
different growth media to determine the impact on toxin levels. Growth in CYGP clearly 
resulted in much higher toxin expression than the other growth media tested with toxin barely 
detectable in BHI, LB and TSB (Figure 3.4). 
When comparing the pattern of high and low level toxin producers to the MLSTs and agr types 
(Table 3.1) it became apparent that the isolates producing the most toxin were all agr group 1 
MLST 22 isolates. This was an interesting finding given the frequency that such isolates with a 
gentamicin and trimethoprim resistant antibiogram were being identified by the Clinical 
Microbiology laboratory as causing community-acquired skin and soft tissue infections. Of all 
of the agr group 1, MLST 22 isolates there was one exception, TS13, which appeared to be 
producing less PVL toxin than the others. Alpha haemolysin production was also lower possibly 
indicating reduced agr activity. 
The other two groups of strains within the collection, ST30/agr 3 and ST772/agr 2, appeared to 
produce much less toxin than the ST22/agr 1 isolates. This gives the impression that strain 
background is an important determinant in the level of exotoxin expression although the 
numbers and diversity of strain types represented here are too small to draw any firm 
conclusions. Strain background has previously been noted to be an important determinant of 
toxin gene expression with the USA300 strain background reported to be associated with high 
level toxin expression (Li et al, 2009b). 
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Figure 3.4  PVL production varies depending on the growth medium used  
Immunoblots (A) probed with anti-LukF antibodies and SDS-PAGE gels (B) showing exotoxin 
production during growth in BHI (1), CYGP (2), TSB (3) or LB (4) medium when incubated 
overnight at 37 oC. PVL production was highest in CYGP. 10 ng of LukF control was used on the 
gel. MW = Molecular Weight markers. 
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3.2.2 PVL expression can be modulated by exogenous autoinducing peptides 
3.2.2.1 Stimulation of agr by exogenous AIP increases PVL production 
The initial exotoxin analysis indicated that PVL production could be lower in some of the clinical 
isolates as a result of reduced agr activity. To investigate this possibility further, a selection of 
clinical isolates with low toxin production were cultured in the presence of the synthetic type 
specific AIP. AIP-1 and AIP-3 were both available having been synthesised by collaborators from 
the School of Pharmacy (Dr. Weng Chan, Centre for Biomolecular Sciences, University of 
Nottingham). 
Exogenous synthetic AIP was added at a final concentration of 100 nM to cultures at the time 
of inoculation and incubated overnight in CYGP with shaking at 37 oC. TS13, the low producing 
ST22/agr 1 isolate, and several low producing group 3 isolates, including TS7, TS12, TS21 and 
TS25, all exhibited a marked increase in toxin production following addition of type specific AIP 
(Figure 3.5, data for TS7, 21 and 25 not shown). 
In addition, if AIP-1 was not added to TS13 until mid-exponential phase of growth (t = 6 h), there 
was no increase in toxin production as compared to TS13 with no exogenous AIP-1 added (TS13 
No AIP; Figure 3.5). 
A further experiment was carried out by adding exogenous AIP-1 to TS13 at inoculation and by 
measuring toxin production at several time points during mid and late exponential and early 
stationary phase (t = 5.5 h, 7 h, 8.5 h) and overnight (t = 24 h). AIP-1 was also added to separate 
cultures at those time points during growth (t = 5.5 h, 7 h, 8.5 h). Toxin production was 
detectable from mid exponential phase if AIP-1 was added at the time of inoculation and 
increased markedly by stationary phase (Figure 3.6). However, AIP-1 added at any point from 
mid-exponential phase did not result in increased toxin production when measured at 24 h. 
  
85 
 
Figure 3.5  Activation and inhibition of agr by exogenous AIP alters PVL production 
Immunoblot (A) probed with anti-LukF antibodies and SDS-PAGE gel (B) demonstrating the 
impact of exogenous type specific AIP or the cross-type AgrC antagonist (ala5)AIP-1 to cultures 
either at inoculation (0 h) or during exponential phase (6 h). PVL production was increased 
when type specific AIP was added to TS12 and TS13 at 0 h but no effect was seen when AIP-1 
was added to TS13 at 6 h. PVL toxin production was inhibited by the addition of (ala5)AIP-1 at 0 
h. ŽŶƚƌŽůůĂŶĞƐǁŝƚŚŽƵƚĂĐƚŝǀĂƚŽƌŽƌŝŶŚŝďŝƚŽƌĂƌĞůĂďĞůůĞĚĂƐ ‘EŽ/W ? ?2.5 µg of LukF control 
was used. Strains were grown in CYGP medium at 37 oC. MW = Molecular Weight markers. 
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Figure 3.6  Timing of exogenous AIP addition effects PVL production 
 Immunoblot (A) probed with anti-LukF antibodies and SDS-PAGE gel (B) demonstrating the 
impact of exogenous type specific AIP at inoculation (0 h) or during exponential and stationary 
phase. Timing (h) of supernatant collection is shown above the blot and on the growth curve 
(C) with timing of AIP-1 addition below. The 24 h samples are shown on the gel (B). PVL toxin 
was barely detectable at 5.5 h even when agr was activated with exogenous AIP at 0 h, although 
high levels of PVL had been produced after 24 h. Adding AIP-1 to cultures at 5.5, 7 or 8.5 h did 
not result in high level PVL production when measured at 24 h. 20 ng of LukF control was used. 
Strains were grown in CYGP medium at 37 oC. MW = Molecular Weight markers.  
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The observation that addition of exogenous AIP-1 significantly enhances toxin production if 
added at inoculation but not during exponential phase is an interesting one. This suggests a 
 ‘ǁŝŶĚŽǁƉĞƌŝŽĚ ?ĚƵƌŝŶŐǁŚŝĐŚĞǆƚĞƌŶĂůƐƚŝŵƵůĂƚŝŽŶŽĨagr dramatically influences the kinetics 
of the system, driving toxin production. During exponential phase, the system appears to be 
unresponsive to exogenous AIP, even though PVL production clearly continues during and after 
exponential phase if agr can be stimulated early enough. One possible explanation for this is 
that if agr activity is low going in to exponential phase, repressor proteins which would normally 
be repressed by agr such as SarS and Rot are expressed in higher quantities. These would then 
bind to the agr and toxin gene promoters and prevent significant toxin production from 
occurring, even if agr is stimulated subsequently. 
 
3.2.2.2 agr inhibition reduces PVL expression 
As PVL production appeared to be dependent, at least in part, on agr expression, experiments 
were conducted to determine whether PVL expression could be suppressed by the global agr 
inhibitor (ala5)AIP-1 (McDowell et al, 2001). 
Several of the isolates which displayed the highest toxin production (TS6, TS14, TS20) were 
grown overnight in CYGP with 100 nM (ala5)AIP-1 added at inoculation. All of these displayed 
significant reductions in the amount of secreted PVL detected in the supernatants, although 
this did not prevent PVL expression altogether. An immunoblot of TS14 inhibition is shown in 
Figure 3.5. Identical results were seen if 300 nM or 600 nM of (ala5)AIP-1 was added at 
inoculation (data not shown). 
To determine whether the timing of inhibitor addition was important, 100nM (ala5)AIP-1 was 
added to cultures of one of the high producing isolates, TS14, at inoculation or 2, 4 or 6 h post-
inoculation. PVL production was reduced in the cultures where the inhibitor was added at 
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inoculation or 2 h into growth, but not if the inhibitor was added at 4 or 6 h where no 
differences were observed (Figure 3.7). 
  
89 
 
0.01
0.1
1
10
0 2 4 6 8
G
ro
w
th
 (
O
D
6
0
0
)
Time (hours)
TS14
(ala5)AIP-1 added 
30
40
60
20
LukFMW TS14
0 h 2 h 4 h 6 h
0 h 2 h 4 h 6 h
(ala5)AIP-1
(ala5)AIP-1
No AIP
No AIP
Figure 3.7  Inhibition of PVL production by the AgrC antagonist (ala5)AIP-1 is time/growth 
phase dependent 
Immunoblot (A) probed with anti-LukF antibodies and SDS-PAGE gel (B) demonstrating the 
impact of the AgrC antagonist (ala5)AIP-1 at inoculation (0 h) or during growth. LukF is indicated 
with an arrow in B. Timing (h) of supernatant collection is shown above the bands and on the 
growth curve (C) with timing of AIP-1 addition below. PVL toxin production was inhibited if the 
AgrC antagonist was added at 0 or 2 h but not at 4 or 6 h into growth compared to the TS14 
control (No AIP inhibitor added). All samples taken at 24 h. 10 ng of LukF control was used. 
Strains were grown in CYGP medium at 37 oC. MW = Molecular Weight markers. 
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Anti-Staphylococcal beta-lactam antibiotics such as flucloxacillin are frequently used in clinical 
settings in the UK to treat presumed or confirmed infections with S. aureus. Culturing PVL 
producing S. aureus in the presence of sub-growth inhibitory concentrations of oxacillin results 
in an increase in PVL expression (Dumitrescu et al, 2007; Dumitrescu et al, 2011)  
The low producing ST22/agr 1 isolate TS13 was grown in oxacillin to determine whether these 
clinical isolates used in this study responded similarly. TS13 was inoculated into CYGP 
containing 0.1, 0.25 or 1 µg/ml oxacillin and incubated for 24 h at 37 oC with shaking. Growth 
was markedly reduced in the presence of 0.25 and 1 µg/ml oxacillin but occurred normally in 
the presence of 0.1 µg/ml oxacillin. Western blotting of exoprotein extracts from the culture 
containing 0.1 µg/ml oxacillin revealed a significant increase in PVL production as compared 
with the control culture in a manner similar to that noted following the addition of exogenous 
AIP-1 (Figure 3.8). TS13 was also cultured overnight with both 0.1 µg/ml oxacillin and 100 nM 
(ala5)AIP-1 added at inoculation. In this case, toxin production was greater than baseline but 
much lower than if only oxacillin had been added. This appeared to indicate that the PVL 
production, even if enhanced by oxacillin, was still largely dependent on agr. 
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Figure 3.8 Sub inhibitory oxacillin enhances PVL production 
Immunoblot (A) probed with anti-LukF antibodies and SDS-PAGE gel (B) demonstrating 
induction of PVL production by a sub inhibitory concentration of oxacillin (0.1 µg/ml) which can 
be partially inhibited by the AgrC antagonist (ala5)AIP-1. Oxacillin and (ala5)AIP-1 were added 
to cultures at the time of inoculation. TS13 was then incubated overnight in CYGP medium at 
37 oC. A high quantity of LukF control was used for the immunoblot (>100 ng). A control lane is 
shown for TS13 without the addition of either oxacillin or inhibitor.  
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3.2.3 Analysis of agr and pvl promoter regions 
3.2.3.1 Promoter sequence analysis for selected clinical strains 
Mutations in promoter regions can result in altered gene expression. An 11 bp deletion in the 
promoter of Mga, a global regulator in Streptococcus pyogenes, resulted in reduced mga 
transcripts and attenuated virulence (Flores et al, 2013). Villaruz et al (2009) found a point 
mutation in the agrP2 promoter of a strain of S. aureus  causing dysfunction of agr resulting in 
abnormally high protein A expression. This mutation occurred in one of the four putative AgrA 
binding sites of which two are present in both the agrP2 and agrP3 promoters (Koenig et al, 
2004; Morfeldt et al, 1995). A separate binding region for SarA has also been proposed, 
covering the gap between agrP2 and agrP3 (Sterba et al, 2003). 
To determine whether there were any obvious mutations/deletions/polymorphisms in 
important promoter regions that could explain the phenotypic variation observed, the agr and 
pvl promoter regions of selected clinical strains representing different agr groups and toxin 
expression phenotypes (TS1, TS2, TS3, TS12, TS13, TS14, TS25) were sequenced and compared 
with reference genomes. 
 
3.2.3.1.1 Analysis of agr promoter sequences 
Following amplification of the entire agr locus of selected strains with primers agrBDCAF and 
agrBDCAR, agr promoter regions were sequenced with primers agrBDCAF and agrpromoR 
(Table 2.4). Promoter sequences were aligned to S. aureus N315 and the ST22 MRSA HO 5096 
0412, which represents EMRSA-15 (Figure 3.9, Table 2.5). The agr group 3 reference genome 
MW2 was identical to N315 across the promoter region so was not included. 
There were no SNPs in any of the AgrA or SarA binding regions of the clinical strains. The 
sequences of the low producing ST22/agr 1 strain TS13 and the high producing ST22/agr 1 
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strain TS14 were identical to each other, and also to HO 5096 0412, so agr promoter variation 
could not account for the phenotypic differences observed between them. 
Compared with N315, TS1, TS3 and TS12 all had an A to T SNP at N315 base 2,079,278 in the 
penultimate base of the agrP3 promoter in the -10 RNA polymerase recognition site (Figure 
3.9). Although TS3 is PVL negative, both TS1 and TS12 showed low expression of PVL toxin. 
Alpha haemolysin production was observed in TS1 and so it appears that agr is still functional 
in this strain. It is conceivable that this polymorphism could interfere with RNAIII transcription, 
particularly by weakening the association with RNA polymerase, although -10 and -35 
recognition site sequences often vary by several bases while still retaining functionality (Zhang 
& Stewart, 2000). 
TS13 and TS14 both had a C to A SNP in the middle of the agrP2 promoter at N315 base 
2,079,373 (Figure 3.9). This substitution was also present in HO 5096 0412 and so appears to 
be a feature of this sequence type and therefore less likely to have any functional significance. 
TS1 had a unique T to A SNP at base 2,079,375. As with the other SNPs, the functional 
significance is difficult to determine without a direct comparison to a similar strain without the 
change, but this was also outside of the AgrA consensus binding sites. 
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Figure 3.9  agr promoter sequences of selected strains aligned to reference genomes 
Alignment of agr promoter regions for selected strains with the reference sequences for N315 
and HO 5095 0412 (EMRSA-15). The agrP2 and agrP3 promoters are indicated, with the -10 and 
-35 RNA polymerase recognition sites, predicted transcription start sites and consensus 
sequences for AgrA binding marked. The SarA binding region is also shown between the two 
AgrA binding regions. The N315 Agr promoter sequence begins after N315 base 2,790,000 so, 
for example, the 230 position marked above the sequences corresponds to N315 2,790,230. 
The notable SNPs are A to T for TS1, TS3 and TS12 in the -10 region of the agrP3 promoter, and 
T to A for TS1 in the middle of the agrP2 promoter. 
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3.2.3.1.2 Analysis of pvl promoter sequences 
Unlike the agr promoter, little is known about the pvl promoter. The promoter region is situated 
in the region upstream of lukS, between lukS and the next upstream coding region (a predicted 
phage amidase gene). Consensus sequences for a ribosomal binding site and RNA polymerase 
recognition sites have been previously identified in this region (Rahman et al, 1991). 
The pvl promoter regions for the selected clinical strains were amplified and sequenced with 
the primers pvlpromoF and pvlpromoR (Table 2.4) and aligned to reference sequences for the 
three most common pvl ĞŶĐŽĚŝŶŐ ƉŚĂŐĞƐ  ?Ɍ^>d ? ɌDt ? ? ɌWs> ?  ?&ŝŐƵƌĞ  ? ? ? ? ? dĂďůĞ  ? ? ? ? ? 
ŶŽƚŚĞƌWs>ƉŚĂŐĞƐĞƋƵĞŶĐĞɌƚƉ ? ? ?-1 was also included in the analysis as it was first identified 
in an ST22 strain and therefore useful to compare to the ST22 strains TS6, TS13 and TS14. 
Once this had been done, the promoter region was analysed by looking for conserved motifs. 
The -10 Pribnow box sequence TATAAT was identified as in the original analysis by Rahman et 
al (1991) and also 4 out of 6 bases of the -35 motif TTGACA, instead occurring as TTATCA (Figure 
3.10). This gave a predicted region for RNA polymerase recognition and binding for pvl 
transcription, along with a predicted transcriptional start region. A predicted ribosomal binding 
site was also identified immediately upstream of the lukS coding sequence with a 4 out of 6 
nucleotide match to the Shine-Dalgarno sequence (Shine & Dalgarno, 1974). 
The SarA binding region previously described in agr by Sterba et al (2003) contained 29 bases. 
This base sequence was used to search in the region of the pvl promoter for any potential 
matches. Two regions each contained 19 of the 29 bases in the agr promoter SarA binding 
region and so were designated as potential SarA binding sites for pvl regulation (Figure 3.10). 
Both of these were downstream of the predicted pvl transcription start site and so could 
conceivably play a role in both transcriptional and post-transcriptional regulation. 
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Finally, Kumarevel et al  (2009) reported a 24 base sequence which acts as a generic binding 
region for MarR-like helix-turn-helix (HTH) regulators, of which the Sar proteins, particularly 
MgrA, are representatives. This sequence was reported as TTTGCTATTGTTAACAATAGCAAA. 
Comparing this to the promoter sequences identified another region downstream of the 
predicted RNA polymerase binding site which was then designated as a generic HTH binding 
site (Figure 3.10). 
Comparing the TS sequences, only one polymorphism was noted distinguishing the strains, a G 
ƚŽƉŽůǇŵŽƌƉŚŝƐŵĨƌŽŵɌWs>ƉƌĞƐĞŶƚŝŶd^ ? ?d^ ? ?d^ ? ? d^ ? ?ĂŶĚd^ ? ? downstream of the 
predicted RNA polymerase binding region and between the two SarA binding regions.  This 
polymorphism was also present in Ɍ^>dĂŶĚɌƚƉ ? ? ?-1 and so, seemed likely to represent the 
differences in PVL phage types in these strains as opposed to acquired polymorphisms (Figure 
3.10) ?dŚĞŽƚŚĞƌƚǁŽƉŽůǇŵŽƌƉŚŝƐŵƐǁĞƌĞƵŶŝƋƵĞƚŽɌWs>ĂŶĚɌ^>dƌĞƐƉĞĐƚŝǀĞůǇ ? 
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Figure 3.10  Analysis of the pvl promoter region 
Alignment of pvl ƉƌŽŵŽƚĞƌƌĞŐŝŽŶƐĨŽƌƐĞůĞĐƚĞĚƐƚƌĂŝŶƐǁŝƚŚƚŚĞƌĞĨĞƌĞŶĐĞƐĞƋƵĞŶĐĞƐĨŽƌɌWs> ?
ɌDt ? ?Ɍ^>dĂŶĚɌƚƉ ? ? ?-1. The predicted pvl promoter region for RNA polymerase binding is 
marked, along with the -35 and -10 consensus sequences. Two predicted SarA binding sites 
were identified with a 19/29 base similarity to the region identified in agr by Sterba et al (2003). 
A further generic helix-turn-helix (HTH) regulatory binding site was identified with a 16/24 base 
similarity to a sequence described by Kumarevel et al (2009). The predicted ribosomal binding 
site is immediately upstream to the start of the lukS coding sequence and has a 4/6 base 
similarity to the Shine-Dalgarno sequence. The only nucleotide polymorphism distinguishing 
the TS strains was a G to A substitution present in TS2, TS6, TS13 and TS14, immediately after 
ƚŚĞĨŝƌƐƚ^ĂƌďŝŶĚŝŶŐƐŝƚĞ ?ǁŚŝĐŚǁĂƐĂůƐŽƉƌĞƐĞŶƚŝŶɌ>^dĂŶĚɌƚƉ ? ? ?-1. 
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3.2.3.2 Development of the promoter pulldown technique in S. aureus 
A number of regulatory proteins bind to the agr promoter to regulate gene expression including 
AgrA, SarA and other transcriptional regulators such as the repressor,  Rot (Cheung et al, 2004; 
McNamara et al, 2000). While the expression of the lukSF-PV genes is regulated by agr (Bronner 
et al, 2000), there are no published data demonstrating direct binding of transcriptional 
regulators to the pvl promoter. 
A promoter pulldown technique was developed to determine which regulatory proteins were 
binding to the agr and pvl promoters of selected clinical strains, and to see if there were any 
obvious differences between the protein binding patterns of the genotypically, apparently 
identical but phenotypically distinct TS13 and TS14. The pulldown technique relies on protein 
binding to biotinylated promoter fragments generated by PCR which can then be separated 
with streptavadin coated magnetic beads and any bound proteins eluted (Figure 3.11). 
 
3.2.3.2.1 Verification that proteins bind selectively to the promoter fragments 
The PVL negative TS3 strain was used as an initial test isolate to determine which proteins 
bound selectively to the agr promoter fragment and for later comparison with the PVL positive 
strains. Biotinylated agr promoter fragments were mixed with streptavadin-coated beads and 
incubated with TS3 cell lysate as described in section 2.7.3. Pooled PCR product from ten 50 µl 
reactions was used so that an excess of promoter DNA would be present. After incubation, the 
beads were separated from the lysate using a magnetic rack, washed and any residual proteins 
eluted (section 2.7.4). Both the eluent and original cell lysate were separated by SDS-PAGE and 
compared. Several discrete bands were present in the eluent compared to a dense smear of 
many mixed proteins in the lysate, confirming that selective binding had occurred. 
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Bands from the eluent lane of the SDS-PAGE gel were sent for Q-TOF protein sequencing. 
Sequencing results confirmed that AgrA and several Sar family proteins including SarA, SarS, 
SarR, SarX and SarV were bound to the agr promoter fragment. Other bound proteins included 
ribosomal proteins, translation initiation factors, DNA directed RNA polymerase and a DNA 
helicase, ruvA (Figure 3.12). 
 
3.2.3.2.2 Confirmation that large cell volumes are required for the cell lysate 
The protocol used for generating the cell lysate requires 400 ml of bacterial culture for a single 
experiment. To ensure that this volume was required for the PVL positive strains too and that 
the assay was not saturated with protein, the pull down experiment was performed again with 
another PVL negative strain TS10, using serial dilutions of cell lysate for the incubation step 
(section 2.7.3).  The eluents derived from promoter fragments incubated with the diluted cell 
lysates contained lower protein concentrations, indicating that cell lysate protein 
concentrations were a limiting factor in the assay and that a large volume of bacterial culture 
was required (Figure 3.13). 
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Figure 3.11  The promoter pull down assay method 
A diagrammatic representation of the promoter pull down assay. The agr promoter on the left 
and pvl promoter on the right were amplified by PCR before binding to magnetic beads. After 
mixing with concentrated lysed cell extract, the beads were separated from the mixture by a 
magnetic rack and the eluent analysed by SDS-PAGE. Gel bands were sent for protein 
sequencing to identify promoter bound products. 
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Figure 3.12  Pull down assay products from a PVL negative strain TS3 
SDS-PAGE gel indicating eluted products from a promoter pull down assay using the TS3 agr 
promoter with lysed TS3 concentrated cell extract. Bands sent for sequencing (A to F) are 
indicated with arrows, with protein sequencing products shown in the boxes. Proteins are 
indicated by mass and identity, with the mass spectrometry quantification shown in brackets. 
The quantification is a relative value accounting for % of spectra and protein molecular weight. 
MW = molecular weight. 
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Figure 3.13  Effect of diluting the pull down cell extract on quantity of eluted protein 
SDS-PAGE gel indicating eluted products from a promoter pull down assay using the TS10 agr 
promoter with lysed TS10 concentrated cell extract. Serial dilutions of cell extract were mixed 
with the biotinylated promoter to determine if the mixture was saturated with protein. A 
control without the addition of promoter was included for comparison. The dilutions indicate 
that reducing the cell extract concentration dramatically reduced the eluted product, 
confirming the need to use a large culture volume. MW = molecular weight. 
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3.2.3.3 Identification and comparison of proteins bound to pvl and agr promoters 
Three PVL positive strains were chosen for investigation of their agr and pvl promoter protein 
binding profiles.  Strains TS13 and TS14 were chosen together with TS12 - a representative of 
agr group 3 which shows very low PVL toxin product. 
Many of the Sar proteins were identified as binding to both the agr and pvl promoters of all 
three isolates tested, particularly SarS and SarA. AgrA was bound to all of the agr promoter 
fragments but none of the pvl promoter fragments indicating that specific binding was 
occurring (Figure 3.14 and 3.15). The proteins bound to the agr promoters were similar to that 
seen previously in TS3. 
Other proteins of interest bound to the promoter fragments included Rot, MgrA and another 
transcriptional regulator, TcaR. All of the proteins bound to the pvl promoter fragments and 
giving clear bands on the SDS-PAGE gel were known transcriptional regulators. 
Although the assay was intended as a qualitative measure of promoter protein binding, peptide 
fragment quantifications were compared to look for possible variations.  When comparing the 
profiles of TS12 and TS13, there were no striking differences between them. There was a visible 
difference in profiles of TS13 and TS14 with fainter bands around 30 kDa in size for TS14. This 
could be explained by less SarS protein bound to the TS14 promoters than for TS13. From the 
protein bands sequenced, the amount of Rot bound to the TS14 promoters was also lower than 
TS13. SarS and Rot are both exotoxin repressors and are associated with repressed agr activity. 
The differences observed could reflect global differences therefore in the agr function of TS13 
and TS14.  
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MW Protein ID Gel Band: Mass spec quantification
30 kDa SarS A1: 119, A2: 139, A3: 112, A4: 209
B2: 52, B4: 35
28 kDa AgrA A1: 24, A3: 20
C1: 22, C3: 14
20 kDa Ferritin B2: 7, B4: 11
19 kDa Rot B2: 11, B4: 9
C1: 20, C2: 71, C3: 34, C4: 66
18 kDa TcaR B2: 30, B4: 27
17 kDa MgrA B2: 121, B4: 113
15 kDa SarA B2: 19, B4: 12
C1: 106, C2: 152, C3: 129, C4: 120
14 kDa SarX C1: 13, C2: 10, C3: 11, C4: 8
SarV C1: 11, C2: 9, C3: 12, C4: 17
SarR C1: 33, C2: 33, C3: 54, C4: 61
A1 A2
A3 A4
B2
B4
C1 C2
C3 C4
TS12 TS13
Figure 3.14  Pull down products bound to the agr and pvl promoters of TS12 and TS13 
SDS-PAGE gel indicating eluted products from a promoter pull down assay using the TS12 and 
TS13 agr and pvl promoters with lysed concentrated cell extract. Bands sent for sequencing (A1 
to C4) are indicated with arrows, with protein sequencing products shown in the boxes. Protein 
products are indicated by mass and identity, with the mass spectrometry quantification shown 
after the gel band label. The quantification is a relative value accounting for % of spectra and 
protein molecular weight. SarS, SarA, Rot and other Sar proteins bound to all the promoters. 
AgrA was only identified from the agr promoters. MgrA was identified binding to the pvl 
promoter only, although the corresponding agr bands were fainter and so not sent for 
sequencing. MW = molecular weight. 
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31
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14
MW Protein ID Gel Band: Mass spec quantification
30kDa SarS A1: 137, A2: 255, A3: 78, A4: 95
28kDa AgrA A1: 25, A3: 51
19kDa Rot C1: 41, C2: 81, C3: 8, C4: 19
18kDa TcaR B1: 8, B2: 33, B3: 13, B4: 18
17kDa MgrA B1: 51, B2: 138, B3: 54, B4: 77
15kDa SarA C1: 157, C2: 146, C3: 106, C4: 112
14kDa SarR C1: 66, C2: 74, C3: 40, C4: 49
14kDa SarV C1: 15, C2: 21, C3: 8, C4: 10
14kDa SarX C1: 13, C2: 10, C3:7, C4:7
A1 A2 A3 A4
B2 B4
C1 C2 C3 C4
B3B1
MW    agr pvl agr pvl
TS13 TS14
Figure 3.15  Pull down products bound to the agr and pvl promoters of TS13 and TS14 
SDS-PAGE gel indicating eluted products from a promoter pull down assay using the TS13 and 
TS14 agr and pvl promoters with lysed concentrated cell extract. Bands sent for sequencing (A1 
to C4) are indicated with arrows, with protein sequencing products shown in the boxes. Protein 
products are indicated by mass and identity, with the mass spectrometry quantification shown 
after the gel band label. The quantification is a relative value accounting for % of spectra and 
protein molecular weight. SarS, SarA, Rot and other Sar proteins bound to all the promoters. 
AgrA was only identified from the agr promoters. SarS and Rot quantities are highlighted in red 
as these appeared to differ between TS13 and TS14. MW = molecular weight. 
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3.2.3.4 Comparison of agr and pvl gene expression by qRT-PCR 
From the immunoblotting data presented in section 3.2.1.2, TS14 clearly produced more PVL 
and alpha haemolysin than TS13. This phenotype suggested global differences in toxin gene 
expression, possibly due to differences in agr. It was unclear from these data whether this was 
due to differences in toxin gene transcription, translation or even secretion.  
To obtain a clearer indication of the source of the observed differences, expression of the agr 
and pvl genes by TS13 and TS14 respectively were compared directly by a SYBR green-based 
quantitative real time PCR assay (section 2.4.9). TS13 and TS14 were grown in CYGP broth and 
cultures harvested in exponential phase (n = 3, t = 4.5 h). Following RNA extraction and cDNA 
synthesis, cDNA samples were tested in triplicate. The pvl and agr genes were amplified using 
the primers RNAIII F and R and lukS-PV F and R with the gyrB gene acting as a constitutive 
control, amplified with the primers gyrB F and R (Table 2.4). 
PCR cycle threshold (CT) was used to quantify each gene in the cDNA samples. agr and pvl gene 
quantities were adjusted based on the gyrB value in order to account for variations in total 
cDNA between samples. As pvl and agr gene expression was higher in TS14 than TS13, relative 
quantities (RQ) of each gene were expressed as a multiple of the average gene quantification 
for TS13. All analyses were performed using the AB7500 Real-time PCR System software 
(Applied Biosystems). RQs were calculated with a range for the minimum to maximum 95 % 
confidence levels (Figure 3.16). Compared with an RQ of 1.0 (0.8 to 1.3) for TS13 agr expression, 
mean TS14 agr expression was over tenfold higher with an RQ of 11.3 (7.0 to 18.4) (p<0.05). 
Expression of the pvl genes was also much higher for TS14 than TS13 with an RQ of 59.7 (37.8 
to 94.1) for TS14 compared to an RQ of 1 (0.8 to 1.3) for TS13 (p<0.01). 
These data suggest that PVL toxin gene expression by TS14 is clearly higher than TS13 due to 
differences in pvl transcription. As with staphylococcal toxins such as alpha-haemolysin, the 
regulation of pvl by agr is probably mediated by RNAIII expression, which acts indirectly through 
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altering the translation of other regulators (Geisinger et al, 2006). RNAIII expression was over 
tenfold higher in TS14 than TS13. Because of the downstream impact a difference in RNAIII 
expression would have on the translation of many of the global regulators such as Rot, SarS, 
SarA and SarR, this could account for the large difference in pvl gene transcription observed 
here. 
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Figure 3.16  qRT-PCR results for RNAIII and pvl gene transcription by TS13 and TS14 
Quantification of lukF-PV and RNAIII gene expression (calculated as RQ  W see section 2.4.9) in 
TS13 and TS14 grown to mid-exponential phase in CYGP medium at 37oC. Expression of lukF-PV 
was 59.7-fold higher and RNAIII expression 11.3-fold higher in TS14 than TS13. Error bars 
indicate the 95% confidence intervals. 
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3.2.4 Analysis of full agr operon sequences 
As differences in agr expression had been observed between strains TS13 and TS14 which could 
have important phenotypic implications, but could not be explained by changes in the promoter 
sequences,  the analysis was extended to the entire agr P2 locus for this and other selected 
clinical isolates. 
To ensure full sequencing coverage of agrBDCA in both directions, several sequencing primers 
were used as follows: Őƌ& ?Őƌ& ?Őƌ ? ? ? ?& ?Őƌ ? ? ?Őƌ ? ? ?Őƌ Z ? Agrfull R 
and AgrC R (Table 2.4). 
 
3.2.4.1 Analysis of agr group 1 sequences 
The agr locus of S. aureus NCTC 8325 (Table 2.5) was used as a reference for the wild type group 
1 sequence. When compared to this sequence there were 30 SNPs in TS14 spread over all four 
agrP2 genes, including 2 in the intergenic region between agrD and agrC. These substitutions 
resulted in 5 amino acid substitutions in the AgrB protein: I49L, I90L, F106P, V119I and L152F 
of which 3/5 were conservative (Figure 3.17A). One substitution, Y251F, was noted in AgrC 
(Figure 3.17B). No nonsense mutations, insertions, deletions or frame shifts were found. The 
AgrD and AgrA protein sequences were identical to the wild type. As the reference sequence 
for the ST22 EMRSA15 strain HO 5096 0412 was available (Table 2.5), this was also compared 
with TS14 and was found to be identical across the entire agr locus. This suggests that the 
changes identified are likely to result from agr mutations which have occurred during the 
divergence of this sequence type.  
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3.2.4.1.1 Identification of a non-synonymous agrC polymorphism in TS13 
The agr genes of several other ST22 isolates in the collection, TS6, TS9, TS13 and TS17, were 
sequenced. The TS6, TS9 and TS17 sequences were all identical to TS14, but TS13 was found to 
have a single nucleotide change in agrC. This was a C to T substitution resulting in a change to 
the AgrC amino acid sequence: N267I (Figure 3.17B). Changing the residue at this position from 
asparagine to isoleucine results in the replacement of an amino functionality with a short 
carbon chain, reducing polarity and increasing hydrophobicity.  
The first 205 amino acids of AgrC are understood to form the transmembrane spanning 
domains, responsible for receiving and recognizing AIP (Jensen et al, 2008). The other domain 
of the protein, from amino acid 205 to 430, forms the cytoplasmic domain which is 
phosphorylated at the H239 residue in response to activation by AIP (George Cisar et al, 2009). 
The N267I substitution may therefore impact on either phosphorylation or the interaction with 
and phosphotransfer to AgrA, and so could explain the differences observed in agr expression 
between TS13 and TS14. 
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Y251F N267I 
(TS13 only)
I49L
I90L F106P V119I L152F 
Figure 3.17  Alignment of the AgrB and AgrC amino acid sequences for TS13 and TS14 
Amino acid alignments demonstrating the variations in AgrB (A) and AgrC (B) sequences for 
TS13 and TS14 compared to the reference sequences NCTC 8325 and HO 5096 0412 
(representing EMRSA-15). Variations from NCTC 8325 are marked with arrows. TS13 and TS14 
have 5 predicted amino acid variations from NCTC 8325 in AgrB and 1 predicted variation, 
Y251F, in AgrC. All of these are present in EMRSA-15. TS13 also has a predicted N267I amino 
acid substitution which is not present in any of the other sequences. 
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3.2.4.1.2 Amino acid sequence changes in S. aureus TS1 AgrBDCA 
TS1 was isolated from a case of fatal necrotizing pneumonia and was found to have a unique 
MLST. Because of these interesting characteristics, the TS1 agr locus was also sequenced to 
look for agr variations from the agr group 1 laboratory reference strain NCTC 8325 (Table 2.5). 
TS1 differed significantly from NCTC 8325, with 126 SNPs across agrBDCA. The TS1 sequence 
had many more amino acid substitutions than any of the other group 1 clinical isolates or 
reference strains used for comparison. As with the other group 1 strains, no nonsense 
mutations, insertions, deletions or frame shifts were noted. 
Nucleotide polymorphisms in TS1 agrB resulted in 14 predicted AgrB amino acid substitutions, 
of which 4 were also present in EMRSA-15, including: K38V, Y67F, I90L, V98L, I99V, F106P, 
I115T, L117I, V119I, S121A, K142R, Y143N, T151I and L152F (Figure 3.18A). 4 of these 15 
substitutions: V98L, I99V, K142R and T151I were also present in the MW2 agr group 3 
sequence, leaving 7 which were unique to TS1. The AgrD amino acid sequence was identical to 
the wild type. 
TS1 has 10 amino acid substitutions in the group 1 AgrC when compared with NCTC 8325: V42G, 
S44T, Y100F, S109N, I127L, T141S, P142S, N308S, S321T and S322R (Figure 3.18B). 4 of these 
10 substitutions: V42G, Y100F, S321T and S322R were also present in MW2, leaving 6 which 
were unique to TS1. There was also a single substitution in AgrA: D194N. 
The large amount of variation in TS1 presumably reflects its divergent sequence type. It is 
unclear why some of the changes seen here are also found in agr group 3. It may be that these 
reflect common mutations with insignificant functional consequences, given that agr appears 
to function in TS1 which produces measurable amounts of alpha haemolysin and PVL toxin. An 
alternative hypothesis may be that the development of the agr locus in TS1 diverged from the 
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rest of the group 1 isolates further back in time, perhaps retaining some residues that were 
originally common to group 1 and group 3. 
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Figure 3.18  Alignment of the AgrB and AgrC amino acid sequences for TS1 
Amino acid alignments demonstrating the variations in AgrB (A) and AgrC (B) sequences for TS1 
compared to the reference sequences NCTC 8325 and HO 5096 0412 (representing EMRSA-15). 
Variations from NCTC 8325 are marked with arrows and variations also shown as red circles on 
the AgrC diagram (C). TS1 has 14 predicted amino acid variations from NCTC 8325 in AgrB and 
10 predicted variations in AgrC. TS1 residues which are identical to EMRSA-15 are labelled with 
E, and those identical to MW2 labelled with M. AgrC variations which are in regions with 
particular functional importance, the surface loops or the cytoplasmic region, are marked with 
small arrows on the AgrC diagram (C). 
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3.2.4.2 Analysis of agr group 3 sequences 
The finding of the AgrC N267I substitution in TS13 focused attention on the potential for 
mutations that may interfere with AgrC phosphorylation and phosphotransfer to AgrA. To 
determine whether there were similar mutations occurring in any of the group 3 isolates, most 
of which produced much less PVL toxin than the group 1 isolates, the agrC and agrA genes of 
several isolates were sequenced and compared with a group 3 reference sequence MW2 (Table 
2.5). 
The only predicted amino acid variations identified arising from non-synonymous nucleotide 
polymorphisms in these genes included an I87T AgrC substitution in TS7, an L156F AgrC 
substitution in TS25 and a K136R AgrA substitution in TS21 (Figure 3.19). The AgrC variations 
were both in the transmembrane regions of the membrane spanning portion of AgrC, rather 
than occurring in the receptor loops. 
The portion of AgrA, in which the TS21 K136R substitution occurs, is in a LytR-like DNA binding 
domain believed to be important for binding of AgrA to the agr promoter, rather than 
interaction with AgrC (Nikolskaya & Galperin, 2002). This variation could conceivably interfere 
with the DNA binding function of AgrA, resulting in reduced agr expression. 
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I87T L156F
K136R
Figure 3.19  Alignment of the AgrC and AgrA amino acid sequences for agr group 3 strains 
Amino acid alignments demonstrating the variations in AgrC (A) and AgrA (B) sequences for agr 
group 3 strains compared to the reference MW2. Variations from MW2 are marked with 
arrows. Predicted variations from MW2 are: TS7 AgrC I87T, TS25 AgrC L156F and TS21 K136R. 
Both of the AgrC variations occur in predicted transmembrane domains whereas the AgrA 
K136R change in TS21 occurs in a DNA binding region, predicted to interact with the agr 
promoter.  
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3.2.5 Whole genome sequence analysis of TS13 and TS14 
3.2.5.1 Generation of sequencing data 
The agr loci of TS13 and TS14 differed by only an N267I change in AgrC possibly accounting for 
their phenotypic differences. Although the isolates appeared to be quite similar genotypically, 
having the same spa type and MLST, the amount of genome wide variation between them was 
unknown. Based on the clinical and patient information available when the isolates were 
collected, there was no immediate obvious relationship between the two strains. PVL positive 
isolates with trimethoprim and gentamicin resistance were frequently identified by the clinical 
laboratory at the time the strains were collected, so these may represent a locally circulating 
strain type. Similar PVL positive ST22 isolates had been detected previously in a study of S. 
aureus strains received by the Staphylococcus Reference Unit (Holmes et al, 2005). 
To gain additional information about this lineage and to enable a more complete comparison 
to be made between TS13 and TS14, whole genome sequences were obtained for both isolates. 
This was carried out at the DeepSeq facility (University of Nottingham) by an Illumina MiSeq 
benchtop sequencer generating 150 bp paired end reads, and the data made available in 
Illumina FASTQ format. 2,091,482 reads were generated for TS13 and 2,642,626 reads for TS14. 
Based on a genome size of approximately 3 Mb, with 300 bases per read, this represents 
approximately 200 times coverage for TS13 and 260 times coverage for TS14. 96.0% of the 
reads were reported as having a quality score (Q) greater than 30 indicating that good quality 
sequences had been obtained. A brief de novo assembly was also performed by the Illumina 
BaseSpace software to aid in selection of a reference genome. 
The de novo assembly returned 344 contigs for TS13 and 257 contigs for TS14 of which 41 of 
the TS13 contigs and 38 of the TS14 contigs were larger than 10 kb. The largest contigs were 
232 kb and 267 kb for TS13 and TS14 respectively.  
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3.2.5.2 Selection of a reference genome 
A complete de novo genome construction for TS13 and TS14 was not attempted as additional 
sequence data would have been required. Instead, the sequence data generated was used to 
map both isolates individually to a reference genome. Once comparisons had been made 
between each isolate and the reference, the differences noted could be compared for TS13 and 
TS14. 
The three largest contigs from TS13 and TS14 were compared to publically available genome 
sequences by BLAST searches to find the closest matches in available reference genomes (Table 
3.2). 
Strain HO 5096 0412 was returned as the closest match for all 6 of the contigs analyzed, with 
99 % identity and 99 % coverage for all but 1 of the contigs. HO 5096 0412 is an MLST22 MRSA 
representative of EMRSA-15, one of the two major HA-MRSA clones in the UK (see Table 2.5 for 
reference source). The genome sequencing and analysis was performed by the Sanger Institute 
(Wellcome Trust, Cambridge). A reconstruction of the ST22-A lineage, which includes the data 
from HO 5096 0412, was reported by Holden et al (2013). Although this isolate is PVL negative 
and MRSA positive, unlike TS13 and TS14, it appeared to be the closest match available among 
the whole genome sequences deposited in GenBank, and also had the advantage of being 
included in a study comparing different strains of the ST22 lineage.  
HO 5096 0412 was therefore selected as the reference genome for the next stage of the 
analysis. 
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Table 3.2  Results for BLAST search of the largest TS13 and TS14 contigs 
The nucleotide sequences for the 3 largest contigs each from an initial de novo assembly of 
TS13 and TS14 were compared by BLAST search with publically available S. aureus sequence 
data at www.ncbi.nlm.nih.gov. The closest match for each contact is shown along with % 
coverage and identity. The ST22 MRSA strain HO 5096 0412 (Genbank identifier HE681097.1) 
was returned as the closest match for all 6 contigs. Contig size represents number of 
nucleotides. 
 
Strain Contig size Closest match Query cover Identity Genbank ID 
TS13 
 
232,249 HO 5096 0412 99 % 99 % HE681097.1 
188,271 HO 5096 0412 99 % 99 % HE681097.1 
173,732 HO 5096 0412 99 % 99 % HE681097.1 
TS14 
 
267,231 HO 5096 0412 97 % 99 % HE681097.1 
188,094 HO 5096 0412 99 % 99 % HE681097.1 
173,578 HO 5096 0412 99 % 99 % HE681097.1 
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3.2.5.3 Alignment of TS13 and TS14 to HO 5096 0412 
The paired end reads from TS13 and TS14 were mapped to the HO 5096 0412 FASTA file 
obtained from GenBank using the Burrows Wheeler alignment tool (Li & Durbin, 2009).  
The TS13 reads covered 98.5% of the HO 5096 0412 genome at least once, with an average 
coverage of 222.8 reads. The TS14 reads had a coverage of 97.6%, with an average coverage of 
281.5 reads. Artemis 14.0.0 (Wellcome Trust Sanger Institute) was used to visualize how the 
sequencing reads aligned with the reference genome so that the specific regions where gaps 
occurred could be identified. 
Unsurprisingly, a large gap occurred in mapping the genomic region between 33 Kb and 57 Kb 
on the reference genome, representing SCCmec (Figure 3.20A). TS13 and TS14 are both MSSA 
strains so are likely to be missing the SCCmec region altogether. HO 5096 0412 has SCCmec IVh 
which contains a type-2 ccr gene complex and class-B mec gene complex. Within the class-B 
mec gene complex are two transposases, IS431 and IS1272 (Ma et al, 2002). Both of these 
transposases were the only genes within the SCCmec region associated with mapped reads 
from TS13 and TS14, presumably reflecting the presence of similar transposases elsewhere on 
the chromosomes of these strains. 
Other gaps in the mapping were identified as follows: 
A 15 kb gap was identified between nucleotides at 1,360 kb and 1,375 kb on the reference 
genome, which appeared to reflect an unidentified mobile genetic element which TS13 and 
TS14 do not possess (Figure 3.20B). BLAST searching of genes within this element indicated it 
could be an ICE6013-like element, first identified by Smyth and Robinson (2009), which possess 
integrative and conjugative functions but no obvious virulence determinants. 
The region between 1,520 kb and 1,565 kb on HO 5096 0412 has a phage inserted, designated 
Ɍ^Ă ?HO 5096 0412, which is defined by the presence of a BcgI-like restriction enzyme (Holden 
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al, 2013). TS13 and TS14 did not appear to carry this enzyme, suggesting a different phage 
inserted at this site (Figure 3.21A). The phages encoding lukSF-PV nearly all insert at this phage 
site ?Ɍ^Ă ?(Goerke et al, 2009), and so it would be expected that the PVL positive TS13 and 
TS14 strains would have a different phage here to the PVL negative HO 5096 0412.  
Gaps were noted sporadically throughout the second phage region on the reference genome 
between 2,040 kb and 2,090 kb which is known to contain a phage, ĚĞƐŝŐŶĂƚĞĚɌ^Ă ?HO 5096 0412, 
encoding Staphylokinase and the immune evasion proteins CHIPS and SCIN (Holden et al, 2013). 
The uneven mapping of the TS13 and TS14 reads suggested that a different but related phage 
was inserted at this site (Figure 3.21B). Reads mapped well to the genes for CHIPS, SCIN and 
Staphylokinase (sak) so it seemed likely that this related phage also contains the immune 
evasion complex (IEC) comprising these genes (de Haas et al, 2004). 
Apart from the regions described above, TS13 and TS14 mapped to the rest of the reference 
genome. Other regions of interest which HO 5096 0412 is known to possess and appear to be 
shared with TS13 and TS14 included the enterotoxins seg and sei, gamma haemolysin, 
fibronectin binding protein A (fnbpA), ĂŶĚ Ă dŶ ? ? ? ůŝŬĞ ƚƌĂŶƐƉŽƐŽŶ ǁŚŝĐŚ ĞŶĐŽĚĞƐ Ă ɴ-
lactamase. 
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Figure 3.20  TS13 and TS14 are missing mobile genetic elements present in HO 5096 0412  
Alignment of sequence reads for TS13 and TS14 with HO 5096 0412 in the region of SCCmec (A) 
and a transposon at reference position 1,360 kb (B). Coverage is indicated by the graphs for 
TS13 and TS14 which represent number of reads matching each position. Gaps in the graphs 
indicate there were no reads matching this portion of the reference genome. TS13 and TS14 
had reads matching the two transposons IS431 and IS1272 but did not appear to possess 
SCCmec, with no reads matching mecA. TS13 and TS14 also appeared to be missing an 
unidentified mobile genetic element (MGE) shown in B. 
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bcgI-like restriction enzyme
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Immune Evasion Complex
Figure 3.21  TS13 and TS14 carry different phages to HO 5096 0412  
Alignment of sequence reads for TS13 and TS14 with HO 5096 0412 in the two phage insertion 
ƐŝƚĞƐĨŽƌɌ^Ă ? HO 5096 0412  ? ?ĂŶĚɌ^Ă ? HO 5096 0412 (B). Coverage is indicated by the graphs for TS13 
and TS14 which represent number of reads matching each position. Gaps in the graphs indicate 
there were no reads matching this portion of the reference genome. The bcgI-like restriction 
enzyme which is a defining feature of Ɍ^Ă ? HO 5096 0412 was not present in TS13 and TS14 (A). 
TS13 and TS14 had reads matching the immune evasion complex (IEC) containing CHIPs and 
StaphǇůŽŬŝŶĂƐĞ ?ďƵƚŚĂĚŐĂƉƐĞůƐĞǁŚĞƌĞŝŶƚŚĞɌ^Ă ?HO 5096 0412 sequence (B). 
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3.2.5.4 SNP calling and comparison of TS13 and TS14 genomes 
Once mapped, single nucleotide polymorphisms (SNPs) occurring between the test strains and 
the reference genome were called using the mpileup and bcftools software (Li et al, 2009a), 
excluding bases with less than 5 times coverage or a quality score less than 13, indicating an 
unreliable base read, and indels. Because the reference genome phages appeared to be 
different to the test strains, SNPs called in these regions were also excluded from the analysis. 
After filtering, a combined total of 835 SNPs were found in TS13 and TS14 when compared with 
HO 5096 0412. Of these, 118 were exclusive to TS14 and 75 were exclusive to TS13, leaving 642 
SNPs in common between the two strains (Figure 3.22). 
A script, written by Hardeep Naghra, was used to compare the SNPs loci to the coding sequence 
annotations for HO 5096 0412. SNPs were then filtered according to their likely impact on gene 
products. 434 SNPs were identified which were likely to change the amino acid sequence of 
gene products (non-synonymous) while 204 were found which would not (synonymous). This 
left 197 SNPs which were found to be in non-coding regions of the genome. 
Analysis was then focused on the 434 non-synonymous SNPs identified in TS13 and TS14. Of 
these, 78 were exclusive to TS13 and 64 to TS14, leaving 292 in common. The SNPs exclusive to 
TS13 and TS14 along with their affected gene products are listed in Appendix 7.1 and 7.2.  
Changes of interest exclusive to TS13 included the A to T substitution in agrC at location 
2,108,636 of the reference and a G to T substitution in a putative staphylococcal accessory 
regulator, CDS 23970, at location 2,589,488. BLAST searching of the base sequence of this 
regulatory gene revealed this to be sarU. 
Changes of interest exclusive to TS14 included a C to T substitution in coding sequence 5930 at 
position 691,792, annotated as being an AraC family regulatory protein. 
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The SNP comparison between the two strains indicates that they are very closely related. 
Excluding the phage regions, the 193 unique SNPs between them represent less than 0.01 % of 
the total genome. 
As the phenotypic analysis focused on differences in agr expression, further analysis was 
carried out to determine whether any of the other genes encoding Sar proteins contained SNPs. 
Not all of the Sar protein genes were annotated on the HO 5096 0412 genome so this required 
BLAST searching with individual Sar protein gene sequences to identify the matching coding 
sequences for each one. The results of this analysis are shown in Table 3.3. 
Four coding SNPs were identified which were all non-synonymous changes. In addition to the 
agrC and sarU changes in TS13 already mentioned above, two additional substitutions were 
identified in both TS13 and TS14 in the saeS gene and another in sarU.  
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TS13 and TS14 
SNPs aligned to 
HO 5096 0412 
(2,832,299 bp)
SCCmec IVh
HO 5096 0412 
CDS (forward)
HO 5096 0412 
CDS (reverse)
TS13 and TS14 SNPs
No SCCmec present
ɌSa2 HO 5096 0412
Ɍtp310-1
ɌSa3 HO 5096 0412
Ɍtp310-3
Tn554
SNPs excluding phages 
(n=835)
TS13
n=75
TS14
n=118
Common 
n=642
SNPs in regulators
agrC (TS13)
sarU (TS13)
sarU (Both)
saeS (Both)
Figure 3.22  Genome map summarising the TS13 and TS14 sequence analysis 
Comparison of the TS13 and TS14 sequence data with the reference genome HO 5096 0412. 
The coding sequences (CDS) for HO 5096 0412 are shown as forward sequences, blue, and 
reverse sequences, purple. Single nucleotide polymorphisms (SNPs) occurring in TS13 and TS14 
are shown in red. Significant differences between the TS strains and HO 5096 0412 are 
indicated, including the lack of SCCmec and the presence of difference phages. Potentially 
important SNPs in regulatory genes are listed on the right with a summary of the SNPs which 
occur in both TS13 and TS14, or exclusively in one or the other, shown in the bottom right. 
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Table 3.3  Summary of SNPs occurring in selected genes known to be involved in 
staphylococcal exotoxin regulation 
The coding sequence annotation identifier each gene is labelled with in the HO 5096 0412 
Genbank file is shown in the 2nd column, with the base ranges marked for these genes in the 3rd 
column. The nucleotide position in HO 5096 0412 that SNPs occur in are shown along with the 
polymorphism in column 4, indicating whether this SNP occurs in TS13 only or in both TS13 and 
TS14. The final column indicates the predicted amino acid substitution that would occur as a 
consequence of the SNP. 
 
Gene Coding Sequence ID Base range SNP Substitution 
sarS SAEMRSA15_00780 100174..100926 no  
sarA SAEMRSA15_05440 640499..640873 no  
sarX SAEMRSA15_05940 692834..693259 no  
mgrA SAEMRSA15_06120 708245..708688 no  
saeS SAEMRSA15_06310 728125..729180 728161 T to C BOTH I341M 
saeR SAEMRSA15_06320 729180..729866 no  
rot SAEMRSA15_16700 1851896..1852396 no  
agrC SAEMRSA15_19460 2107837..2109129 2108636 A to T TS13 N267I 
sigB SAEMRSA15_19740 2148019..2148789 no  
sarV SAEMRSA15_21650 2344373..2344723 no  
sarR SAEMRSA15_21920 2366747..2367094 no  
sarY SAEMRSA15_21940 2367912..2368655 no  
sarZ SAEMRSA15_22850 2465242..2465688 no  
sarT SAEMRSA15_23960 2588442..2588801 no  
sarU 
 
SAEMRSA15_23970 2589089..2589865 2589392 T to C BOTH C102R 
2589488 G to T TS13 D134Y 
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3.2.5.5 Identity of genetic material not mapping to the reference genome 
The genome mapping approach used enabled SNPs to be identified within the core genome. To 
determine whether there were other significant portions of genetic material from TS13 and 
TS14 which did not map to the reference sequence, the de novo sequences were aligned to HO 
5096 0412 by Hardeep Naghra (Centre for Biomolecular Sciences). Aligned contigs were filtered 
out, leaving only those contigs which did not align to the reference genome. This left 7 contigs 
for TS13 and 5 contigs for TS14 which were over 1 kb in length.  
These unaligned contigs were used in BLAST searches in order to try and identify their contents. 
Table 3.4 summarises the results of these searches and indicates their most likely components. 
Two patterns emerged from these data. The first was the large number of hits against phages 
designated tp310 which are unpublished but recorded in the database as occurring in ST22 
strains of S. aureus. Hits against S. aureus genomes for these fragments occurred in regions 
where phage was inserted into the genome, presumed to be similar or identical to tp310 
phages. 
The other hits of interest were to plasmids, one each for TS13 and TS14. The pSAP076A plasmid 
matching the TS13 contig appeared to mostly contain heavy metal ion transporters and it was 
unclear whether any of these represented antibiotic resistance genes. The pSK77 plasmid, 
however, which matched one of the TS14 contigs, encoded a dihydrofolate reductase and an 
aminoglycoside phosphotransferase in the region matching the contig. These enzymes are 
known to confer resistance to trimethoprim and gentamicin respectively which could therefore 
explain the antibiotic resistance phenotype of the strains (gentamicin and trimethoprim 
resistant only). 
  
Table 3.4  BLAST search data for unaligned contigs of TS13 and TS14 
TS13 and TS14 contigs were aligned to HO 5096 0412 and remaining unaligned contigs filtered for further analysis. BLAST searching with these contigs yielded 
the following matches. Contigs are identified by source, either TS13 or TS14, and size in base pairs. The first 3 matches for each contig are shown where the 
first leƚƚĞƌ ‘Ő ?ŝŶĚŝĐĂƚĞƐĂŐĞŶŽŵĞƐĞƋƵĞŶĐĞ ? ‘Ɖ ?ĂƉůĂƐŵŝĚƐĞƋƵĞŶĐĞĂŶĚ ‘Ɍ ? a phage sequence. Conclusions were drawn about the potential contents of each 
contig based on reviewing the annotation data available from the BLAST sequence results. The majority of the matches were to phage fragments similar to 
Ɍtp310 phages, previously found in ST22 strains but unpublished. A large (33 kb) contig was also identified in TS13 representing a plasmid, although antibiotic 
resistance genes could not be identified in the annotation data for the plasmid matches. Also of note, a 5.5 kb contig in TS14 which contained antibiotic 
resistance genes for trimethoprim and gentamicin. 
Source Size (bp) Match 1 Match 2 Match 3 Contents  
TS13 
 
33096 pSAP076A pSAP102A pSAP075A Plasmid borne heavy metal transporters 
27593 g04-02981 gJH1 gJH9 Phage terminase 
9462 g55/2053 Ɍtp310-3 gED133 Parts of Ɍtp310-3 
7178 Ɍtp310-3 g55/2053 gM1 Parts of Ɍtp310-3 
4316 gBmb9393 gMSSA476 gMW2 Phage integrase 
3472 g11819-97 Ɍtp310-3 Ɍtp310-1 Parts of ɌƚƉ ? ? ?ƉŚĂŐĞƐ 
3006 gJKD6008 pSK77 pSAP068A Transposases 
TS14 
 
17397 g 55/2053 Ɍtp310-3 Ɍtp310-1 Parts of ɌƚƉ ? ? ?ƉŚĂŐĞƐ 
6748 Ɍtp310-3 g55/2053 gNCTC8325 Parts of Ɍtp310-3 
5494 pSK77 pLW043 gJKD6008 Dihydrofolate reductase (trimethoprim resistance), 
Aminoglycoside phosphotransferase (gentamicin resistance) 
3608 Ɍtp310-3 gM013 gSA957 Parts of Ɍtp310-3 
3555 gSA957 gM913 gNCTC8325 Phage fragments, other hypothetical proteins 
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3.2.5.6 Identification of TS13 and TS14 phages 
dŚĞďĞƐƚĐŚĂƌĂĐƚĞƌŝƐĞĚƉŚĂŐĞƐǁŚŝĐŚĞŶĐŽĚĞWs>ŝŶĐůƵĚĞɌWs> ?ɌDt ?ĂŶĚɌ^>d ?ĂůůŽĨǁŚŝĐŚ
insert at a genomic location around 1.5 Mď ? ŽĐĐƵƉŝĞĚ ďǇ Ɍ^Ă ?HO 5096 0412 on the reference 
genome. PCR based phage typing of TS13 and TS14 had already been carried out by Kome 
KƚŽŬƵŶĞĨŽƌĂŶĚŝĚĞŶƚŝĨŝĞĚďŽƚŚĂƐŚĂǀŝŶŐɌWs>(Otokunefor et al, 2012). 
The large number of hits of unaligned contigs to Ɍtp310 phages raised the possibility that TS13 
and TS14 have a PVL encoding phage which is related to ɌWs> but has a greater similarity to 
Ɍtp310 phages. The reference sequence for the Ɍtp310-1 phages includes the sequences for 
lukSF-PV ?ǁŚĞƌĞĂƐɌƚƉ ? ? ?- ĚŽĞƐŶŽƚ ?ƚŚĞƌĞĨŽƌĞĂůŝŐŶŵĞŶƚƐŽĨd^ ? ?ĂŶĚd^ ? ?ƚŽɌWs>ĂŶĚ
ɌƚƉ ? ? ?-1 were carried out initially. 
Mapping the sequenceƐĨŽƌd^ ? ?ĂŶĚd^ ? ?ĂŐĂŝŶƐƚƚŚĞƌĞĨĞƌĞŶĐĞƐĞƋƵĞŶĐĞĨŽƌɌWs>ƐŚŽǁĞĚ
uneven mapping over the first 17 kb of the phage and again towards the final portion between 
37 and 44 kb. There appeared to be even mapping over lukSF-PV (Figure 3.23A). 
Ǉ ĐŽŶƚƌĂƐƚ ? ƐĞƋƵĞŶĐĞ ŵĂƉƉŝŶŐ ĨŽƌ ɌƚƉ ? ? ?-1 showed consistent coverage over the whole 
phage, indicating a greater likelihood of this phage type being present in TS13 and TS14 rather 
ƚŚĂŶɌWs> (Figure 3.23B). 
ƐŵĂŶǇŽĨƚŚĞĐŽŶƚŝŐƐŵĂƚĐŚĞĚƐƉĞĐŝĨŝĐĂůůǇĂŐĂŝŶƐƚɌƚƉ ? ? ?-3, TS sequences were also mapped 
against the reference sequence for this phage. The sequences aligned without gaps, indicating 
TS13 and TS14 encode a phage with a high degree of similarity to Ɍtp310-3 (Figure 3.24). This 
phage encodes staphylokinase and the immunomodulatory proteins CHIPS and SCIN and so is 
also more likely to be present in the TS strains than Ɍ^Ă ?HO 5096 0412 at the 2.1 mb phage insertion 
site. 
Without a full de novo construction of these two strains, any integrated phages could not be 
characterised with certainty. Based on a combination of the contig matches and phage 
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alignment however, it seems that TS13 and TS14 ƉƌŽďĂďůǇĐĂƌƌǇďŽƚŚƚŚĞWs>ƉŽƐŝƚŝǀĞɌƚƉ ? ? ?-
 ?ĂŶĚƚŚĞ/ĞŶĐŽĚŝŶŐɌƚƉ ? ? ?-3.  
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TS13 coverage
TS14 coverage
TS13 coverage
TS14 coverage
lukSF-PV
TS13 coverage
TS14 coverage
TS13 coverage
TS14 coverage
lukSF-PV
Figure 3.23  PVL phage alignments for TS13 and TS14 
ůŝŐŶŵĞŶƚŽĨƐĞƋƵĞŶĐĞƌĞĂĚƐĨŽƌd^ ? ?ĂŶĚd^ ? ?ǁŝƚŚɌWs> ? ?ĂŶĚɌƚƉ ? ? ?-1 (B). Coverage is 
indicated by the graphs for TS13 and TS14 which represent number of reads matching each 
position. Gaps in the graphs indicate there were no reads matching this portion of the reference 
ŐĞŶŽŵĞ ?dŚĞƐĞƋƵĞŶĐĞŵĂƉƉŝŶŐĨŽƌd^ ? ?ĂŶĚd^ ? ?ƚŽɌWs>Đontained gaps (A) whereas the 
ŵĂƉƉŝŶŐƚŽɌƚp310-1 did not (B). 
  
A 
B 
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TS13 coverage
TS14 coverage
TS13 coverage
TS14 coverage
IECStaphylokinase
SCIN
CHIPS
Figure 3.24  Alignment of TS13 and TS14 ƚŽɌƚƉ ? ? ?-3 
ůŝŐŶŵĞŶƚŽĨƐĞƋƵĞŶĐĞƌĞĂĚƐĨŽƌd^ ? ?ĂŶĚd^ ? ?ǁŝƚŚɌƚƉ ? ? ?-3. Coverage is indicated by the 
graphs for TS13 and TS14 which represent number of reads matching each position. Gaps in the 
graphs indicate there were no reads matching this portion of the reference genome. TS13 and 
TS14 sequences mapped well to ɌƚƉ ? ? ?-3, which encodes the immune evasion complex (IEC), 
indicating this phage type is probably present in the TS strains. SCIN = Staphylococcal 
complement inhibitor. CHIPS = chemotaxis inhibitory protein. 
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3.2.5.7 Summary of functionally relevant differences 
The whole genome sequence analyses for TS13 and TS14 were summarised in Figure 3.22. As 
the likely identity of the phages is known, these ĂƌĞ ůĂďĞůůĞĚ ĂƐ ɌƚƉ ? ? ?- ? ĂŶĚ ɌƚƉ ? ? ?-3 
alongside Ɍ^Ă ?HO 5096 0412, and Ɍ^Ă ?HO 5096 0412 respectively. This confirms that TS13 and TS14 
are PVL positive, and also that they carry the immune evasion complex genes.  
The TS strains did not possess SCCmec, as expected. Although gentamicin and trimethoprim 
resistance genes were only identified in a contig from TS14 and not TS13, it seems likely that 
TS13 also possesses these genes given they are both resistant to gentamicin and trimethoprim. 
In terms of potentially important polymorphisms in regulators, SNPs in agrC and sarU in TS13 
were identified. Also, in both strains, another SNP in sarU and one in saeS were also present. 
These are discussed in more detail later (Section 3.3.4.4).  
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3.3 Discussion 
3.3.1 Why does PVL production vary between clinical isolates? 
Large variations in PVL production were noted in vitro between the clinical isolates tested. 
Taken together, the data from the alpha haemolysin western blots, agr activation and inhibition 
experiments and pull-down assays indicate that variable expression of global regulators, 
particularly agr, probably explains the majority of this variation. 
In the strains tested, there was no clear correlation between the amount of PVL produced and 
the severity of clinical infections. Most of the high producing ST22 strains caused skin and soft 
tissue infections, with the cases of severe pneumonia being caused by strains from other 
lineages which produced much less toxin. The numbers are obviously too small to draw any 
firm conclusions, but the limited numbers tested do not support the theory that severe 
infections are always caused by strains which are high PVL producers in vitro. 
The MSSA ST22 lineage was highly represented, and despite some variations in spa profiles 
between isolates, levels of PVL production were similar within this lineage. There are reports 
of CA-MRSA lineages, notably USA300, which are associated with high level toxin expression 
mediated by agr (Li et al, 2010). In a study of a very successful locally circulating strain ST93 CA-
MRSA in Australia, 58 ST93 isolates were found to have similar phage profiles and lukSF-PV 
expression (Coombs et al, 2012). 
There may be a number of reasons why production of PVL and other toxins is similar within 
lineages. This is most likely to reflect historic acquisition of point mutations or horizontal gene 
transfer. Point mutations in global gene regulators or two-component systems which 
coordinate environmental responses could give lineages distinct patterns of toxin expression.  
One possible explanation for the enhanced agr and toxin expression of USA300 is a mutation 
in the pknB gene, a kinase involved in cell wall metabolism, which resulted in reduced 
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expression of sigB and increased expression of agr (Tamber et al, 2010). This however is at 
variance with another study of a sigB mutant which showed hyper production of alpha 
haemolysin and elevated SarA expression (Cheung et al, 1999). In addition to enhanced agr 
expression, the agr regulon was also reported to be altered in USA300 such that higher than 
expected expression of toxin genes including alpha haemolysin (hla) and lukSF-PV resulted. The 
mechanism for this was not clear but speculated to involve non coding RNAs (Cheung et al, 
2011). 
Mutations in toxin repressor genes could influence toxin gene expression both directly and 
indirectly through binding to the promoters of global regulators such as agr and sarA. Rot was 
originally identified from a strain harbouring a Rot-inactivating mutation which showed 
upregulation of toxins (McNamara et al, 2000). 
Horizontal gene transfer could alter global regulation by bringing in repressor genes or 
increasing the overall metabolic load on the bacteria. psm-mec carried by certain SCCmec types 
was found to bind to AgrA mRNA and suppress translation (Kaito et al, 2013). 
Finally, differences in agr activity could be inherently different between agr groups. RNAIII 
expression was noted to be higher in agr group 1 as compared to groups 2 and 3 which could 
partly explain differences in toxin expression between lineages belonging to different agr 
groups (Geisinger et al, 2012). 
In the context of variable PVL production, before considering specific findings in the clinical 
strains studied which could explain the variations it is clearly important to examine how PVL is 
regulated. As differences between strains probably largely revolve around expression of global 
regulators, understanding the role of agr is key.   
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3.3.2 How is PVL production regulated? 
3.3.2.1 The role of agr in regulating PVL production 
It has been known for some time that agr plays a role in regulation of pvl gene expression. agr 
and sarA mutants display markedly reduced transcription of pvl as measured by RT-PCR 
(Bronner et al, 2000). Comparing RNAIII and pvl transcription by the low PVL producing TS13 
and high PVL producing TS14 strains demonstrated a ~60-fold difference in pvl expression with 
a ~10-fold difference in RNAIII expression. This could either indicate that agr is only playing a 
partial role in determining the differences in exotoxin gene expression between the strains or 
that because agr influences the expression of several regulators, the final effect on exotoxin 
expression is amplified.  
In the strains studied, alpha haemolysin production was highest in the strains which also 
produced high levels of PVL toxin, suggesting shared global regulation of both exotoxins in 
these strains. Similarly when exogenous AIP was added to cultures at time of inoculation, 
overnight exotoxin expression of both alpha haemolysin and PVL were much higher. This gives 
a clearer indication of the importance of agr in upregulating PVL production. Conversely, the 
AgrC antagonist (ala5)AIP-1 inhibited PVL production in the strains tested if added early enough 
to cultures. 
The results above are perhaps not surprising given that pvl expression is known to be at least 
in part dependent on agr. The unexpected findings were that the timing of addition of 
exogenous activators or inhibitors is crucial in determining whether they effect PVL production 
or not. TS13, the low producing isolate, responded to exogenous AIP-1 but only if this was 
added early enough. Once the bacteria had entered exponential phase, adding 100 nM of 
exogenous AIP-1 did not appear to have an appreciable effect on toxin production. There was 
a similar effect observed with the agr inhibitor (ala5)AIP-1 which no longer appeared to be 
effective in inhibiting PVL production by TS14, the high producing strain, once 4 h had elapsed 
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from ŝŶŽĐƵůĂƚŝŽŶ ? dŚĞƐĞ ĨŝŶĚŝŶŐƐ ? ƚĂŬĞŶ ƚŽŐĞƚŚĞƌ ? ŝŶĚŝĐĂƚĞ Ă  ‘ǁŝŶĚŽǁ ƉĞƌŝŽĚ ? ĚƵƌŝŶŐ ǁŚŝĐŚ
directly modulating agr with exogenous peptides influences exotoxin production, but once this 
window period has elapsed, agr inhibition or activation no longer has an appreciable impact on 
exotoxin production. From measuring PVL production over time in selected isolates, it seems 
that most of the PVL is produced after exponential phase outside of the window period 
identified, so the unresponsiveness to late addition of the AgrC antagonist is not because the 
PVL has already been produced and secreted. 
RNAIII, the effector mRNA of the agr system, is well characterised as influencing translation by 
forming complexes with other mRNAs as opposed to directly influencing  transcription 
(Geisinger et al, 2006). Comparing gene expression in TS13 and TS14 showed a large enough 
difference to account for differences in exotoxin production without any additional regulation 
at the translational or post-translational levels. In terms of the role of agr in regulating pvl gene 
transcription, this was hypothesised to be due to regulatory proteins whose translation is 
regulated by RNAIII binding directly to the pvl promoter. 
 
3.3.2.2 What do the promoter pull down experiments reveal about pvl regulation? 
The promoter pull down experiments were designed to identify the regulatory proteins which 
interact directly with the pvl promoter. The agr promoter was included in the analysis for 
comparison. The identification of AgrA binding to the agr but not the pvl promoter indicated 
specific regulator-protein binding interactions were occurring. The portion of AgrA that 
interacts with promoters contains a LytR type DNA binding domain (Nikolskaya & Galperin, 
2002). This has been shown to bind to other promoters besides agrP2 (Queck et al, 2008), 
particularly in PSM regulation, but does not appear to interact with the pvl promoter.  
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Consistent results were observed between the isolates tested in terms of the regulators 
identified binding to the promoters. Some of the products such as the ribosomal subunit 
proteins, the DNA topoisomerase and gyrase represent generic DNA binding proteins which are 
not acting as regulators. The Sar family of transcriptional regulators bound to all of the 
promoters in significant amounts, particularly SarA, SarS and SarR. MgrA and Rot, other helix-
turn-helix regulators from the same family were also observed binding to both agr and pvl 
promoters. The involvement of these regulators makes perfect sense from the point of view of 
transcriptional regulation of pvl.  
From comparisons with the regulation of other toxins, SarA is likely to be an important factor 
in upregulating pvl expression, itself being upregulated by agr. As mentioned previously, a SarA 
mutant demonstrated a marked reduction in pvl expression (Bronner et al, 2000). By contrast, 
SarS, SarR and Rot are likely to act as transcriptional repressors. SarS has been previously 
identified as binding to the hla and agr promoters, with knockout mutants demonstrating it has 
a strong repressive effect, itself being repressed by agr and SarA  (Tegmark et al, 2000). MgrA 
is known to regulate spa and hla gene transcription in both an agr dependent and independent 
fashion. (Ingavale et al, 2005). It appears that this regulator may also play a role in regulating 
pvl gene transcription. MgrA seems to act in concert with agr with similar regulator effects and 
so is likely to have a positive effect on pvl gene transcription (Luong et al, 2006). 
Another protein which was identified binding to both pvl and agr promoters was TcaR, which 
shares sequence homology with the other MarR-like transcriptional regulators and is known to 
be a positive regulator of SarS (McCallum et al, 2004). Based on this, it would seem possible 
that TcaR could act to repress PVL toxin production either act directly through binding to the 
pvl promoter, or indirectly by upregulating SarS. 
The pulldown assay was not set up to be a quantitative assay, however large differences in SarS 
and Rot binding were observed between the low PVL producing TS12 and TS13 and the high 
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PVL producing TS14. This could reflect differences in the production of these regulators 
contingent on differences in agr function. As an excess of promoter DNA was used, some of the 
bound protein products identified may not be functionally relevant. Quantifying and optimising 
the quantity of promoter DNA required for the assay would be one approach to attempt to 
distinguish high affinity from low affinity binding. Heterodimer complexes combining different 
Sar subunits could also be another factor further complicating the interactions between 
promoter and regulator which would not have been identified in this assay. 
The involvement of a number of transcriptional activators and repressors in regulating pvl gene 
ĞǆƉƌĞƐƐŝŽŶŵĂǇĞǆƉůĂŝŶƚŚĞ ‘ǁŝŶĚŽǁĞĨĨĞĐƚ ?ĚŝƐĐƵƐƐĞĚĂďŽǀĞĂƐŝƚǁŽƵůĚĞǆƉůĂŝŶƚŚĞŝŵƉŽƌƚĂŶĐĞ
of determining agr expression as early as possible. The regulatory proteins would be 
transcribed and translated during exponential phase of growth, and so their production would 
be determined by RNAIII levels. Once produced, it may be too late to significantly alter their 
production by stimulating or inhibiting agr such that a significant downstream impact on 
exotoxin gene expression would not be observed. 
 
3.3.2.3 Environmental and other factors influencing PVL production 
Activating and inhibiting agr affected PVL production. In addition, well characterised 
staphylococcal transcriptional regulators known to play a role in regulating gene expression 
were identified binding to the pvl promoter. Two other additional factors which may influence 
PVL production were briefly investigated; exposure to sub-inhibitory concentrations of 
antibiotic and the growth medium. 
Adding a sub-inhibitory concentration of oxacillin to the low producing TS13 resulted in much 
higher production of PVL, consistent with previous reports (Dumitrescu et al, 2008). In a follow 
up paper, Dumitrescu et al (2011) analysed the upregulation of pvl gene expression in the 
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presence of several antibiotics by RT-PCR. They found that affinity of the antibiotics for PBP1 
was essential, with non-selective oxacillin and PBP1 selective imipenem demonstrating a clear 
effect, but PBP2 and PBP3 specific antibiotics ineffective. By comparing knockout mutants of 
the regulators Rot, SarA, Agr and SaeRS, they were able to show that Rot and SarA were 
essential for the induction effect, whereas Agr and SaeRS were not.  
Growing TS13 in the presence of both oxacillin and (ala5) AIP-1 resulted in an observable 
reduction in PVL toxin production compared to oxacillin alone, indicating that the induction 
effect does not operate independently of agr even if it is mediated by upstream effects on SarA 
and Rot. 
The exotoxin upregulation observed in the presence of certain beta-lactam antibiotics has been 
put forward previously as a drawback to using these for treatment in situations where toxin 
production plays a major role in pathogenesis; upregulation of alpha haemolysin by oxacillin 
has been known for some time (Ohlsen et al, 1998). The upregulation of shiga toxin by 
quinolones in E. coli is another example of an undesirable antibiotic effect (Kimmitt et al, 1999). 
The exact mechanism for the beta-lactam effect is unknown, although, as mentioned above 
appears to involve both PBP-mediated effects and global regulators. In a recent study of CA-
MRSA, agr repression was observed in the presence of oxacillin, believed to be mediated by 
induction of PBP2a (Rudkin et al, 2013). Surprisingly, although Agr-mediated PSM production 
was reduced, the expression of both alpha-haemolysin and PVL were increased as observed in 
the studies mentioned above. Hence it is not clear if this is an effect that is specific to CA-MRSA, 
which have been shown to constitutively express lower levels of PBP2a than other MRSA strains 
carrying the larger mec cassettes such as type II (Rudkin et al, 2012). As only USA300 and 
USA400 were tested in the study, it is also possible that the agr repression observed is strain 
dependent because of  mutations in key regulators involved in stress responses, such as the 
PknB kinase mutation in USA300 (Tamber et al, 2010). At the present time there does not 
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appear to be any conclusive data besides in vitro experiments to support the hypothesis that 
the use of beta-lactam antibiotics to treat PVL and other exotoxin associated infections worsens 
outcome due to induction of elevated toxins. 
Growth medium is known to influence expression of toxins and global regulators in S. aureus. 
Addition of yeast extract to defined media, the use of rich media and low pH all increase agr 
and alpha haemolysin expression (Jassim et al, 1989; Regassa & Betley, 1992). A brief 
comparison of PVL production by TS13 and TS14 in selected growth media demonstrated that 
growth in CYGP medium resulted in the highest production of PVL. BHI appeared to support 
slightly higher production of PVL by TS14 than TSB or LB. This is broadly consistent with other 
reports of the impact of growth medium on PVL; pvl expression was observed to be 100 fold 
higher in a medium containing yeast extract and casamino acids, similarly to CYGP, than in BHI 
medium (Bronner et al, 2000). pvl expression in CCY medium, another medium containing both 
yeast extract and casamino acids, was noted to be much higher than in TSB and BHI media 
(Malachowa et al, 2011). The presence of yeast extract and casamino acids might favour 
metabolic pathways which are associated with stimulation of agr expression, or perhaps result 
in metabolic byproducts which change the culture environment thereby upregulating agr. 
The potential role for environmental factors in determining gene expression is important as this 
could explain the severity of certain types of infections. Necrotising pneumonia is thought to 
involve a feedback cycle of neutrophil attraction and destruction, leading to the release of 
inflammatory mediators and further tissue damage (Diep et al, 2010). Conditions of 
inflammation and contact with neutrophils could be potential factors that enhance PVL 
production in vivo, contributing to pathogenesis and explaining any mismatch between in vitro 
expression and in vivo severity. A study that compared pvl expression in drained abscess pus to 
in vitro expression found that higher in vivo expression could be only partially explained by 
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higher agr expression. The mismatch in expression was hypothesised to be due to in vivo 
neutrophil exposure (Loughman et al, 2009). 
There are a few other potential factors involved in regulating PVL which were not explored in 
this study. There appears to be strain and phage dependent variation in enhanced PVL 
production in response to induction, with USA300 having defective prophage excision (Wirtz et 
al, 2009). This could be implicated in the response to antibiotics, perhaps also explaining the 
potentially strain dependent nature of antibiotic induction effects. Although there is no 
definitive evidence in the literature to suggest that the type of PVL phage determines 
expression, PVL haplotypes with variations in the gene sequence have been associated with 
different lineages (Chen et al, 2013). PVL phages are also known to integrate into different sites 
depending on the strain background, and this could conceivably influence gene expression 
(Boakes et al, 2011a). 
In summary, PVL production is heavily influenced by agr activity and appears to be also 
regulated by the Sar family of global regulators. Environmental factors are important including 
exposure to antibiotics and the growth media used. Addition of the AgrC antagonist (ala5)AIP-
1 inhibits PVL toxin production if added early enough in growth raising the possibility that AgrC 
antagonists could have a role to play in reducing the severity of PVL and other toxin associated 
infections (Chan et al, 2004). However, the narrow in vitro window period in which these 
inhibitors are effective may be a significant drawback, as in many clinical situations bacterial 
growth is likely to be well established before a patient is symptomatic, with a further delay to 
presentation and treatment. Further studies of the impact agr inhibitors in vivo is required. 
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3.3.3 Do the promoter and agr variations explain the variable PVL production? 
In an attempt to explain the observed differences in PVL production between the clinical 
isolates, pvl and agr promoter and operon-wide agr sequence analysis was performed. The agr 
promoter sequence polymorphisms identified occurred in regions where the functional 
significance is not known. Some of these polymorphisms, particularly the C to A substitution in 
agrP2 found in TS13, TS14 and HO 5096 0412, are probably conserved in certain lineages 
without functional significance. Importantly, no polymorphisms were identified in the AgrA 
DNA-binding regions, a point mutation in which was previously found to cause a marked 
reduction in agr expression (Koenig et al, 2004; Villaruz et al, 2009). agrP2 and agrP3 can still 
activate in an AgrA-independent manner although much less effectively (Reynolds & 
Wigneshweraraj, 2011). 
Even less is known about the pvl promoter, and this made it difficult to draw any firm 
conclusions from the sequence data. As already described, the three promoter sequence 
polymorphisms which were identified were present across several strains with all of the ST22 
strains TS6, TS13 and TS14 having identical sequences. It appears as though the polymorphisms 
probably reflect different PVL phage types and in the absence of clear patterns between those 
and PVL production, they were not taken forward for further analysis. While it seems plausible 
that pvl promoter mutations could occur which significantly reduce pvl production, these would 
be unlikely to impact on global regulation or expression of other toxins in a manner that would 
explain the expression patterns observed in the clinical strains. This is in contrast with 
staphylococcal proteases which appear to be key mediators of secretion and accumulation of 
several other virulence factors including PVL and alpha haemolysin (Kolar et al, 2013). 
The analysis of the complete agr operon in selected strains identified many variations from the 
reference sequences, particularly in TS1 which appears to be from an unusual strain 
background. Without recreating each of these in a reporter system it is difficult to determine 
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what impact they may have on agr expression and hence exotoxin production. One of the 
drawbacks of this diverse collection of strains is that there are insufficient numbers 
representing each of the different strain types to build up a clear picture of which nucleotide 
substitutions are associated with particular backgrounds. Fortunately, there were a large 
enough number of ST22 strains to draw attention to the lower PVL production of TS13. 
Comparing the ST22 sequences then confirmed that the observed agr polymorphisms were 
common to all of the isolates except that observed in the TS13 agrC cytoplasmic domain region. 
This mutation clearly warranted further study and will be investigated and discussed in more 
detail in the next chapter. There are a number of other agrC cytoplasmic domain region 
mutations reported in the literature as occurring in clinical isolates which have impaired agr 
functionality (Somerville et al, 2002; Traber et al, 2008). 
While little is known about the specific functions of different regions of the AgrC cytoplasmic 
domain, other parts of the AgrC protein have been better characterised, particularly the AgrC 
AIP binding domain. This is predicted to have three surface loops which are important for AIP 
binding and recognition (Jensen et al, 2008). While the ST22 isolates and the agr group 3 
isolates tested did not have any predicted amino acid substitutions in these loops, TS1 had 
three; V42G, S44T and S109N, all of which could potentially impair receptor functionality. 
While no polymorphisms were found in the agrD sequences, some were observed in agrB which 
could potentially effect AgrD processing and therefore AIP production. As TS1 produces both 
PVL and alpha haemolysin it seems likely that agr is functioning and that some AIP is being 
produced however. 
Finally, there were two polymorphisms in agrA which were predicted to change the amino acid 
sequences of the LytR-like DNA binding region, AgrA K136R in TS21 and AgrA D194N in TS1. As 
there were no other isolates with a similar strain background or identical changes to compare 
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these two, they were not investigated further, but could conceivably impact on AgrA binding 
to DNA. 
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3.3.4 What do the whole genome sequences reveal about the ST22 strains? 
3.3.4.1 How do TS13 and TS14 compare with other reported S. aureus genomes? 
There were several reasons for selecting TS13 and TS14 for whole genome sequencing. The 
ST22 PVL MSSA strains were the most heavily represented in the strain collection and appeared 
to be the PVL strain most commonly identified by the clinical laboratory at the time the strains 
were collected. Furthermore, the genotypic similarity but phenotypic incongruence of TS13 and 
TS14 presented a unique opportunity to study naturally occurring differences which impacted 
significantly on exotoxin production. 
There are other reports in the literature about PVL producing ST22 strains, predominantly 
focusing on CA-MRSA strains as opposed to MSSA. A PVL positive ST22 SCCmecIV strain which 
was also resistant to gentamicin and trimethoprim caused an outbreak in a neonatal unit in 
Australia (Pinto et al, 2013). The strain appeared to be highly transmissible and caused several 
severe infections with 2 fatalities over a 7 month period. In the UK, the Staphylococcus 
Reference Unit reported that CC22 strains, including the HA-MRSA EMRSA15, have caused 
significant public health problems. They studied PVL positive CA-MRSAs which were identified 
as belonging to CC22 by PFGE and found that the majority were spa type t005, carried 
SCCmecIVc and ɌPVL and were resistant to gentamicin and trimethoprim (Boakes et al, 2011b). 
The authors also observed that EMRSA-15 is epidemiologically distinct from the CC22 PVL 
positive strains. From comparison with their data it seems that TS13 and TS14 are very closely 
related to these PVL CA-MRSAs  W the ST22 PVL MSSAs probably represent a reservoir of 
circulating strains that SCCmec acquisition events could occur in. Alternatively, loss of mec 
elements has been speculated to occur such that successful circulating CA-MRSAs revert back 
into MSSAs when selective pressure is lacking. A study in the United States identified CC8 MSSA 
strains which bore close similarity to USA300, having the same R variant PVL phage and 
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sequence type (Brown et al, 2012). Phages are often acquired, lost and transferred between 
lineages (McCarthy et al, 2012). 
When compared with the publicly available genome sequence data by BLAST searching, the 
reference genome HO 5096 0412 was the closest available match to TS13 and TS14. HO 5096 
0412 is representative of EMRSA-15, one of the two predominant HA-MRSA clones established 
in the UK. In an analysis of the development of EMRSA-15 within the ST22 lineage, Holden et al 
(2013) traced the divergence of the ST22-A cluster of which EMRSA-15 is a member. EMRSA-15 
and relatives are genetically distinct from non-ST22-A strains, having acquired SCCmecIVh as a 
defining event for this cluster. In addition, a large proportion of the clade, designated ST22-A2, 
have a point mutation conferring resistance to fluoroquinolones and most have the ermC gene 
conferring resistance to erythromycin. ST22-A strains carrying the pvl genes have not been 
identified so far, possibly because they already have a phage inserted at the ɌSa2 site which 
encodes a BcgI-like restriction enzyme. 
TS13 and TS14 do not have any of the defining features of the ST22-A group and this is again 
consistent with the notion that they are non-ST22-A strains, more closely related to the ST22 
PVL CA-MRSAs analysed by Boakes et al (2011), probably representing the pool from which mec 
acquisition could occur (Figure 3.25). 
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Figure 3.25  The hypothetical development of PVL positive ST22 MRSA  
ST22-MSSA spa type t005 strains may have acquired a PVL phage, creating a pool of successful, 
circulating PVL MSSA strains which subsequently acquired SCCmec elements on numerous 
occasions. Adapted from Boakes et al (2011b) 
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3.3.4.2 What does the sequence analysis reveal about the virulence of TS13 and TS14? 
Genome wide comparison of TS13 and TS14 to HO 5096 0412 confirmed a number of virulence 
factors which were present in all of the strains. The presence of the immune evasion complex 
(IEC) carried on the phage integrated at ɌSa3 is potentially important. The IEC includes the 
immunomodulators CHIPS, SCIN and staphylokinase (SAK) which confer the bacteria with a 
significant advantage in avoiding phagocytosis. CHIPS, the chemotaxis inhibitory protein, 
interferes with activation of neutrophils by complement signaling while SCIN, the 
staphylococcal complement inhibitor, prevents the formation of C3b on the bacterial cell 
surface by blocking C3 convertase (van Wamel et al, 2006). SAK is understood to interfere with 
the innate immune system in various ways to inhibit opsonisation (Rooijakkers et al, 2005b). 
The combination of several virulence factors that inhibit phagocytosis with the production of 
PVL is likely to be potent as this would provide synergistic benefit for both evading and 
destroying neutrophils before they can prevent bacterial invasion. 
In addition to these phage-encoded virulence determinants, the expected collection of core 
genome encoded genes were also present which promote epithelial surface binding and 
colonization including the fibronectin binding protein A (fnbpA), clumping factors A and B (clfA 
and clfB) and collagen binding protein (cna). 
In terms of exotoxins, TS13 and TS14 were already known to carry two of the enterotoxin genes, 
seg and sei, and while beta-haemolysin is inactivated by the presence of the hlb converting 
phage inserted at ɌSa3, genes for alpha, delta and gamma-haemolysin were present. 
As expected, TS13 and TS14 did not have an SCCmec element which was confirmed by the 
observation that sequences from these strains did not map to the HO 5096 0412 SCCmecIVh 
sequence. All of the strains did, however, appear to have the Tn554-like transposon which 
encodes a beta-lactamase and confers resistance to penicillin. The aminoglycoside transferase 
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and dihydrofolate reductase conferring resistance to gentamicin and trimethoprim respectively 
were identified through plasmid fragment analysis. Gentamicin resistance is unlikely to be of 
much benefit in the community as aminoglycoside antibiotics are usually only administered 
intravenously in hospitals. Trimethoprim resistance may be of greater benefit to the bacteria in 
colonising certain patient groups as this is a widely used first line to treat uncomplicated urinary 
tract infections. 
The disadvantage in a comparative genome analysis as conducted here instead of a complete 
de novo genome reconstruction is that virulence factors which are encoded by the test strains 
but not the reference strain may be missed. Analysing the larger unmapped contigs with BLAST 
searches was carried out to identify any larger mobile genetic elements that may not have been 
picked up in the direct comparative analysis, but smaller elements such as transposons may not 
have been identified.  
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3.3.4.3 Phage identification 
Identifying the specific phages carried by TS13 and TS14 was difficult due to the reasons 
described above  W these were the regions of the genomes that differed the most from HO 5096 
0412. 
Phages in S. aureus are tailed, termed Caudoviridae, and are generally of the subtype 
Siphoviridae, being about 40 kb in size (Goerke et al, 2009). Distinct patterns of phage clustering 
are seen by sequence type as phage insertion appears to be restricted by lineage. The ordering 
of genes within the Siphoviridae phages are as follows: lysogeny (including integrase), 
replication, packaging, head, tail and lysis (Deghorain & Van Melderen, 2012). Virulence genes 
are found at either end of the phage sequence, presumably because these were originally 
 ‘ƉŝĐŬĞĚƵƉ ?ďǇƚŚĞƉŚĂŐĞƐĚƵƌŝŶŐŝŶƚĞŐƌĂƚŝŽŶŝŶƚŽŽƚŚĞƌůŝŶĞĂŐĞƐŽƌƐƉĞĐŝĞƐĂŶĚƐƵďƐĞƋƵĞŶƚůǇ
carried as part of the phage genetic material. Staphylococcal phages are classified according to 
the integrase genes which also define where they integrate on the staphylococcal chromosome 
(Xia & Wolz, 2013). 
There appear to be two phages in TS13 and TS14, with the PVL and IEC phages integrating at 
the second and third phage integration site respectively. Nearly all of the known PVL encoding 
phages integrate at ɌSa2 (Goerke et al, 2009). HO 5096 0412 has a different phage at this site 
which encodes the BcgI-like restriction enzyme but not PVL. PCR based phage typing had 
indicated that TS13 and TS14 were both carrying ɌWs> ?ĂůƚŚŽƵŐŚƚŚĞƐĞƋƵĞŶĐŝŶŐƌĞĂĚƐĚŝĚŶŽƚ
align consistently with this phage. Based on the unaligned fragment analysis and the 
comparison of TS mapping to ɌWs>ĂŶĚɌƚƉ ? ? ?- ? ?ŝƚƐĞĞŵƐƚŚĂƚɌƚƉ ? ? ?-1 is the closest match. 
dŚŝƐƉŚĂŐĞŚĂƐĂƚǇƉĞ ?ŝŶƚĞŐƌĂƐĞ ?ƐŽǁŽƵůĚŝŶƚĞŐƌĂƚĞĂƚƚŚĞɌ^Ă ?ŝŶƐĞƌƚŝŽŶƐŝƚĞĂƐĞǆƉĞĐƚĞĚ ?
and also carries the pvl genes (Xia & Wolz, 2013). Without a complete de novo strain 
construction this cannot be conclusively determined. 
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The beta haemolysin converting phage integrating at the ɌSa3 site, rendering the strains hlb 
negative, appears to be similar to that in HO 5096 0412 as already discussed. hlb converting 
phages occur more commonly in colonising strains, perhaps because of the advantage the IEC 
confers against the innate immune system (Goerke et al, 2009). As already discussed, ɌƚƉ ? ? ?-
 ?ĂƉƉĞĂƌƐƚŽďĞƚŚĞďĞƐƚŵĂƚĐŚĨŽƌƚŚĞƉŚĂŐĞƐƉƌĞƐĞŶƚĂƚɌSa3 in TS13 and TS14, carrying the 
three genes of the IEC and having a type 3 phage integrase (Xia & Wolz, 2013). 
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3.3.4.4 Does the whole genome sequencing data explain the phenotypic differences? 
One of the principal reasons for analysing the genome sequences of these strains was to 
determine whether any other explanations could be found for their differing exotoxin 
production phenotypes. 
The survey of staphylococcal regulators which included the Sar family, rot, mgrA, saeRS and agr 
revealed SNPs in saeS and sarU in addition to the change already identified in agrC. 
Holden et al (2013) produced a comparison of gene polymorphisms which distinguish the ST22-
A clade from non-ST22-A strains. The supplementary data for their paper, Table S3, lists the 
SNPs that differentiate ST22-A from non-ST22-A strains, which should encompass TS13 and 
TS14. The substitution identified in saeS is included in this list, indicating that this SNP likely 
occurred during the development of the ST22-A lineage and that TS13 and TS14 have the 
original saeS sequence. 
The function of SarU is described by Manna and Cheung (2003) as a SarA homolog which 
regulates agr expression in conjunction with SarT (Manna & Cheung, 2003). A sarT mutant 
showed increased transcription of sarU indicating that SarT is likely activating as a 
transcriptional repressor of sarU. A sarU mutant showed reduced expression of RNAII and 
RNAIII. 
Both TS13 and TS14 were predicted to have a C102R amino acid substitution in SarU compared 
to HO 5096 0412. The reference sequence for SarU in GenBank (Accession ID AFD54311.1) 
however, also has an arginine at residue 102 so it appears as though this change is not unique 
to TS13 and TS14 and may reveal a mutation from the wild type acquired by HO 5096 0412. 
TS13 also has an aspartate to tyrosine substitution D134Y in SarU. As SarU is known to be a 
positive regulator of agr, a mutation in SarU could conceivably result in reduced agr expression 
and the resulting phenotype associated with TS13 as compared to TS14. A change of aspartate 
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to tyrosine could potentially have a functional impact on the protein, substituting a carboxyl 
group for a phenol group. SarU binding was not observed in significant quantities to the agr 
promoter during the promoter pulldown experiments so it is not possible to conclude whether 
SarU had failed to bind in TS13 as compared to TS14. Transcriptional profiling of sarU by RT-
PCR may provide more information, however if this mutation impacted the translation or 
subsequent functioning of SarU rather than transcription, no difference would be observed. 
Based on the whole genome sequencing data, it appeared that the AgrC N267I and SarU D134Y 
substitutions were the best candidates for explaining the phenotypic differences observed in 
TS13 and TS14. This observation mandated further exploration of the functional impact of AgrC 
cytoplasmic domain mutations, such as that identified in TS13, including reconstruction of this 
and other mutations in a different S. aureus strain background. 
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3.3.5 Key Findings  
 
1. In a collection of PVL positive clinical isolates from Nottingham, large variations in PVL 
production were noted. 
2. MLST 22 PVL positive MSSA isolates were the largest subgroup and all showed high 
levels of toxin production except for one isolate, TS13. 
3. PVL production could be stimulated by exogenous AIP or repressed by an AgrC 
competitive antagonist (ala5)AIP-1 if these were added early enough during growth. 
4. Promoter pull down assays demonstrated (i) the binding of Sar family proteins to the 
agr and pvl promoters, particularly SarA, SarR and SarS but also MgrA and Rot and (ii) 
the lack of AgrA-binding directly to the pvl promoter. 
5. Analysis of promoter and agr locus sequences did not give a clear indication as to why 
differences in PVL production occurred between strains except for the presence of a 
single nucleotide polymorphism in the agrC gene of the low PVL producer TS13.  
6. Expression of agr and pvl is lower in TS13 than the high PVL producer TS14 when 
measured by RT-PCR. 
7. Whole genome sequence analysis of TS13 and TS14 revealed they both carry the 
immune evasion complex in addition to the PVL genes and are very similar genetically.  
8. The predicted amino acid substitutions in TS13 AgrC N267I and SarU D134Y are the best 
candidates for explaining the differences in exotoxin expression between TS13 and 
TS14.  
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4 Agr kinetics and agrC cytoplasmic domain polymorphisms 
 
4.1 Introduction 
4.1.1 agr polymorphisms in clinical strains 
There are numerous reports of agr dysfunction in clinical S. aureus strains, with mutations 
identified throughout the locus from the promoter regions, as previously discussed, to those 
impacting on AIP processing (agrB), AIP recognition (agrC) and signal transduction (agrC and 
agrA) (Somerville et al, 2002; Traber et al, 2008; Villaruz et al, 2009). These mutations are 
usually described as resulting in an agr null phenotype with no observable haemolytic activity, 
and involve amino acid substitutions, deletions resulting in frame shifts or premature stop 
codons. 
The agrC SNPs investigated in this chapter were all found in the cytoplasmic domain region of 
agrC. The receptor domain has been reasonably well characterized (although the three 
dimensional structure has not been elucidated), with transmembrane domains and loops 
predicted, and the consequences of substituting specific amino acids analysed (Jensen et al, 
2008). By contrast, the cytoplasmic domain has not been studied in detail. The function of 
several key residues was investigated by George Cisar et al (2009) by using a dual plasmid 
expression system to analyse AgrC dimerisation. AgrC H239 is phosphorylated following 
dimerisation by a kinase domain on the dimer counterpart, in which G394 and G396 appear to 
be important. Replacing both the glycines in the kinase domain with alanine inactivated AgrC. 
The impact of several agrC SNPs, including that found in TS13, was investigated here through 
site specific mutagenesis of an agr group 1 bioreporter and the implications for our 
understanding of agrC structure discussed. 
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4.1.2 Analysis of agr kinetics 
The data for exogenous AIP activation of exotoxin production presented in the previous chapter 
indicate that timing of AIP production is important. Exotoxin production in S. aureus is already 
known to be growth phase dependent, with late exponential phase representing a key 
population density for exotoxin expression (Tegmark et al, 2000). 
In light of these findings, clinical isolates were analysed for AIP production over the growth 
curve, comparing those with and without agrC cytoplasmic mutations. This was intended to 
provide further evidence as to the importance of a window period during exponential phase in 
which agr must be activated for high level exotoxin production to occur.  
Aside from agr sequence variation, the presence of specific SCCmec elements has also been 
shown to determine agr expression and hence exotoxin production (Rudkin et al, 2012). The 
impact on agr kinetics of deleting the mecA gene from an HA-MRSA strain was investigated to 
determine whether changes in agr kinetics could be a universal marker for altered agr function. 
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4.1.3 Chapter Overview 
 
1. Selected clinical isolates were assayed for AIP production over the growth curve to 
identify any differences in Agr kinetics between strains with varying phenotypes. 
2. Deleting mecA from a HA-MRSA strain was demonstrated to affect agr kinetics. 
3. The agrC polymorphism in TS13 and several other agrC polymorphisms associated with 
large reductions in exotoxin expression were introduced into a bio reporter to assess 
the impact on AgrC function. 
4. The N267I amino acid substitution in TS13 was introduced into a neutral background 
with a complete auto induction circuit and demonstrated to delay agrP3 activation. 
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4.2 Results 
4.2.1 Kinetics of AIP production  
4.2.1.1 AIP production as a function of growth in TS13 and TS14 
Having identified the agrC mutation in TS13, a series of experiments were conducted to 
determine whether it impacts on the onset of AIP-1 production in TS13 compared with TS14. 
This is particularly relevant in the context of the earlier series of western blots demonstrating 
that exogenous AIP-1 must be added to TS13 before late-exponential growth (~OD 1 in CYGP 
medium) otherwise only low level toxin production occurs. The hypothesis was that 
accumulation of AIP-1 in TS13 had not reached a sufficient concentration by this key point. 
Overnight cultures of TS13 and TS14 were inoculated at a final concentration of 1:1000 in CYGP 
and broth and grown for 6 h until exponential phase. After centrifugation, supernatants from 
these cultures were assayed for AIP-1 using the group 1 agrP3-lux bioreporter ROJ143 which 
has the agrP2C1A genes on a plasmid and so does not produce AIP-1 but will respond to 
exogenous AIP, producing light (Jensen et al, 2008). The assay was performed as described in 
section 2.8.3. Light output was measured on a luminometer and expressed as relative light units 
divided by the bioreporter optical density (RLU/OD). 
The TS14 supernatant collected at 6 h activated the bioreporter; giving a peak RLU/OD of 294.7 
compared to the background luminescence peak of 38.3 if no supernatant was added. The 6 h 
TS13 supernatant did not activate the reporter however, with a peak RLU/OD of 33.0, similar 
to the background luminescence. The lower limit of detection of AIP-1 in supernatant, which is 
diluted 1:10, is 10 nM based on a minimum concentration of AIP-1 required to activate the 
reporter of 1 nM. The TS13 AIP-1 concentration at 6 h must therefore have been less than 10 
nM. 
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To give a clearer picture of the differences in the onset and accumulation of AIP, this 
experiment was repeated, using BHI as bacterial growth is faster and higher population 
densities are reached, and using a higher starting inoculum of 1:500. Cell pellets from overnight 
cultures were washed 3 times in BHI prior to inoculation to ensure there was no carryover of 
residual AIP. Cultures were set up in triplicate. After a 2 h incubation, 500 µl volumes of culture 
were removed every 30 min until stationary phase and the supernatant assayed for AIP-1. 
Compared to CYGP where AIP-1 was previously undetectable in TS13 supernatants at 6 h (~OD 
2), in BHI AIP-1 was detected in TS13 from 4 h (OD 5.0) onwards, reflecting the faster growth 
and higher cell densities. 
To quantify AIP-1 production over time, the response of ROJ143 to serial dilutions of a known 
concentration of AIP-1 was also measured. RLU/OD values for known concentrations of AIP-1 
were compared with RLU/OD values for the test supernatants and the original AIP-1 
concentrations of the cultures calculated (Figure 4.1). 
AIP-1 was undetectable at 3 h (OD 1.1) in both TS13 and TS14, however at 4 h (OD 5.0), TS14 
AIP-1 concentration was 125 nM (+/- 52.3) compared to 12.8 nM (+/- 3.5) for TS13. An hour 
later (TS13 OD 8.0, TS14 OD 7.0), TS13 AIP-1 concentration had increased to 246 nM (+/- 50.4) 
but TS14 AIP-1 concentration had already peaked at 941 nM (+/- 127). In addition to the delay 
observed in AIP-1 production by TS13, final AIP-1 concentration in stationary phase (t = 6 h, 
TS13 OD 11.0, TS14 OD 10.5) was approximately half in TS13 compared with TS14 at 546 nM 
(+/- 32.3) compared with 1050 nM (+/- 40.2) (p<0.0001). 
From these data it seems that AIP-1 production by TS13 is delayed by about 1 h under these 
growth conditions and that the final AIP-1 concentration achieved in stationary phase is also 
lower. This raises the hypothesis that the mutation in AgrC could potentially impact on the 
efficiency of autophosphorylation and subsequent phosphotransfer to AgrA in response to AIP-
1 receptor activation. Even with the agr autoinduction loop still functioning, the reduction in 
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efficiency could be sufficient to delay the time taken to drive up AIP-1 production resulting in 
lower overall levels of signal molecule and hence toxins. 
A delay in AIP-1 reaching concentrations of over 100 nM by only 1-2 h could be important 
because the critical period in exponential phase when RNAIII levels determine the translation 
of other staphylococcal regulators, particularly Rot, would be missed (Geisinger et al, 2006). 
Although TS13 agr is clearly active by late exponential and early stationary phase, it is possible 
that by this point many of the toxin repressors such as SarS, Rot and SarR have already been 
produced in sufficient quantities to prevent high level toxin production from occurring. 
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Figure 4.1  AIP-1 production by TS13 and TS14 as a function of growth 
Comparison of AIP-1 production by TS13 and TS14 throughout growth. TS13 unlike TS14 has an 
AgrC N267I amino acid substitution. AIP-1 concentrations (solid lines) were determined by 
assaying culture supernatants with a bio-reporter. Growth curves (dotted lines) show the 
transition from late exponential to stationary phase at about 4 h (OD 5.0), at which point AIP-1 
was detectable in TS14 supernatants. The AIP-1 concentration in the TS14 supernatants is 
almost double that of TS13 at stationary phase (TS13 OD 11.0, TS14 OD 10.5). Error bars indicate 
standard deviations based on testing triplicate culture supernatants. 
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4.2.1.2 AIP production by other clinical isolates with AgrC cytoplasmic mutations 
Additional, naturally occurring AgrC cytoplasmic domain mutations were identified by Dr Ruth 
Massey at the University of Bath in a large group of genetically related PVL negative ST239 
clinical isolates from Turkey. These strains were being evaluated as as part of a larger study to 
test the feasibility of using genome wide association study to predict staphylococcal virulence. 
Hence, they presented an opportunity to broaden the investigation of agrC cytoplasmic 
mutations.  
 
4.2.1.2.1 AIP production by strains with I311T and A343T AgrC amino acid substitutions 
Compared with the NCTC8325 group 1 agrC sequence, some of the ST239 strains had a T to C 
base change resulting in an I311T amino acid substitution in AgrC. Many of these strains were 
found to be highly lytic in their T-cell assay (Ruth Massey, personal communication), although 
a subgroup of strains with reduced lysis was also found to have a G to A base change resulting 
in an A343T substitution in AgrC. The T-cell assay involves incubating T cells with bacterial 
supernatant for 10 minutes and measuring cell death (Collins et al, 2010). It therefore 
represents the overall activity of several cytolytic exotoxins. 
AIP-1 production by two of these strains, IU12, which has the I311T change, and HU24 which 
has both I311T and A343T, were compared by repeating the same experiment performed with 
TS13 and TS14 (Figure 4.2). AIP-1 production was delayed in both of these strains with AIP 
barely detectable by 8 h (OD 9.0) in HU24 at 52.1 nM (+/- 7.8) but with a significantly higher 
concentrations in IU12 (OD 8.0) supernatant at 463 nM (+/- 92.3) (p<0.01). 
The delay observed in both of these strains may be a factor of the strain background, or could 
result from the I311T change. The very low AIP-1 production by HU24 would be in keeping with 
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a greater functional impact of the double substitution I311T-A343T than that observed in TS13 
with N267I. 
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Figure 4.2  AIP-1 production by HU24 and IU12  as a function of growth 
HU24 and IU12 both have an AgrC I311T amino acid substitution, while HU24 also has an 
additional AgrC A343T substitution. AIP-1 concentrations (solid lines) were determined by 
assaying culture supernatants with a bioreporter. Growth curves (dotted lines) show the 
transition from late exponential to stationary phase at about 5 h. AIP-1 was first detectable in 
IU12 supernatants at 6 h (OD 5.5) and concentrations increased markedly after that to ~10 fold 
greater than HU24 at 8 h (IU12 OD 8.0, HU24 OD 9.0). Error bars indicate standard deviations 
based on testing culture supernatants in triplicate. 
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4.2.1.2.2 AIP production by strains differing by a T247I AgrC amino acid substitution 
Among the ST239 strains in the Bath University collection were two very closely related strains 
ICP5014 and ICP5062 which differed across their genomes by only 111 nucleotides, one of 
which conferred a T247I AgrC amino acid substitution. When tested in the T-cell assay (Ruth 
Massey, personal communication), the ICP5062 strain with the T247I change was less cytolytic 
with only 4 % T cell death compared to 85 % for ICP5014. 
When AIP-1 concentrations were assayed over the growth curve as above, ICP5014 produced 
moderate amounts of AIP-1 compared with the other strains tested previously, with AIP-1 
detectable by 4 h (OD 3.5) at 46.8 nM (+/- 15.1), rising to a concentration of 607 nM (+/- 115) 
by 7 h (OD 6.5) (Figure 4.3). ICP5062 on the other hand, barely produced any AIP-1 over the 
time frame tested, with a significantly lower AIP-1 concentration at 7 h (OD 7.0) of 53.4 nM (+/- 
6.0) (p<0.01). 
These findings are consistent with T247I having a significant impact on agr function, probably 
accounting for the large reduction in T cell cytolysis observed for ICP5062 as compared with 
ICP5014. 
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Figure 4.3  AIP-1 productionby ICP5014 and ICP5062 as a function of growth 
ICP5062 but not ICP5014 has an AgrC T247I amino acid substitution. AIP-1 concentrations (solid 
lines) were determined by assaying culture supernatants with a bioreporter. Growth curves 
(dotted lines) show the transition from late exponential to stationary phase at about 4 h. AIP-1 
was first detectable in ICP5014 supernatants at 4 h (OD 3.5) with concentrations peaking at 
around 600 nM by 7 h (OD 6.5), more than 10-fold higher than ICP5062 AIP-1 concentrations 
at the same time point (7h, OD 7.0). Error bars indicate standard deviations based on testing 
triplicate culture supernatants. 
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4.2.1.3 Impact of mecA on AIP production 
Studying AIP-1 production by strains with agrC cytoplasmic domain SNPs demonstrated delays 
in AIP-1 production. This raised the question as to whether differences in agr kinetics, the 
timing and concentration of AIP-1 produced, may be a broader marker of differential in agr 
activity. 
Rudkin et al (2012) had previously shown that deleting the mecA gene enhanced the T cell 
cytolytic activity of a HA-MRSA strain BH1CC by upregulating agr expression, although the 
precise mechanism for this effect was not fully understood. By  externally treating the cell wall 
of whole BH1CC cells with lysostaphin, a similar increase in cytolysis was observed and 
therefore hypothesized that the modified cell wall present in HA-MRSA strains could impact on 
the capacity for AIP to access and bind to the cell membrane. 
The HA-DZ^ , ? ƵƐĞĚ ŝŶ ƚŚŝƐ ƐƚƵĚǇ ĂŶĚ ŝƐŽŐĞŶŝĐ ȴmecA mutant were tested for AIP-1 
production during growth, to see if the differences in agr expression previously identified in 
terms of RNAIII expression and cytolysis were matched by changes in agr kinetics. BH1CC 
ȴmecA produced AIP-1 earlier than BH1CC (4.5 h, OD 4.5), resulting in a higher concentration 
by stationary phase (6h, OD 7.0) of 373 nM (+/- 26.5) compared with BH1CC (6h, OD 7.5) which 
had a concentration of 144 nM (+/- 39.6) (p<0.01) (Figure 4.4). 
 This finding is consistent with the enhanced agr expression and T-cell lysis observed by Rudkin 
et al (2012) following the deletion of the mecA gene. Whatever the mechanism by which the 
activity of MecA is interfering with agr expression it would appear that AIP-1 production is 
consequently delayed and reduced. 
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Figure 4.4  AIP- ?ƉƌŽĚƵĐƚŝŽŶďǇ, ?ĂŶĚ, ?ȴmecA as a function of growth 
AIP-1 concentrations (solid lines) were determined by assaying culture supernatants with a 
bioreporter. Growth curves (dotted lines) show the transition from late exponential to 
stationary phase at about 4 h. AIP-1 was first detectable in BH1CC ȴmecA supernatants at 4.5 
h (OD 4.5) with concentrations peaking at ~375 nM by 6 h (OD 7.0), more than double those 
found in BH1CC at the same time point (6h, OD 7.5). Error bars indicate standard deviations 
based on testing triplicate culture supernatants. 
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Table 4.1  Kinetics of AIP production by clinical strains 
Summary of AIP production profiles of paired clinical strains analysed throughout growth. 
Strains are shown with corresponding AgrC mutations in brackets. The timing when AIP was 
first detected is indicated with the mean final AIP concentrations shown in nM (+/- standard 
deviation). Growth rate (µ) was calculated as ln2/doubling time (h) during exponential phase. 
 
Strain  
(AgrC substitution) 
Peak OD Growth 
rate (h-1) 
Time of AIP 
induction (h) 
Final AIP 
concentration (nM) 
     
TS14  10.5 1.54 3.5 1050 (+/- 40.2) 
TS13 (N267I) 11.0 1.54 4.5 564 (+/- 32.3) 
     
IU12 (I311T) 8.0 1.24 6.0 463 (+/- 92.3) 
HU24 (I311T/A343T) 9.0 1.25 7.0 52.1 (+/- 7.8) 
     
ICP5014 6.5 1.36 4.0 607 (+/- 115) 
ICP5062 (T247I) 7.0 1.32 7.0 53.4 (+/- 6.0) 
     
BH1CC 7.5 1.48 5.5 144 (+/- 39.6) 
BH1CC ȴmecA 7.0 1.45 4.5 373 (+/- 26.5) 
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4.2.2 Analysis of functional impact of AgrC mutations 
4.2.2.1 Site directed mutagenesis of the Agr group 1 bioreporter 
While it was clear that the clinical strains tested with AgrC cytoplasmic mutations showed 
differences in the AIP production profiles, it was not possible to be certain whether the AgrC 
substitutions were responsible, wholly or partly, for the observed phenotype. The presence of 
an autoinduction circuit could also mask the impact of the mutations, or conversely may amplify 
the effect of small reductions in AgrC sensitivity to AIP and signal transduction efficiency. 
To attempt to elucidate more precisely the functional impact of the AgrC mutations identified 
so far, site directed mutagenesis was performed on the plasmid, encoding agrP2CA, carried by 
the group 1 agrP3-lux bioreporter (Jensen et al, 2008). This bioreporter is responsive to AIP-1 
but does not produce AIP, enabling reductions in signal response to be quantified directly. 
Phosphorylated primers containing the required base substitutions (Table 2.4) were used to 
amplify the agrP2CA plasmid before transformation back into the ROJ48 reporter strain which 
has an agrP3-lux fusion in place of the agr locus (section 2.8.2). 
The mutated reporters were incubated with serial dilutions of AIP-1 and bioluminescence 
values used to generate EC50 values which could be compared with the wild type group 1 
reporter. 
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4.2.2.2 Functional impact of AgrC mutations found in TS13 and TS14 
When compared to S. aureus NCTC8325, TS13 and TS14 were both found to have a Y251F AgrC 
substitution, with only TS13 harbouring the N267I change. 
To determine whether either or both of these substitutions would impact on AgrC function, 
three reporters were made; one with AgrC-N267I only, one with AgrC-Y251F and one with both 
AgrC-N267I and AgrC-Y251F. 
The AgrC-Y251F mutation, when introduced into ROJ48, resulted in little difference compared 
with the control with EC50s of 2.8 nM (+/- 1.2 nM) and 3.4 nM (+/- 0.6 nM) (p>0.05) respectively 
(Figure 4.5). The AgrC-N267I mutation however exhibited a significant, ~3-fold reduction in 
sensitivity to AIP-1 with an EC50 value of 9.6 nM (+/- 1.6 nM) (p<0.01) (Figure 4.6A). Although 
the AgrC-Y251F-N267I reporter also had reduced sensitivity with an EC50 of 9.3 nM (+/- 1.8 nM) 
(p<0.01), this did not differ significantly from the EC50 for AgrC-N267I (p>0.05) (Figure 4.6B). 
In summary, the AgrC-N267I appears sufficient to cause an approximately three-fold reduction 
in reporter sensitivity, while AgrC-Y251F had no effect.  
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Figure 4.5  Functional impact of a Y251F  substitution on AgrC functionality 
Sigmoidal dose response curves demonstrating the sensitivity to AIP-1 of the agr group 1 AgrC 
bioreporter and AgrC1 Y251F mutant reporter. The response to serial dilutions of AIP-1 was 
measured as RLU divided by bioreporter OD. To account for background luminescence, and 
variations in the maximum light output between assays and bioreporters, the raw data (A) were 
also normalized (B). This was achieved by subtracting background luminescence and adjusting 
values so that the peak of the sigmoidal dose response curve was 100. The difference between 
reporter sensitivity for AgrC1 and AgrC1 Y251F is not significant. Graphs represent one assay. 
EC50 values were calculated from triplicate assays +/- standard deviation. 
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Figure 4.6  Functional impact of N267I and Y251F-N267I substitutions on AgrC activity 
The response to serial dilutions of AIP-1 was measured as RLU divided by bio-reporter OD. Data 
were normalized as described in Figure 4.5. The difference between reporter sensitivity for 
AgrC1 and AgrC1 N267I was significant (p<0.01) (A) but not that between AgrC1 N267I and 
AgrC1 N267I-Y251F was not (B). Graphs represent one assay. EC50 values were calculated from 
triplicate assays +/- standard deviation. 
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4.2.2.3 Functional impact of AgrC mutations found in the ST239 lineage strains 
As described in Section 4.2.1.2, a study of a collection of Turkish ST239 clinical isolates at Bath 
University identified a group of strains with an AgrC I311T substitution, an example being IU12, 
with a subgroup of these, like HU24, also having an AgrC A343T substitution. Three different 
reporters were made by site directed mutagenesis, introducing each mutation individually and 
in combination. 
The AgrC-A343T substitution in ROJ48 surprisingly was as sensitive as the agr group 1 control 
with an EC50 of 2.8 nM (+/- 0.8 nM) (p>0.05) (Figure 4.7A). Compared with an EC50 value of 3.4 
nM (+/- 0.6 nM) for the control reporter, the AgrC-I311T substitution resulted in an ~6-fold 
reduction in sensitivity to AIP-1 with an EC50 value of 20.9 nM (+/- 0.6 nM) (p<0.01) (Figure 
4.7B).  
Testing the combined AgrC-I311T-A343T mutant, however, revealed an even greater effect 
than I311T alone with an EC50 of 38.1 nM (+/- 1.7 nM) (p<0.01) (Figure 4.7B), giving a greater 
than ten-fold reduction in reporter sensitivity as compared with the control. 
The observations show that not only could the amino acid residues modified give cumulative 
effects, , but that certain combinations of mutation might be required in order to  confer any 
functional impact at all. This may suggest that that these two residues are in close proximity in 
the folded protein, perhaps on different strands of a loop structure (or on two different but 
spatially close loops). 
AgrC T247I was identified in ICP5062 as described in Section 4.2.1.2. This substitution resulted 
in an EC50 value of 22.9 nM (+/- 2.6 nM) (Figure 4.9), also significantly different to the AgrC 
group 1 control reporter (p<0.01). 
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Figure 4.7  Functional impact of C I311T and A343T substitutions on AgrC functionality 
The response to serial dilutions of AIP-1 was measured as RLU divided by bio-reporter OD. Data 
were normalized as described in Figure 4.5. The difference between reporter sensitivity for 
AgrC1 and AgrC1 A343T was not significant (p>0.05) (A). AgrC1 I311T had reduced sensitivity 
compared to AgrC1 (p<0.01) but greater sensitivity than AgrC1 I311T-A343T (p<0.01) (B). 
Graphs represent one assay. EC50 values were calculated from triplicate assays +/- standard 
deviation. 
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Figure 4.8  Functional impact of a T247I substitution on AgrC functionality 
The response to serial dilutions of AIP-1 was measured as RLU divided by bio-reporter OD. Data 
were normalized as described in Figure 4.5. The difference between reporter sensitivity for 
AgrC1 and AgrC1 T247I was significant (p<0.01). Graphs represent one assay. EC50 values were 
calculated from triplicate assays +/- standard deviation. 
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4.2.2.4 Functional impact of other selected AgrC mutations 
There are a number of other reports in the literature of cytoplasmic AgrC mutations occurring 
in clinical strains which show altered to agr functionality. Changes reported included L245S and 
T399P (Traber et al, 2008), F264A (Shopsin et al, 2008) and G394A (Somerville et al, 2002). 
Other reported mutations resulted in either frame shifts or premature stop codons. 
As L245 and F264 are close to N267, two different AgrC mutants were made for these residues, 
replacing them both with alanine. Each of these substitutions had a significant impact on 
reporter sensitivity (Figure 4.9) with EC50 values of 8.0 nM (+/- 2.1 nM) for L245A (p<0.05) and 
8.3 nM (+/- 1.3 nM) for F264A (p<0.01) respectively.    
An N308S substitution had been identified in TS1, close to the I311T substitution already tested. 
An AgrC-N308A reporter was made and tested to see if the asparagine was important for 
function but was found to make no difference to reporter sensitivity, resulting in an EC50 value 
of 2.7 nM (+/- 0.9 nM) (p<0.05) (Figure 4.10). 
A summary of all of the EC50 values for the AgrC cytoplasmic mutations is shown in Table 4.2. 
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Figure 4.9  Functional impact of L245A and F264A substitutions on AgrC functionality 
The response to serial dilutions of AIP-1 was measured as RLU divided by bio-reporter OD. Data 
were normalized as described in Figure 4.5. The difference between reporter sensitivity for 
AgrC1 and AgrC1 L245A (A) was significant (p<0.05) as was the difference between AgrC1 and 
AgrC1 F264A (B) (p<0.01). Graphs represent one assay. EC50 values were calculated from 
triplicate assays +/- standard deviation. 
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Figure 4.10  Functional impact of N308A substitutions on AgrC functionality 
The response to serial dilutions of AIP-1 was measured as RLU divided by bioreporter OD. Data 
were normalized as described in Figure 4.5. The difference between reporter sensitivity for 
AgrC1 and AgrC1 N308A was not significant (p>0.05). Graphs represent one assay. EC50 values 
were calculated from triplicate assays +/- standard deviation. 
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Table 4.2  Summary of functional impact of AgrC cytoplasmic domain mutations 
Response to AIP-1 by the Group 1 AgrC bioreporter and AgrC mutants expressed as the 
concentration of AIP-1 required for 50 % activation (EC50). EC50 values given are the mean value 
for 3 separate assays plus the standard deviation (SD). Statistical significance is shown in 
comparison with the group 1 AgrC control reporter. Amino acid substitutions, alone or in 
combination, which were present in clinical strains and associated with reduced or null exotoxin 
phenotype are shown in red. The AgrC T247I (EC50=22.9 nM) and AgrC I311T-A343T (EC50=38.1 
nM) reporters showed the greatest reduction in sensitivity. Sources for the original mutations 
are given as either the TS strain collection (Table 2.2), the ST239 Turkish isolates (Table 2.2) or 
other published studies. 
 
AgrC mutation  EC50 (nM)  SD  Significance  Source  
     
Group 1 AgrC  3.4  0.6    
     
Y251F  2.8  1.2  p>0.05  TS13/14  
N267I  9.6  1.6  p<0.01  TS13  
Y251F/N267I  9.3  1.8  p<0.01  TS13  
     
I311T  20.9  0.6  p<0.01  ST239  
A343T  2.8  0.8  p>0.05  ST239 
I311T/A343T  38.1  1.7  p<0.01  ST239 
T247I  22.9  2.6  p<0.01  ST239 
     
L245A  8  2.1  p<0.05  Traber et al (2008) 
F264A  8.3  1.3  p<0.01  Shopsin et al (2008) 
N308A  2.7  0.9  p>0.05  TS1  
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4.2.2.5 Impact of key agrC mutations on agr autoinduction  
All of the data gathered on AgrC cytoplasmic domain mutations so far used a plasmid-based 
reporter system incapable of AIP synthesis. Although the reduction in sensitivity observed for 
AgrC-N267I was significant, it was conceivable that the impact would be magnified when placed 
in the context of an autoinduction circuit. 
A chromosomal agr group 1 reporter strain MY15 had previously been constructed by Maho 
Yokoyama (Centre of Biomolecular Sciences) by inserting the agrP2BDCA genes into an ectopic 
chromosomal site of an integration strain and transducing this into the agrP3-lux reporter 
ROJ48 (section 2.5.3). MY15 both produces and responds to AIP, producing light when agrP3 is 
activated. MY20 was also constructed by introducing the appropriate SNP into agrC, resulting 
in AgrC-N267I. 
To compare the light production profiles of these strains, reflecting the timing of agr activation 
as a result of their native AIP-1 production, both strains were incubated over a 20 h period in 
96 well plates with luminescence recorded at 20 min intervals (Figure 4.11A). MY15, encoding 
the NCTC8325 reference agrC sequence, showed measurable bioluminescence by 6 h, which 
continued to rise over the following 12 h. agrP3 activation in MY20, harbouring the AgrC-N267I 
mutation, did not show measurable bioluminescence until 14 h, a delay of 8 h. While this delay 
was much greater than that observed in the clinical strain TS13, this is likely to reflect a reduced 
overall efficiency of the agr autoinduction circuit when placed in an ectopic chromosomal 
location, with a delay also seen in the control reporter. 
When both strains were grown under the same conditions in the presence of 100 nM AIP-1, 
added at inoculation, early activation was observed in both MY15 and MY20, although MY20 
activation was still slightly higher up to 16 h (Figure 4.11B). The AgrC antagonist                  
(ala5)AIP-1 abolished agrP3 activation by both MY15 and MY20.  
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Figure 4.11  agr autoinduction is delayed in a chromosomal AgrC-N267I reporter 
agrP3 activation of bioluminescent reporters expressed as RLU per OD over 20 h. Bioreporters 
consist of an agrP3-lux fusion, with the agrP2 locus inserted at an ectopic chromosomal 
mutation to allow the introduction of the N267I AgrC substitution. A negative control without 
the agrP2 locus is shown, with no light output, compared with a reporter with the NCTC8325 
agrC sequence activating around 6 h (AgrC1) and an AgrC1-N267I mutant reporter activating 
around 14 h (A). While the AgrC antagonist (ala5) AIP-1 abolished agrP3 activation, addition of 
exogenous AIP-1 resulted in early activation, at around 2 to 4 h, for both the AgrC1 and AgrC1-
N267I reporters (B). 
 
  
A 
B 
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4.3 Discussion 
4.3.1 Variable exotoxin production and AIP production kinetics 
The direct comparison of TS13 and TS14 was the ideal natural experiment to investigate 
differences in agr function underlying variable exotoxin expression. 
Serial collection of culture supernatants through exponential to stationary phase revealed a 
delay of about 1 h in the production of AIP-1 by TS13 as compared to TS14 with a lower final 
AIP-1 concentration reached by TS13 in stationary phase. Given the differences in agr 
expression already identified by the RT-PCR analysis, this result was in good agreement.  
As there were no other genotypically matched but phenotypically variable pairs of isolates in 
the strain collection, other strains with predicted AgrC substitutions and large phenotypic 
differences were sought for comparison. 
HU24 and IU12 were two ST239 strains which had been identified with collaborators at Bath 
University as having identical agr sequences except for a predicted A343T AgrC substitution. 
While IU12 was highly lytic in a T-cell assay indicating production of high levels of exotoxin 
production, particularly haemolysins and phenol soluble modulins, HU24 demonstrated lytic 
activity that was around 20-fold lower. As with the TS isolates, there was a marked difference 
between these two strains in AIP-1 production. While IU12 was approaching a 100 nM AIP-1 
concentration at 6 h, HU24 had barely reached this by 7 h and 1 h later the AIP-1 concentration 
did not change. 
The other pair of ST239 isolates identified with significant phenotypic differences (4 % 
compared with 85 % T cell lysis) were ICP5014 and ICP5062, with ICP 5062 harbouring a 
predicted T247I AgrC substitution. The variation in AIP-1 production between these strains was 
the most marked with a delay of at least 3 h by ICP5062 which had a barely detectable 
concentration of AIP-1 when measured well into stationary phase. 
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While the delays observed here were only 1 h for the first 2 comparisons, the exogenous AIP 
addition experiments indicated that the concentration of AIP present going into exponential 
phase is a crucial determinant of global exotoxin production. Whether the delay or eventual 
peak of AIP-1 production is a bigger factor in determining the downstream regulatory effects is 
not clear. 
The agr system exhibits classical quorum sensing such that activation is primarily due to 
changes in cell density, which can occur during growth and also due to changes in the 
environment. It may be, therefore, that a mismatch between AIP concentration and bacterial 
population density defines exotoxin production such that low AIP concentration in the presence 
of high bacterial population density results in low exotoxin production. 
A recent report analysing AIP-1 production from culture supernatants by mass spectrometry 
found that in USA300, AIP-1 was detectable from about 4 h, although they estimated the 
concentration at this point to be 1 µM, much higher than the ~125 nM detected in TS14 at 4 h 
(Junio et al, 2013). This could be because USA300 produces much higher levels of AIP-1 than 
the strains tested here, in keeping with higher levels of agr expression. Alternatively, the MS-
based method may be much more sensitive than the lux-based bio reporter assay. As seen here, 
AIP-1 concentrations in USA300 increased rapidly following initial detection to around 8 µM in 
early stationary phase although continued to increase slowly to a final peak of 12 µM at 16 h. 
As the experimental data presented here was predominantly intended to give an indication of 
differences in the initial AIP production timing, AIP-1 concentrations were not studied beyond 
early stationary phase. Through comparison of culture supernatants taken from stationary 
phase, Junio et al were also able to show that AIP-1 concentrations correlated with red blood 
cell lysis in several different strain backgrounds, particularly for USA300 and COL. However, 
when comparing a number of CC45 strains, poor correlation was observed with some isolates 
that only produced lower levels of AIP-1 still showing marked (75 %) lysis of red blood cells. It 
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is interesting to note that this study did not investigate the timing of AIP-1 production between 
these strain types to see if this was a better predictor of haemolytic activity. 
Differences in the timing of agr expression have been linked to exotoxin gene expression by 
other investigators. A study of the timing of agr expression compared the effect of variations 
in agr sequence between the four agr groups on RNAIII and exotoxin gene expression using 
transcriptional reporter fusions (Geisinger et al, 2012). Of note, RNAIII expression occurred at 
a much earlier time point when controlled by the group 1 agr locus as compared with group 3. 
Earlier RNAIII expression was associated with higher expression of hla and pvl but lower 
expression of spa and rot. Four of the group 3 isolates from the strain collection TS12, TS16, 
NRS162 and NRS255 were briefly tested for AIP-3 production with the group 3 bio reporter 
ROJ154 but AIP could not be detected until 12 h of growth. As it was unclear if this was 
comparable with the group 1 bioreporter data or simply due to reduced sensitivity of the group 
3 bioreporter, the data was not included in this thesis. None of the group 3 isolates in the clinical 
strain collection exhibited high level PVL production however, so this effect may well be 
genuine and in keeping with the study by Geisinger et al (2012).  
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4.3.2 Causes and consequences of changes in AIP production kinetics 
In the study by Geisinger et al (2012), the authors explained differences in the timing of agr 
expression in terms of polymorphisms between groups in important functional regions, 
particularly in agrB and agrC. The strains studied here all harboured polymorphisms in the agrC 
gene which were predicted to alter the amino acid sequence. This raises the obvious 
mechanistic question as to whether changes in the AgrC amino acid sequence could delay the 
autoinduction circuit resulting in slower accumulation of AIP and consequently delayed 
activation of agrP3. 
As AIP autoinduction depends on a positive feedback circuit, introducing inefficiencies in the 
system could potentially have a marked and cumulative impact on quorum sensing. 
Accumulation of AIP would occur slowly at first, accelerating as higher concentrations were 
reached. Limiting this initial accumulation could have an amplified impact on autoinduction 
potentially causing the delays observed here. This will be discussed in more detail in the context 
of the data generated by introducing AgrC mutations into the bioreporter ROJ48 strain 
background. 
The delays in AIP production by the strains tested occur during late exponential or early 
stationary phase. RNAIII expression is essential for post-exponential hla expression but also, 
when RNAIII was placed under the control of an inducible promoter and expressed at various 
time points, delays in expression during late exponential phase resulted in large increases in 
spa expression (Vandenesch et al, 1991). As spa expression is heavily dependent on the 
transcriptional regulator SarS, which also represses toxin gene transcription, this is a potentially 
important indicator that the transition from exponential to stationary phase is pivotal in 
determining the timing of virulence gene expression in S. aureus.  
As discussed previously, the other potentially important transcriptional regulator which is 
translationally repressed by RNAIII is Rot through RNAIII to rot mRNA complex formation 
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(Geisinger et al, 2006). The effect of Rot on exotoxin expression is significant; deleting rot 
partially restored toxin expression in an agr null mutant (McNamara et al, 2000). Carrying out 
a greater range of experiments studying the precise timing when exogenous AIP addition no 
longer impacts exotoxin expression would clarify the window period. Furthermore, employing 
RT-PCR to study rot and sar gene expression over time may yield even greater insight into the 
window period, identifying exactly when exotoxin repressor mRNA is present in high levels. 
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4.3.3 The role of mecA in reducing AIP production 
Rudkin et al (2012) had previously observed that deleting mecA in a HA-MRSA strain BH1CC 
enhanced virulence in a mouse model. They were able to demonstrate that mecA expression 
reduced agr expression and hypothesised this was related to changes in the cell wall which 
interfered with AIP signaling/autoinduction. Reducing the cell walls with lysostaphin abolished 
the differences in agr ĞǆƉƌĞƐƐŝŽŶďĞƚǁĞĞŶ, ?ĂŶĚƚŚĞ, ?ȴmecA mutant. This raises 
the possibility that PBP2a alters the cell wall architecture in some way, perhaps interfering with 
AIP access to the cell membrane. This could in turn delay autoinduction and lead to lower final 
AIP concentrations. 
Comparing AIP-1 production between the strains used in their study demonstrated that AIP-1 
was both delayed in BH1CC and less than half of the overall concentration in early stationary 
ƉŚĂƐĞǁŚĞŶĐŽŵƉĂƌĞĚƚŽƚŚĞ, ?ȴmecA mutant. This is consistent with their data and lends 
more weight to the overall hypothesis that AIP production, either the time to reach a threshold 
concentration or the final level reached at stationary phase, could be used as an indication of 
agr activity and consequently virulence factor expression. 
While alterations in penicillin binding protein activity and hence cell wall architecture may 
mediate this effect, other researchers have speculated that SCCmec may alter global gene 
regulation through other mechanisms. Psm-mec was noted to repress agr activity by directly 
inhibiting translation of AgrA (Kaito et al, 2013). The effect noted by Rudkin et al appeared to 
occur regardless of whether the entire SCCmec element or just the mecA gene was deleted, 
suggesting a specific role for mecA. Interestingly, mecA was observed to be constitutively 
expressed at higher levels in BH1CC as compared to CA-MRSA strains suggesting the existence 
of another mechanism for the enhanced virulence of CA-MRSA. 
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The finding of reduced AIP production in BH1CC is consistent with the experimental data 
presented by Junio et al (2013). As discussed previously, they found that AIP-1 production was 
higher in USA300 than HA-MRSA strains and associated with superior red cell lysis. 
Delays in AIP production resulting from the presence of the mecA element indicates that factors 
upstream of agr can produce this effect and this phenomenon is not just a consequence of 
polymorphisms in agr. This also underlies the association between delayed and reduced AIP 
production, reduced agr activity, lower production of exotoxins and reduced toxin associated 
virulence.  
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4.3.4 Mutation of the cytoplasmic domain of AgrC 
4.3.4.1 Do the agrC polymorphisms explain the attenuated exotoxin expression? 
The marked differences in PVL and alpha haemolysin production between TS13 and TS14 
despite their genotypic similarities pointed to the possibility of a pivotal mutation in a global 
regulator. The agrC polymorphism in TS13 that was predicted to result in an asparagine to 
isoleucine substitution at the 267th amino acid residue of AgrC remained the best candidate to 
explain this change after whole genome analysis. Expression of RNAIII in exponential phase was 
noted to be 10-fold lower in TS13 by qRT-PCR and AIP production was delayed by 1 h. 
Introduction of this agrC SNP into the group 1 bioreporter by site directed mutagenesis resulted 
in a ~3-fold rise in EC50, representing a fall in sensitivity to AIP-1. Although this effect was small, 
this could explain the differences in exotoxin phenotype and Agr kinetics. As the autoinduction 
loop depends on a positive feedback effect, a small reduction in efficiency when AIP 
concentration is low may result in a bigger delay in the amplification loop. 
Mutagenesis of the membrane spanning receptor domain of AgrC has previously shown that 
key residues in loops 1 and 2 are important for AIP binding and recognition (Jensen et al, 2008). 
Introducing mutations into these residues also resulted in increases in the AgrC EC50 in response 
to AIP.  While the AgrC receptor is fairly well characterised in terms of transmembrane spanning 
regions, loops and key residues, little is currently known about the structure or key functional 
residues of the AgrC cytoplasmic domain. 
As the plasmid based AIP reporter does not produce endogenous AIP and therefore does not 
represent a strain with an intact autoinduction circuit, the N267I AgrC substitution was 
introduced into a bioreporter harbouring the Agr P2 locus at an ectopic site, with the agrP3 
promoter fused to lux. When light output was compared with an identical bioreporter without 
the N267I substitution, a clear delay in onset was observed, providing further evidence that the 
change was probably sufficient to explain the change in agr kinetics. It therefore seems likely 
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that the phenotypic variation observed between TS13 and the other ST22 strains in the original 
collection of clinical isolates can be accounted for by this agrC polymorphism. This underlines 
the importance of the cytoplasmic region domain of agrC as pivotal to global gene regulation 
in S. aureus. 
Paired strains with marked differences in exotoxin expression and other agrC polymorphisms 
were also analysed by introducing the substitutions found in these strains into the bioreporter. 
Both I311T and T247I had an even bigger impact on the sensitivity of AgrC with EC50 values 
greater than 20 nM compared with the control EC50 of 3.4 nM. The T247I AgrC substitution is 
therefore also likely to explain the phenotypic variation observed between ICP5014 and 
ICP5062 with exotoxin dependent lysis being potent in ICP5014 but barely apparent in ICP5062 
which harbours the AgrC substitution. 
Comparing the data for I311T, A343T and the double mutant presents a slightly more 
complicated picture. When comparing ST239 strains that were highly lytic to those that were 
not, the agrC SNP resulting in A343T was associated with reduced lysis. When A343T was 
introduced alone into the bioreporter, there was no apparent difference from the control 
reporter. All of the ST239 strains analysed in this cluster harbour the agrC SNP resulting in 
I311T, suggesting this was a common feature of this clade. Despite this substitution, which 
would be expected to result in impaired agr activity, some of the strains were still highly lytic 
in the T-cell assay. Hence it may be that other changes in global regulation in these strains 
compensates for a baseline reduction in the efficiency of AgrC such that agr functionality is 
preserved. Introducing A343T into the bioreporter containing the I311T substitution did 
however result in the biggest increase in EC50 to ~38 nM. This suggests that these residues are 
interacting in some way, possibly within a single loop or between two regions of the 
polypeptide that are in contact with each other. The difference in EC50 between the I311T and 
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the I311T-A343T mutant strains would be sufficient to explain the phenotypic differences seen 
within this subgroup of strains. 
Finally, two AgrC residues which were reported in the literature to potentially result in 
reduction in exotoxin production were L245 and F264. These were both replaced with alanine 
to determine whether these residues are important for AgrC function. Both resulted in small 
but significant reductions in receptor sensitivity, which are in keeping with the original reports 
(Shopsin et al, 2008; Traber et al, 2008).  
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4.3.4.2 How do the polymorphisms relate to AgrC function? 
While the AgrC cytoplasmic domain has not been well characterised, histidine kinase signal 
transducers like it occur throughout the bacterial kingdom with key regions conserved between 
species (Grebe & Stock, 1999). AgrC is understood to form a dimer, enabling trans-
autophosphorylation of the histidine at residue 239 by a kinase domain in the dimer pair 
located at the end of the cytoplasmic region around residues 394 and 396 (George Cisar et al, 
2009). Modification of several residues around H239, particularly R238, have been reported to 
result in constitutive activation of AgrC (Geisinger et al, 2009). Type 1 histidine kinases have 
ďĞĞŶƌĞůĂƚŝǀĞůǇǁĞůůĐŚĂƌĂĐƚĞƌŝƐĞĚǁŝƚŚĨŝǀĞĐŽŶƐĞƌǀĞĚ ‘ďŽǆĞƐ ?ƌĞĐŽŐŶŝǌĞĚŝŶĐůƵĚŝŶŐƚŚĞ ‘,ďŽǆ ?
containing the histidine, but also X, N, D and G boxes (Grebe & Stock, 1999). AgrC is classified 
as a type 10 histidine kinase, having H, N and G boxes but no X or D box (see Figure 4.12). While 
the H box is important for autophosphorylation as already discussed and the G box probably 
represents the kinase, the N box may play a role in ATP binding prior to trans-
autophosphorylation. Highlighting the AgrC amino acid substitutions analysed in this study in 
relation to the functional regions indicates that many of them fall in the less well conserved 
regions of unknown functionality. T247I occurs quite close to the histidine and so could 
potentially interfere with phosphorylation, perhaps explaining the large impact this appears to 
have on transduction efficiency. N267I on the other hand, is situated between the H and N 
boxes and so it is unclear whether this affects ATP binding or phosphorylation directly, or 
protein structure in some other way. Both T247I and N267I are in a region predicted to form a 
large coiled-coil dimerisation domain so could conceivably interfere with dimerization prior to 
trans-autophosphorylation (George Cisar et al, 2009). As I311T and A343T are both close to the 
N box, it is conceivable that they interfere with the structure of this region, perhaps impairing 
ATP binding. Mutations in the G box at AgrC residues 394 and 399 have been reported in the 
literature and it is likely then that these impair the functionality of the kinase, reducing the 
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efficiency of phosphotransfer to AgrA (Somerville et al, 2002; Traber et al, 2008). Whether 
phosphotransfer depends on direct interaction and binding of AgrC to AgrA is not known. 
There would be several potential ways of investigating further the functionality of AgrC. One 
possibility would be to set up a bacterial two hybrid binding assay to look at the interaction 
between the cytoplasmic region of AgrC and AgrA. Amino acids could then be substituted in 
the AgrC fragment to determine whether they interfere with the AgrC-AgrA interaction. 
Alternatively, an expanded programme of alanine scanning may give a clearer picture of 
essential and non-essential residues in regions of interest. Finally, comprehensive in silico 
modelling of the predicted AgrC three-dimensional structure may indicate where the loops and 
residue to residue interactions occur and therefore explain why some of the substitutions 
tested here have more of an impact than others. 
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T247IL245A F264A N267I I311T A343T G394A T399P
Figure 4. 12  Position of mutations compared to functionally important regions of AgrC  
AgrC is divided into a transmembrane sensor domain and a cytoplasmic histidine kinase domain 
as shown in A. The cytoplasmic domain has been further subdivided into a dimerisation and 
histidine phosphotransfer domain (DHp) and a catalytic/ATP binding subdomain (CA) 
containing the kinase. The DHp subdomain is predicted to form a coiled ɲ-helical structure 
which is important for dimerisation, with a supercoiled region around the H239 marked with a 
grey rectangle underneath the H box (George Cisar et al, 2009). 
An alignment of histidine phosphate kinases (HPKs) is shown in B, demonstrating the similarity 
in the key functional H, N and G boxes between type 10 HPKs along with the sequences of 
divergent HPKs found in E. coli. The H box histidine is phosphorylated by the G box kinase. 
The locations of the cytoplasmic domain amino acid substitutions which attenuate AgrC 
function, both investigated in this study and reported in the literature, are marked on the 
structural map (green arrows) and the alignment (blue lines).  F264A, N267I and I311T fall 
outside of the functional boxes but may have an impact on dimerisation. 
A and B are both adapted from George Cisar et al (2009). 
 
  A 
B 
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4.3.4.3 What is the significance of agrC polymorphisms in clinical isolates? 
While it appears that agrC SNPs occur naturally, both within clades and spontaneously in single 
isolates, raising the question as to why these changes occur and whether they could be 
adaptive.  
Isolates with a defective Agr system as a consequence of SNPs, premature stop codons and 
frame shifts have been identified in clinical samples, usually mixed with isolates in which Agr is 
fully functional  (Traber et al, 2008). agr mutants occur during the course of an infection, for 
example within abscesses, and in this comparatively more stable environment than, for 
example, the bloodstream, appear to have a survival advantage over non-mutants (Schwan et 
al, 2003). The TS13 clinical strain harbouring the AgrC N267I substitution was isolated from 
abscess pus. In the context of chronic infection, such as in the cystic fibrosis lung, agr appears 
to become less and less important, with the inevitable consequence of accumulating agr 
mutations (Goerke & Wolz, 2004). 
Shopsin et al (2008) identified isolates from family members with identical agr mutations, 
suggesting agr mutation does not prevent transmission. They also observed a greater incidence 
of agr mutation in hospital strains, suggesting that the hospital environment may be more 
favourable to their emergence. If a fully functional Agr system is required for breaching the 
physical barriers of the host and overcoming the innate immune system but also represents a 
fitness burden, it is perhaps not surprising that Agr-impaired strains would more easily spread 
in hospitals in the context of immunocompromised hosts.  A follow up study of HA-MRSA strains 
by Shopsin et al (2010) indicated however that the majority of agr mutants are sporadic and 
did not appear to spread beyond the initial host or close contacts suggesting they are primarily 
adaptive for host survival not spread.  
One agr mutation identified in an epidemic strain is the AgrC G55R substitution in the CC30 
EMRSA-16 strain which, accompanied with a frame shift in the alpha haemolysin gene, appears 
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to attenuate exotoxin-associated virulence (DeLeo et al, 2011). This indicates that, as expected, 
the success of epidemic HA-MRSA clones depends primarily on colonisation and antibiotic 
resistance as opposed to an aggressive virulent phenotype. 
Quorum sensing mutations have also been identified in other Gram positive pathogens, for 
example Enterococcus faecalis. Teixeira et al (2012) found a mutation in the sensor domain of 
FsrC, analogous to AgrC,  predicted to truncate the ATPase sensor domain. The strain in which 
the mutation occurred had markedly reduced gelatinase expression compared to similar strains 
without the mutation. 
Most of the aforementioned studies of Agr dysfunction have focused solely on a haemolysin 
positive or negative phenotype as observed on blood agar. The clinical isolates studied here 
were characterised by a number of methods including an assay for AIP production kinetics, 
western blots of exotoxin production for the TS strains and T-cell lysis assays for the ST239 
strains. The advantage of this approach is that it identified subtler changes in Agr function which 
did not fit into the recognised paradigm of Agr positive and Agr negative. Rather, there appears 
to be a continuum of Agr functionality where the autoinduction system can remain intact, but 
with reduced exotoxin production as a consequence of agrC SNPs. This could give an added 
advantage to the strains acquiring these mutations as they would retain the capacity to respond 
dynamically to growth and environmental changes, while expending fewer resources on 
exotoxin production once successfully established within the host. 
While the TS strains were collected directly from the clinical laboratory and stored at -80 oC, 
the acquisition of mutations before this cannot be excluded, as isolates in the clinical laboratory 
are routinely subcultured at least once before storage. Somerville et al (2002) passaged S. 
aureus isolates several times before agr sequencing and found that agrC and intergenic agrC-
agrA mutations were common. 
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The dramatic difference in phenotype between TS13 and TS14 as the result of a single base 
change in agrC highlights the importance of this region of the agr locus in determining exotoxin 
expression. The potential implications of this are two-fold. The first is that in building up a 
picture of which AgrC residues are essential for normal Agr functionining, it should be possible 
to identify strains which are predicted to have reduced exotoxin expression directly from 
sequence data. The second is that AgrC to AgrA signal transduction, and more broadly 
staphylococcal signal transduction, are essential for virulence regulation and therefore present 
an attractive target for the design of novel antivirulence drugs. A signal transduction blocker 
with broader spectrum would interfere with multiple cellular processes and also potentially 
have activity beyond S. aureus, but with sufficient specificity to avoid toxicity to eukaryotic cells. 
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4.3.5 Does high level expression matter in vivo? 
As alluded to previously, the study of exotoxin expression in vitro raises questions about the 
relevance to clinical infections in vivo. One aspect of this debate is how representative in vitro 
exotoxin production is to that found in vivo. Another is whether high level exotoxin production 
in vivo determines severity or not. Finally, while exotoxin production may be critical to the 
pathogenesis of certain types of infection, particularly those involving abscess formation, it may 
be less critical or even counterproductive in the course of other infections. 
Several animal studies have confirmed that strains such as USA300 with high level expression 
of agr in vitro are more virulent than other strains with lower agr expression (Li et al, 2010). 
Cheung et al (2011) observed that alpha haemolysin transcript levels correlated with abscess 
size. Varshney et al (2010) demonstrated that strains which produced more PVL in vitro caused 
larger skin abscesses with more inflammation. As this study was performed using a mouse 
model, it is debatable whether they were observing a PVL-dependent effect or rather a broader 
effect of increased agr expression, probably mediated by a combination of exotoxins. 
The mismatch between in vitro and in vivo expression observed by Loughman et al (2009) was 
hypothesised to be related to the interaction between human neutrophils and staphylococci. 
Staphylococci may be able to bypass agr and sar dependent expression pathways through the 
upregulation of saeRS in response to environmental factors. This was observed in a strain 
specific manner by Goerke et al (2001). saeRS mediated exotoxin expression may ensure high 
level toxin expression in response to environmental triggers regardless of agr activity in vitro. 
It has also been noted that RNAIII can be activated in a time, density and tissue specific manner, 
independently of RNAII (Xiong et al, 2002). 
AIP-1 is known to be gradually inactivated in vitro by the oxidation of the methionine thioether 
side-chain to form a methionyl sulphoxide with around 60% of AIP-1 inactivated at 14 h 
(McDowell et al, 2001). This rate of oxidation could be similar in vivo, or could be enhanced by 
202 
 
environmental conditions. In addition, AIP-1 may be inactivated by other enzymes, bound to 
plasma proteins or diluted by fluid movement, as would undoubtedly occur in the bloodstream. 
In terms of whether high level exotoxin production determines severity, it was interesting to 
note that TS1, which caused a fatal nectrotising pneumonia, was not a high level toxin producer. 
Boakes et al (2012) compared PVL production by ELISA with strain background and type of 
clinical presentation (pneumonia, skin and soft tissue infection, bacteraemia), finding a 
correlation with strain background but not presentation. They concluded that the amount of 
PVL produced is unimportant in determining severity. The difficulty with this approach is that 
different clinical presentations are not really indicators of severity but rather distinct 
syndromes, probably with varying importance of exotoxin. For example, the majority of cases 
of PVL pneumonia could be caused by nasal colonisation strains, with severe inflammation 
facilitated by preceding viral infections. In addition, the huge variety of host factors which could 
determine outcome cannot be accounted for when viewing clinical severity retrospectively. 
Animal models are probably the only way to investigate this potential phenomenon effectively. 
Genestier et al (2005) observed concentration dependent neutrophil lysis in vitro with a 
transition from controlled apoptosis to frank necrosis occurring at high PVL concentrations. It 
may be that once a critical concentration of toxin is reached, neutrophils are lysed effectively 
and any additional PVL above this does not confer any further advantage. Whether this 
concentration is easily reached in vivo is not currently known.   
Investigating in vivo exotoxin expression could be achieved through a number of means, 
although is likely to be technically challenging. Reporter gene fusions would be one potential 
method and have previously been employed to show distinct expression profiles of 
staphylococcal genes in vitro versus in vivo, although not in real time (Cheung et al, 2004). 
Measuring RNA transcript levels would be another approach as employed in clinical samples by 
Loughman et al (2009) generating information on multiple genes at once, or even the whole 
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RNA transcriptome. While a reporter gene fusion method could potentially generate real time 
data in live animals using PET, SPECT and luminescence recording, RNA work would inevitably 
require animal sacrifice however, preventing dynamic, temporal data recording. 
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4.3.6 Key Findings 
 
1. AIP production was delayed by ~1 h in TS13 and 50% that of TS14. 
2. ST239 strains with reduced exotoxin production and the AgrC substitutions I311T or 
T247I also demonstrated delayed AIP production compared with genetically related 
strains without these changes. 
3. Comparing a HA-MRSA BH1CC with an isogenic mecA deletion mutant indicated that 
the presence of mecA delays and reduces overall AIP production. 
4. Introducing AgrC N267I into the plasmid based group 1 bioreporter raised the EC50 in 
response to AIP-1 while AgrC Y251F had no effect. 
5. The combined presence of AgrC I311T and A343T substitutions, or AgrC T247I had the 
greatest impact on AgrC function. 
6. Several other potentially important AgrC residues identified by other studies of agr 
dysfunction were investigated. This demonstrated an observable impact of substituting 
AgrC L245 and F264 for alanine. 
7. Introducing AgrC N267I onto a chromosomally encoded agr bioreporter with a fully 
functional autoinduction circuit delayed agrP3 activation. 
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5 Conclusions 
 
The starting point for this study was the analysis of a collection of PVL producing S. aureus 
strains isolated from patients in Nottingham. While the collection was never intended to be a 
comprehensive study of locally circulating PVL strain types, ST22 agr group 1 and ST30 agr 
group 3 strains made up the majority of those investigated. ST30 agr group 3 PVL MSSA strains 
have been identified spreading worldwide (Rasigade et al, 2010) and both groups are common 
in the UK (Holmes et al, 2005). A comparison of these strains revealed a wide variation in PVL 
production between lineages, which appears to be due primarily to differences in agr activity. 
Based on the observation that USA300, the most notorious of CA-MRSA clones, is a high level 
PVL producer, it is possible that the success of the ST22 MSSAs in Nottingham was in part 
related to their high level exotoxin production. By contrast, TS1 was not a high level toxin 
producer and appears to be unrelated to any of the successful staphylococcal lineages in the 
UK. Nonetheless, this strain was responsible for a fatal necrotising pneumonia, possibly 
indicating the importance of host factors in determining the severity of PVL associated 
infections, and the mismatch between strain transmissibility and potential for causing severe 
disease. 
 
PVL production in the Nottingham strain collection was regulated by agr. The addition of 
exogenous autoinducing peptides or the competitive AgrC antagonist (ala5)AIP-1 demonstrated 
that agr activation and inhibition has a major role to play in determining the final level of PVL 
production achieved.  The AIP concentration required for agr activation must be present before 
a critical cell population density is reached equivalent to mid-exponential growth. Further 
investigation of the pvl promoter indicated potential binding sites for staphylococcal regulators, 
particularly the SarA protein family, which was confirmed via promoter pull down experiments. 
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Hence PVL production is subject to multiple levels of regulation involving these well 
characterised staphylococcal regulators acting directly at the pvl promoter as well as via agr. 
The similarities between PVL and alpha haemolysin regulation, and evidence of PVL 
overexpression in vivo (Loughman et al, 2009) lends weight to the hypothesis that PVL 
expression could occur through both agr-dependent and agr-independent mechanisms. 
 
The comparison of TS13, a low PVL producing spa t005 ST22 MSSA, with the high PVL producing 
spa t005 ST22 TS14 presented a useful natural experiment to investigate why PVL production 
might vary within lineages. Studying the whole genomes sequences of these isolates also gave 
additional insights into how the ST22 MSSAs compared to similar staphylococcal strains. 
TS13 and TS14 differ by around 190 SNPs in their core genome which indicates they are closely 
related. Apart from the phage differences, they shared many of the core genome features 
found the UK epidemic MRSA clone EMRSA-15, with the most important differences being the 
lack of an SCCmec ĞůĞŵĞŶƚ ĂŶĚ ƚŚĞ ƉƌĞƐĞŶĐĞ ŽĨ ƚŚĞ Ws> ĞŶĐŽĚŝŶŐ ƉŚĂŐĞ ɌƚƉ ? ? ?-1. The 
coŵďŝŶĂƚŝŽŶŽĨƚŚĞ/ ?ĨŽƵŶĚŽŶɌƚƉ ? ? ?-3, and PVL production is likely to confer a significant 
advantage in terms of overcoming the innate immune defenses to S. aureus which is highly 
dependent on phagocytosis by neutrophils. 
The finding of a SNP in TS13 agrC conferring an N267I substitution probably explains the 
phenotypic difference observed between these strains, based on the importance of agr in 
determining PVL production, and the differences in both RNAIII and pvl transcription observed 
between them. The D134Y substitution in TS13 SarU could also be a contributing factor, 
although this was not tested.  
Given the large number of SNPs varying between the two isolates, and the possibility that there 
is other genetic material distinguishing them which could not be identified, the predicted 
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impact of the N267I substitution in AgrC cannot be confirmed from the sequence data and 
requires biological investigation.  The response to AIP-1 was reduced by the AgrC N267I 
substitution, lending further weight to the hypothesis that it was responsible for the low 
producing PVL phenotype seen in TS13. As the clinical isolates were difficult to manipulate, the 
AgrC N267I mutation could not be repaired in TS13 or introduced into TS14. Instead, AgrC N267I 
was introduced into a chromosomal agr bio reporter, resulting in a delay in AIP autoinduction. 
As TS13 was also observed to exhibit a delay in the initial production and lower final 
concentrations of AIP compared to TS14, the conclusion was that slight reductions in AgrC 
efficiency resulted in delayed AIP autoinduction. This, in turn, reduced AIP concentrations 
around the critical cell population density in exponential phase resulting in reduced PVL 
concentrations.  
To show this was not an isolated occurrence, other clinical strains with naturally occurring agrC 
cytoplasmic mutations were also studied and found to have delayed, reduced AIP production 
associated with reduced exotoxin levels. These agrC mutations also caused reductions in the 
sensitivity of AgrC to AIP-1 when evaluated in agr biosensor strains carrying the mutation. 
Furthermore, comparing a mecA deletion mutant of a HA-MRSA BH1CC indicated that other 
factors influencing agr expression can also alter the kinetics of AIP production in a similar way.  
 
This study also explored variations in exotoxin production between clinical isolates, regulation 
of PVL production and the impact of naturally occurring agrC cytoplasmic mutations on agr 
kinetics and exotoxin production. An important question underlying all of this is the role of PVL 
in determining pathogenesis, in particular whether the level of PVL production is a major factor 
in determining the severity of infections. While there is some indication that the level of PVL 
production is important in vivo, further investigation of this would be best served by analysis of 
real time gene expression in animal models relevant to PVL. 
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dŚĞ ‘ǁŝŶĚŽǁĞĨĨĞĐƚ ?ĚƵƌŝŶŐǁŚŝĐŚƚŚĞůĞǀĞůŽĨWs>ƉƌŽĚƵĐƚŝŽŶĐĂŶďĞĂĐƚŝǀĂƚĞĚŽƌŝŶŚŝďŝƚĞĚďǇ
addition of exogenous peptides is one of the more interesting findings and would require 
further study to characterise completely. More experiments could be done to determine the 
exact OD or point during growth when the bacteria no longer respond to exogenous peptide, 
how strain and growth medium dependent this effect is, and whether using high doses of AIP 
or (ala5)AIP-1 overcomes the lack of response observed after the window period. 
An initial analysis of the pvl promoter region by studying the promoter sequence and 
developing the pulldown technique gave fresh insight into how pvl is regulated. Experiments 
could be conducted with fragments of the pvl promoter, to confirm whether Sar proteins will 
bind to the predicted region between the putative RNA polymerase recognition sites and the 
start of the coding sequence. Comparisons of other low and high producing strains from other 
lineages, and analysis of promoter binding profiles at different time points, in different 
conditions and in the presence of activators and inhibitors of agr would also be valuable. 
Finally, the cytoplasmic domain region of agrC was found to be of crucial importance for 
exotoxin expression, and appears to be vulnerable to mutation in vivo. A thorough analysis of 
this region to determine its 3-dimensional structure and key functional residues would yield 
important information which could be exploited in a number of ways. Understanding the 
molecular interactions required for signal transduction could lead to the development of novel 
anti-virulence agents, potentially with a broader spectrum of activity. Furthermore, if residues 
can be identified which are essential for unimpaired AgrC functionality, thereby reliably 
reducing exotoxin expression if mutated, this could contribute towards efforts in predicting 
staphylococcal virulence from sequence data.  
Advances in genome sequencing have provided the research community with huge volumes of 
data, however interpreting and making use of this data in a clinical setting still presents a 
formidable challenge. This study demonstrates how through careful investigation of clinical 
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strains, phenotypic and genome sequencing data can be analysed side by side to guide 
mechanistic analysis. By bridging the gap between genomics and functionality, the anticipation 
is that the Clinical Microbiology service of the future will be able to provide users with timely, 
clinically relevant information about virulence and resistance based on genome sequencing 
data, which will in turn guide treatment and infection control. 
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7 Appendices 
 
7.1 Non-synonymous SNPs found in TS13 only 
A complete list of SNPs which were unique to TS13 and resulted in coding sequence changes (section 3.2.5.4). The location numbers indicate the base position 
on the reference strain HO 5096 0412 with both the reference base and TS13 variant shown. The coding sequence ID from the reference annotation is in 
column 4 with the annotated gene name (if known) in column 5 and description in column 6. 
 
Location Reference TS13 Coding Sequence ID Gene product Description  
116754 G A 920 - putative_membrane_protein 
116755 G A 920 - putative_membrane_protein 
182155 G A 1480 argJ putative_arginine_biosynthesis_bifunctional_protein 
296240 G A 2370 - putative_membrane_protein 
303593 G A 2420 - putative_membrane_protein 
352330 C G 2880 - putative_PTS_multidomain_regulator 
413095 G A 3490 - hypothetical_protein 
440311 G T 3770 - putative_NADH-Ubiquinone/plastoquinone_(complex_I)_protein 
458517 C T 3960 - LysR-family_regulatory_protein 
499087 G A 4280 - putative_peptidyl-tRNA_hydrolase 
546662 G A 4570 - conserved_hypothetical_protein 
594078 T C 4930 - conserved_hypothetical_protein 
637356 G A 5400 - putative_hydrolase  
676430 C G 5800 - putative_membrane_protein 
714778 C T 6180 - putative_membrane_protein 
  
736167 T C 6410 - putative_para-aminobenzoate_synthetase_component 
933720 A G 8230 - putative_oligopeptide_transport_system_permease_protein_(pseudogene) 
1044535 C T 9260 pdhD dihydrolipoamide_dehydrogenase 
1074548 G A 9580 isdB iron-regulated_heme-iron_binding_protein_(pseudogene) 
1243331 T C 11110 - conserved_hypothetical_protein 
1253375 A G 11200 - transposase_(fragment) 
1256697 A G 11240 - putative_pyruvate_flavodoxin/ferredoxin_oxidoreductase 
1314907 A G 11870 - putative_membrane_protein 
1322367 T A 11930 - putative_exonuclease 
1384978 G C 12500 - ABC_transporter_ATP-binding_protein 
1449776 C T 12970 ebh very_large_surface_anchored_protein_(pseudogene) 
1481909 C A 13120 - putative_exported_protein 
1605227 T A 14460 - conserved_hypothetical_protein 
1606147 G A 14470 accC biotin_carboxylase_subunit_of_acetyl-CoA_carboxylase 
1638949 A G 14840 - conserved_hypothetical_protein,_pseudogene 
1663284 A T 15070 - putative_membrane_protein 
1713713 T A 15560 tgt queuine_tRNA-ribosyltransferase 
1827886 T C 16530 - putative_aminopeptidase 
1853199 C T 16710 - transposase  
1881489 T G 16990 pckA phosphoenolpyruvate_carboxykinase 
1883817 C A 17020 - conserved_hypothetical_protein 
1924033 G A 17480 - putative_membrane_protein 
1995463 C A 18090 putP high_affinity_proline_permease 
2007441 A G 18180 - transposase_(fragment) 
2007881 C A 18190 - transposase_(fragment) 
2007902 T C 18190 - transposase_(fragment) 
2017193 C T 18280 - isochorismatase_family_protein 
2027595 T A 18370 - Tn554-related,_transposase_B 
  
2035006 C T 18470 - putative_ABC_transporter_ATP-binding_protein 
2038477 T C 18510 - hypothetical_protein 
2108636 A T 19460 agrC autoinducer_sensor_protein 
2160133 G A 19870 kdpA putative_potassium-transporting_ATPase_a_chain 
2293253 G A 21030 - hypothetical_protein 
2405583 G A 22290 hutU urocanate_hydratase 
2424120 G A 22480 - hypothetical_protein 
2492551 A T 23120 - transport_system_membrane_protein 
2509829 G A 23280 - transposase_(fragment) 
2509877 G A 23280 - transposase_(fragment) 
2510039 A G 23280 - transposase_(fragment) 
2540395 T G 23510 - putative_carboxylesterase 
2584539 G T 23940 - putative_membrane_protein 
2586266 C T 23950 sasG LPXTG_surface_protein_(pseudogene) 
2586704 A G 23950 sasG LPXTG_surface_protein_(pseudogene) 
2589488 G T 23970 - putative_staphylococcal_accessory_regulator 
2595084 G A 24010 gntP putative_gluconate_permease 
2597763 T C 24030 gntR gluconate_operon_transcriptional_repressor 
2608565 G T 24120 - ABC_transporter_ATP-binding_protein 
2614629 G T 24170 - putative_dioxygenase 
2639555 G A 24450 - LysR-family_regulatory_protein 
2645865 A G 24510 clpL putative_ATP-dependent_protease_ATP-binding_subunit_ClpL 
2664626 G T 24660 - putative_glycosyltransferase 
2666092 C T 24670 - putative_phytoene_dehydrogenase_related_protein 
2737433 G A 25350 clfB fibrinogen_and_keratin-10_binding_surfaced_anchored_protein 
2737646 T C 25350 clfB fibrinogen_and_keratin-10_binding_surfaced_anchored_protein 
2737658 A G 25350 clfB fibrinogen_and_keratin-10_binding_surfaced_anchored_protein 
2737661 A G 25350 clfB fibrinogen_and_keratin-10_binding_surfaced_anchored_protein 
  
2737673 G A 25350 clfB fibrinogen_and_keratin-10_binding_surfaced_anchored_protein 
2737685 A G 25350 clfB fibrinogen_and_keratin-10_binding_surfaced_anchored_protein 
2791513 A G 25750 icaB intercellular_adhesion_protein_B 
2810175 T C 25930 cna collagen_adhesin_precursor 
2810187 A G 25930 cna collagen_adhesin_precursor 
2810190 T C 25930 cna collagen_adhesin_precursor 
2810331 C T 25930 cna collagen_adhesin_precursor 
 
 
 
  
  
7.2 Non-synonymous SNPs found in TS14 only 
A complete list of SNPs which were unique to TS14 and resulted in coding sequence changes (section 3.2.5.4). The location numbers indicate the base position 
on the reference strain HO 5096 0412 with both the reference base and TS14 variant shown. The coding sequence ID from the reference annotation is in 
column 4 with the annotated gene name (if known) in column 5 and description in column 6. 
 
Location Reference TS14 
Coding 
Sequence ID Gene product Description 
36913 G T 270 - putative_transposase 
68139 A T 520 - TetR_family_regulatory_protein 
68141 A C 520 - TetR_family_regulatory_protein 
131435 T C 1070 - binding-protein-dependent_transport_system_membrane_component 
166233 G A 1380 - putative_lipoprotein 
168047 T G 1400 - conserved_hypothetical_protein,_pseudogene 
271844 C T 2160 - hypothetical_protein 
284663 G A 2260 bglA 6-phospho-beta-glucosidase 
361479 C A 2960 - putative_membrane_protein 
382759 A G 3160 - putative_membrane_protein 
540747 C T 4520 radA putative_DNA_repair_protein 
561505 A G 4720 rpsL 30S_ribosomal_protein_S12 
688820 G A 5910 - putative_exported_protein 
691792 C T 5930 - AraC_family_regulatory_protein 
704056 A C 6090 bacA putative_undecaprenol_kinase 
720120 C T 6250 - putative_phosphofructokinase 
742346 G A 6460 - ABC_transporter_ATP-binding_protein 
787395 C T 6850 uvrA excinuclease_ABC_subunit_A 
  
878668 A G 7770 mnhF Na+/H+_antiporter_subunit 
886859 G A 7860 - NADH:flavin_oxidoreductase_/_NADH_oxidase_family_protein 
963079 G A 8500 prfC peptide_chain_release_factor_3 
1015251 C T 9000 purL putative_phosphoribosylformylglycinamidine_synthase_II 
1125117 C T 10100 - conserved_hypothetical_protein 
1143560 A G 10270 - glyoxalase/bleomycin_resistance_protein/dioxygenase_superfamily_protein_(pseudogene) 
1158601 G A 10410 - conserved_hypothetical_protein 
1224943 G T 10970 polC DNA_polymerase_III_PolC-type 
1228731 C T 10990 nusA putative_N_utilization_substance_protein_A 
1253708 C A 11200 - transposase_(fragment) 
1271854 G A 11360 - putative_hydrolase 
1351231 A T 12150 trpE anthranilate_synthase_component_I 
1432637 C T 12970 ebh very_large_surface_anchored_protein_(pseudogene) 
1567552 G A 13480 - hypothetical_protein,_pseudogene 
1589216 C G 14310 - glyoxalase/bleomycin_resistance_protein/dioxygenase_superfamily_protein 
1652227 A G 14990 dnaJ chaperone_protein 
1673889 T C 15210 - hypothetical_phage_protein 
1686714 G C 15360 alaS putative_alanyl-tRNA_synthetase 
1705223 C T 15510 relA GTP_pyrophosphokinase 
1851017 C A 16680 - conserved_hypothetical_protein 
1883618 C T 17020 - conserved_hypothetical_protein 
1916224 G A 17390 trap signal_transduction_protein 
2162741 G T 19880 kdpD sensor_kinase_protein 
2177589 T C 20030 tenA transcriptional_activator 
2178861 C T 20040 - putative_exported_protein 
2235170 A G 20620 mtlA PTS_system,_mannitol-specific_IIBC_component 
2240552 C G 20660 fmtB putative_surface_anchored_protein 
2249903 T C 20690 - putative_membrane_protein 
  
2477430 G A 22960 narG nitrate_reductase_alpha_chain 
2529128 T C 23420 - hypothetical_protein 
2586650 C T 23950 sasG LPXTG_surface_protein_(pseudogene) 
2592008 C A 23990 fnbA fibronectin-binding_protein_FnbA 
2632747 A G 24370 - transposase_(pseudogene) 
2634271 A G 24410 glcB PTS_system,_glucose-specific_IIABC_component 
2650324 T C 24550 - putative_transport_protein 
2657496 G A 24600 copA putative_copper_importing_ATPase_A 
2673509 T C 24730 - putative_membrane_protein 
2682118 G A 24840 - alcohol_dehydrogenase 
2702279 T G 25060 ldh2 L-lactate_dehydrogenase_2 
2737436 T G 25350 clfB fibrinogen_and_keratin-10_binding_surfaced_anchored_protein 
2810244 G A 25930 cna collagen_adhesin_precursor 
2810302 G C 25930 cna collagen_adhesin_precursor 
2810622 G A 25930 cna collagen_adhesin_precursor 
2810673 A G 25930 cna collagen_adhesin_precursor 
2810748 G A 25930 cna collagen_adhesin_precursor 
2810781 A G 25930 cna collagen_adhesin_precursor 
 
  
  
 
